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Abstract
Approximately one in six South African adults is infected with HIV, making it the
country with the largest population of HIV positive individuals in the world. Strate-
gies for monitoring this epidemic are an important area of research. In particular,
estimation of incidence, the rate at which individuals are being infected, is a key indi-
cator of the scale of the epidemic. Since it is cheaper, quicker, easier and potentially
less biased than prospective follow-up, incidence estimation from the cross-sectional
application of a biomarker that tests for recent infection has gained much atten-
tion. There is, however, controversy over how best to account for individuals that
present anomalous biomarker responses. The central contribution of the thesis is
to derive a consistent incidence estimation approach that accounts for anomalous
responses. This approach is compared with other cross-sectional incidence estima-
tors found in the literature and shown to be less biased. Implications of the new
approach to survey design and the development of new biomarkers are explored.
Application to survey data gathered by the Africa Center for Health and Population
Studies showed consistent results when compared with incidence estimates derived
from follow-up. Aside from other theoretical contributions, the thesis also provides
a systematic review of the application of the BED assay in incidence estimation with
recommendations on best current practice.
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Chapter 1
Introduction
Prevalence and incidence are the two most important indicators of the state of an
epidemic. Prevalence is the proportion of a population that has contracted an infec-
tion, while incidence is a measure of the risk of uninfected individuals contracting
the disease and is usually expressed as a rate, i.e. the proportion of the at-risk (un-
infected) population that become infected per unit time. Prevalence is the easier of
the two indicators to measure, requiring only that the proportion of infected indi-
viduals be estimated by direct sampling in the population of interest. By contrast,
considerable effort must be expended to estimate incidence.
In South Africa it is particularly important to have information on the state of the
HIV epidemic since it has the largest population of HIV infected individuals of any
country in the world (one in six South Africans aged 15-49 is infected [91]). Large-
scale intervention is required to reduce the rate of new infections. The South African
National Strategic Plan for HIV AIDS [95] has stated that one of its primary aims is
to “Reduce the rate of new HIV infections by 50% by 2011.” It is therefore necessary
to have good estimates of incidence to ensure effective targeting and evaluation of
interventions.
The most common way in which incidence is measured is by follow-up of an
initially uninfected cohort. Over the duration of surveillance, individuals in the co-
hort are regularly tested, and incidence is estimated as the number of new infection
events observed divided by the number of person-years of observation. The incidence
estimated in this way is effectively an average incidence over the duration of the sur-
vey. Unfortunately, such longitudinal surveillance is expensive, logistically complex
and prone to biases. These biases include the fact that certain individuals may be-
come unavailable for follow-up, which may be correlated with risky behaviour, and
that risk-reduction counselling, which must be extended to participants on ethical
grounds, may affect behaviour during participation.
For infections with a relatively short duration (e.g. less than a year), another
method for estimating incidence is available. By performing a cross-sectional survey
of the population of interest, one can identify the number of individuals infected.
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Incidence may then be calculated by inverting the well-known epidemiological rela-
tionship that prevalence is equal to incidence multiplied by the duration of infection.
So, incidence can be calculated by dividing prevalence by the average duration of
infection (given that an accurate estimate of the mean duration is available). Sim-
plistically, this means that the difficult incidence measurement problem has been
replaced by an easier problem of measuring infection prevalence. The incidence
measured in this manner is effectively an average of the incidence over an historical
period with length approximately equal to the duration of the infection.
Unfortunately, HIV has a long asymptomatic phase before the onset of immune
failure and AIDS. This means that HIV infections last for many years and may not
be diagnosed until long after the infection event. Furthermore, with the advent of
antiretroviral therapy (ART), individuals who are enrolled on treatment programs
may now survive for many decades. As a result, if one implemented the cross-
sectional approach described above for HIV, the incidence estimate would be an
average of incidence over decades of epidemic history. Such an incidence estimate
would not be very useful. In the mid 1990s, however, a novel way of using cross-
sectional surveys to estimate HIV incidence was proposed. The idea is to observe a
biological marker (also known as a biomarker) indicating an immune system response
to early infection and classify individuals as either recently infected or non-recently
infected. Since individuals remain classified as recent infections by the biomarker for
a much shorter period than they remain infected with HIV, the biomarker results
can be used to estimate incidence in the same way that a short duration infection
facilitates incidence estimation. An incidence estimate is computed in the same way
as before, with one slight difference—the prevalence of recently infected individuals
must be determined in the sub-population of the cross-section that excludes those
that are non-recently infected.
Prior to conducting cross-sectional surveys to estimate incidence using a bio-
marker, it is necessary to estimate the mean duration that individuals spend in the
recently-infected state. Since being classified as recent by the biomarker is sometimes
referred to as “being in the window period”, this mean duration is usually called
the mean window period. Estimating (or calibrating) the mean window period
requires longitudinal follow-up of individuals with approximately known infection
dates. This requires considerable effort and cost, but need only be conducted once.
Unless there is good reason to suspect that the mean window period is different in
different contexts (e.g. as a result of sub-type diversity), all subsequent incidence
surveys use the same value of the mean window period.
Brookmeyer and Quinn were the first to propose the biomarker-based approach
in HIV monitoring [17]. They used the presence of p24 antigen (present in the
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HIV protein shell) in a blood sample prior to HIV antibody production by the im-
mune system (seroconversion) as an indication of recent infection. Unfortunately,
the mean window period for this biomarker is very short (about three weeks), which
means that to get good statistics, unreasonably large sample sizes for the incidence
cross-section surveys are needed. Later, Janssen et al. [47] proposed a method
based on the increase of a serological response (in particular they used ‘detuned’
assays to detect recently infected individuals). Depending on how the assays are
applied, the mean window period for this approach is longer (between 100 and 200
days), facilitating better precision in the incidence estimates. This approach later
became known as the Serological Testing Algorithm for Recent HIV Seroconversion
(STARHS). Unfortunately, the use of detuned assays did not prove reliable due to
the variability in immune response due to subtype diversity. In order to improve
biomarker characteristics, a number of other assays that test for recent HIV infec-
tion have been developed, including the much used BED assay, which is a capture
enzyme immunoassay (CEIA) based on protein sequences from the B, E and D HIV
subtypes [79].
As the method of using biomarkers of recent infection in cross-sectional surveys
was more widely applied, it became apparent that the results obtained from surveys
invariably overestimated incidence. It was then realized that for the most useful
assays (i.e., those with the mean window periods long enough for good statistics) a
proportion of individuals remained perpetually classified as “recent” as a result of in-
sufficient immunological response to HIV infection. The reasons for these anomalous
responses are not completely understood, but it is well known that elite controllers
(those individuals that have an innate ability to control the progress of HIV thus
avoiding AIDS) fall into this category. It was also found that certain individuals on
ART or with end stage disease experience immune system changes that may result
in incorrect classification. These complications mean that the simple relationship
between incidence and the prevalence of recently infected individuals is no longer
obeyed. As a result alternative techniques for analysing data from such imperfect
biomarker based surveys were needed.
To account for these anomalous results, McDougal and colleagues [63] at the
Centers for Disease Control and Prevention (CDC), using statistical concepts from
diagnostic testing, introduced an ‘adjusted’ incidence estimator which required not
only the mean window period to be calibrated, but also a sensitivity and two speci-
ficity parameters (short- and long-term). This meant that, although imperfect tests
like the BED assay could not be used for individual diagnosis, incidence could be
estimated in surveys, provided that the calibration parameters were accurate for the
population being surveyed. While this approach provided a way forward in analysing
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data, it did so at the cost of requiring a complicated calibration exercise. To date,
this calibration has only been carried out once in the context of North America.
Since this innovation, it was realized that the most important parameter for
characterizing anomalous results is the long-term specificity parameter of the Mc-
Dougal estimator. John Hargrove and colleagues [40] from SACEMA were the first
to realize that the McDougal estimator is over-parameterised and provided a new
estimator that depends only on the mean window period and a false-recent rate.
The false-recent rate can be expressed as one minus the long-term specificity, and
is essentially the proportion of non-recently infected individuals, infected for more
than a certain time, that are incorrectly classified as recently infected. Later, Alex
Welte and I [71] showed that an incidence estimator (different from that of Hargrove
et al.), which also depends only on the mean window period and the false-recent rate,
could be directly derived using a survival analysis of the problem. This estimator
has been shown to be the least biased of the estimators available [69]. We were
also able to derive a theoretically consistent way of reducing the number of calibra-
tion parameters in the McDougal estimator, in effect conclusively showing why their
approach is over-parameterised [69].
An important consequence of the reduction of the number of calibration param-
eters in the McDougal estimator is that the complexity of the techniques required
to calibrate the parameters that remain is less than the complexity required for the
parameters that are eliminated. Another important fact that emerges from our anal-
ysis is that, under realistic conditions, the false-recent rate will vary with location
and time. Our new estimator has been validated in an incidence study conducted
in rural KwaZulu-Natal by the Africa Centre for Health & Population Studies [10].
This study showed that the local estimate for the false-recent rate was significantly
lower than the equivalent false-recent recent rate found by McDougal et al. in the
North American calibration exercise.
Recently, there has been some debate as to whether incidence estimates should
be adjusted for false-recent results or not. Brookmeyer [15] has suggested that rather
than using an estimator that accounts for false-recent results, one should consider
all recent classifications as valid (i.e., within the window period) and use the simple
estimator with a “better” estimate of the mean window period. While this approach
is theoretically correct, it has some serious practical problems, including the fact
that a calibration of such a mean window period must naturally happen over a
very long period, since it must include a small proportion of individuals who may
remain classified as recently infected for decades. Since such individuals are only
removed from the population as a result of death, the calibration must be locally
relevant. For example, it would be inappropriate to use a mean window period of
1.1 Contributions and Structure of the Ph.D. 5
this type calibrated in North America for a study conducted in Africa, since access
to basic healthcare, ART, nutrition and the mix of opportunistic infections in these
two locations will lead to very different survival profiles for HIV infected individuals.
Clearly, as these factors may change with time, the mean window period thus defined
would also vary as a function of time.
While we disagree with the approach of Brookmeyer, the debate has, however,
highlighted that there is a need for a more precise definition of the calibration
experiments that are needed to characterise the performance of biomarkers. Further
work in this direction is ongoing [65].
While there has been some controversy on how best to interpret data derived
from cross-sectional surveys using biomarkers that test for recent HIV infection, the
work undertaken has shown that there is a consistent, tractable and reliable method
for producing incidence estimates using biomarker-based cross-sectional surveys. We
continue to contribute to ongoing research in this area, and are also active in ensuring
that these results are publicised to a wider audience of researchers and public health
officials through various journal publications and contributions to the World Health
Organization Working Group on HIV Incidence Assays. For example, we have pro-
vided a suite of spreadsheet tools for assay based incidence estimation (ABIE) avail-
able at http://www.sacema.com/page/assay-based-incidence-estimation/.
1.1 Contributions and Structure of the Ph.D.
In tackling this area of research, the primary goal has been to disseminate ideas as
quickly as possible through peer-reviewed research articles. This has been achieved
through the publication of five journal articles [71, 69, 118, 10, 8], two correspondence
articles [117, 116] and a number of conference presentations (including [65, 70, 66, 54,
11]). These publications form a coherent body of work with a natural progression
of ideas, and the chapters of the thesis reproduce the work roughly in the order
that the material was conceived. The only modifications to the original papers have
been some minor corrections, slight reformatting of the material and a unified set
of references. At the beginning of each chapter a list of coauthors with whom the
work was originally written and a reference to the original publication is provided.
The structure of the rest of the Thesis now follows.
In Chapter 2 the original work on a consistent incidence estimator is presented.
Here we derive a weighted incidence estimator that directly accounts for the phe-
nomenon of assay non-progression (one source of anomalous results mentioned previ-
ously). We also explore the biases introduced due to simplifications made and derive
an uncertainty relationship for the estimator that includes the effect of counting error
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and parameter uncertainty.
Chapter 3 provides a rigorous comparison between the estimator derived in Chap-
ter 2 and the estimators of McDougal et al. [63] and Hargrove et al. [40]. Initially,
we prove a result that shows that, under their own assumptions, there is a redun-
dancy inherent in the parameters required for the McDougal estimator. This result
shows that the sensitivity and short-term specificity parameters are not needed for
incidence estimation, and that a description of biomarker performance based only
on the window period and long-term specificity (alternatively false-recent rate) pro-
vides an equally precise description of biomarker performance. The three paradigms
are then compared under a model steady-state epidemic, with our estimator being
shown to be the least biased of the three. This is consistent with the findings of
Wang & Lagakos [112] who showed that this estimator is also the maximum likeli-
hood estimator.
One of the consequences of the analysis in Chapter 3 is that the McDougal
estimator can be simplified. In Chapter 4 we provide a short note that advertises
this.
In chapter 5 we explore the consequences of the new framework for study sample
size requirements, uncertainty and bias, under a variety of different scenarios. Given
statistical requirements, we also provide an indication of the practical challenges
that developers of tests for recent infection face. In an appendix to this chapter
we show briefly how a general false-recent rate (as opposed to the probability of
not progressing used in Chapter 2) can be used in conjunction with the incidence
estimator. This means that, with a good estimate of the associated false-recent
rate, it is possible to account for all the sources of anomalous results (i.e. assay
non-progressors and regressors).
Work in this area would not be complete without at least one application of
the statistical techniques to real data. In conjunction with our collaborators at the
Africa Center for Health and Population Studies [2], we were able to show that the
estimator performed well when compared to incidence derived from follow-up. One
important finding in this work was that the false-recent rate for the population being
studied was significantly different from other estimates of this parameter. This work
is presented in Chapter 6.
There has been a progression in the sophistication of techniques used to analyse
data from surveys that use biomarkers. Again, in conjunction with collaborators
from the Africa Center, we performed a systematic literature review of the use and
analysis of the BED assay in incidence estimation. Produced here as Chapter 7, there
are a number of interesting findings that arose from the thirty nine studies reviewed.
In particular, it was found that no less than ten distinct incidence estimators have
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been used to analyse data from cross-sectional incidence surveys. Unfortunately, a
large number of studies did not account for the presence of anomalous results, which
may undermine the validity of their findings. Based on the findings in this work we
provide recommendations on best current practice.
Recently Brookmeyer [15] has contested the need to “adjust” incidence estimates
for anomalous results. In particular he suggests that the McDougal and Hargrove
estimators do not increase the accuracy of incidence estimates, but that improved
estimates of the mean window period are required. Chapter 8 reproduces corre-
spondence in response to this work, in which we argue for the use of “adjusted”
estimators.
In responding to Brookmeyer, a number of issues were raised—in particular,
the need for a precise definition of the false-recent rate. Chapter 9 explores this
in detail. By providing a precise characterisation of the calibration parameters
(window period and false-recent rate) in terms of a predetermined cutoff time, a
new estimator is derived. We provide an analysis of bias introduced as a result of
simplifying assumptions, and compare the new estimator with previous estimators.
All of the graphs included in the Thesis were produced using MATLAB. In
Appendix A, some examples of MATLAB code used are presented. Appendix B
reproduces one of the conference posters presented at the International AIDS Soci-
ety Conference held at Cape Town in 2009—it serves as an executive summary of
Chapters 2-6.
Chapter 2
Relating Recent Infection Prevalence to
Incidence with a Sub-population of Assay
Non-progressors
∗ This chapter was coauthored with A. Welte [71], and is reproduced with permission
from Springer Science+Business Media: Journal of Mathematical Biology (2010)
60:687-710 DOI: 10.1007/s00285-009-0282-7.
Abstract
We present a new analysis of relationships between disease incidence and the
prevalence of an experimentally defined state of ‘recent infection’. This leads to
a clean separation between biological parameters (properties of disease progres-
sion as reflected in a test for recent infection), which need to be calibrated, and
epidemiological state variables, which are estimated in a cross-sectional survey.
The framework takes into account the possibility that details of the assay and
host/pathogen chemistry leave a (knowable) fraction of the population in the
recent category for all times. This systematically addresses an issue which is
the source of some controversy about the appropriate use of the BED assay for
defining recent HIV infection. The analysis is, however, applicable to any assay
that forms the basis of a test for recent infection. Analysis of relative contri-
butions of error arising variously from statistical considerations and simplifi-
cations of general expressions indicate that statistical error dominates heavily
over methodological bias for realistic epidemiological and biological scenarios.
2.1 Introduction
Reliable estimation of disease incidence (rate of occurrence of new infections) and
prevalence (the fraction of a population in an infected state) are central to the de-
termination of epidemiological trends, especially for the allocation of resources and
evaluation of interventions. Prevalence estimation is relatively straightforward, for
example by cross-sectional survey. Incidence estimates are notoriously problematic,
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though potentially of crucial importance. An approximate measure of incidence in a
population is required for the proper planning of sample sizes and costing for clinical
trials and other population based studies. Repeated follow-up of a representative co-
hort is often referred to as the ‘gold standard’ for estimating incidence, but is costly,
time intensive and still prone to some intrinsic problems. For example, there may be
bias in the factors determining which subjects are lost to follow-up. Furthermore,
ethical considerations demand that a cohort study involve substantial support for
subjects to avoid becoming infected, which may make the cohort unrepresentative
of the population of interest.
Numerous methods [17, 26, 40, 47, 63, 79, 80, 83, 122] have been proposed
for inferring incidence from single or multiple cross-sectional surveys rather than
following up a cohort. A central idea in most of these [17, 26, 40, 47, 63, 79, 80]
is to count the prevalence of a state of ‘recent infection’, which naturally depends
on the recent incidence. The relationship between the two is in general not simple
and depends in detail on the recent population dynamics as well as distributions
which capture the inter-subject variability of progression through stages of infection,
as they are observed by the specific laboratory assays used in the test for recent
infection (TRI). For this approach to be sensible, a working definition of ‘recent
infection’ must be calibrated, for example by repeatedly following up subjects over
a period during which they become infected. This is effectively as much effort as
one measurement of incidence by follow-up. The calibration can then be used to
infer incidence from subsequent independent cross-sectional surveys.
Owing to the devastating impact of the HIV epidemic, and the many challenges
of research and intervention design, the problem of estimating HIV incidence has
attracted considerable interest in recent years. The prospect of using a TRI is in
principle very attractive. Given the range of values of incidence likely to be observed
in populations with a major epidemic (say 1-10% per annum) a mean definition of
‘recent’ of approximately half a year is desirable to yield reasonable statistical con-
fidence for sample sizes of a few thousand. The BED assay1 is currently the leading
candidate for such a test, but controversy has arisen about the possibility of con-
ducting a reliable calibration. This stems from the fact that a subset of individuals
(approximately 5% [63, 40], potentially variable between viral and host popula-
tions) fail to progress above any statistically useful threshold set on the assay in the
definition of ‘recent’ infection. This subset of individuals who remain persistently
classified as ‘recently infected’, the so called assay non-progressors, poses a problem
to which there is currently no consensus remedy. We emphasize that the analysis
1 The BED assay is a capture enzyme immunoassay which uses protein sequences from HIV-1
subtypes B, E, and D [79].
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performed in this paper is not only applicable to the BED assay, but applies to any
assay that forms the basis of a TRI.
Of the references cited above, only McDougal et al. [63] and Hargrove et al. [40]
have proposed approaches for addressing the issue of assay non-progression. In the
former work four calibration parameters are used, being the window period (ω), the
sensitivity (σ), the short-term specificity (ρ1) and the long-term specificity (ρ2) of
the TRI. Some of these parameters are difficult to calibrate, requiring frequent and
long-term follow-up. In an attempt to reduce the number of parameters, Hargrove
et al. [40] provide a simplified formula under the assumption that σ ≈ ρ1.
We present a new analysis of the interaction between epidemiological trends and
a model of inter-subject variability of progression through an experimental category
of ‘recent infection’. Our model yields simple formulae for inference even when
a fraction of the population fails to progress out of the recent category. The only
physiological assumption required to deal with the assay non-progressors is that
their survival after infection is the same as the progressors. This assumption is also
implicit in previous work on using TRIs to estimate incidence, as shown in [117,
67]. Our analysis shows that only two calibration parameters are required for the
specification of the model, namely the proportion of seroconverters who do not
progress above the threshold and the mean time it takes for progressing individuals
to cross the threshold set by the TRI.
A key conceptual point about our analysis, which distinguishes it from all others
of which we are aware, is that we confront the fundamental limitation of what can
be inferred from a cross-sectional survey. In particular, even perfect knowledge of
an instantaneous population state does not uniquely determine the instantaneous
incidence. At best, a weighted average of recent incidence can be inferred. Although
the discrepancies between this weighted average and instantaneous incidence can
be shown to be small compared to statistical errors (for our application), it can
in principle be systematically incorporated into estimation of trends from multiple
cross-sectional surveys.
The article is organized as follows. In Section 2.2 we develop a basic continuous
time model defined by a time dependent incidence and susceptible population, a
distribution of times after infection spent under the threshold on a TRI and a distri-
bution of post-infection survival times. We note that there is in principle no specific
relationship between the instantaneous incidence and the prevalence of individuals
who are infected and under the threshold. At best, one obtains a relationship be-
tween the prevalence of under-threshold individuals and a convolution of the recent
incidence with a specific weighting function which is implied by the use of a TRI.
This relationship in principle includes all moments of the distribution of the waiting
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times that individuals spend under the threshold. We show that, for realistic rates
of variation in the susceptible population, only the mean of the waiting time distri-
bution is needed, and a simple expression for a weighted average of the incidence is
obtained. The basic model is extended to allow some fraction of individuals (speci-
fied by a new parameter) to be assigned infinite waiting times under the threshold
of the TRI. This leads to only very minor modifications of the previous expression
for weighted incidence, namely a systematic ‘subtraction’ of over-counted ‘not re-
cently infected’ individuals which are included in the experimental category ‘under
threshold’.
Section 2.3 explores the consequences of designing a cross-sectional survey with
a sample size N based on the relations derived in Section 2.2. Using a delta method
expansion of the incidence estimator, we derive an approximate expression for its
coefficient of variation. These expressions facilitate error estimation both for study
design and data analysis. On calibration, we note that trends, as opposed to absolute
values, for incidence can be obtained without any information about the distribution
of finite waiting times under the threshold. However, an estimate of the fraction of
assay non-progressors is essential. A key observation is that, for realistic population
dynamics and sample sizes, statistical error is much larger than bias.
Numerical simulations are presented in Section 2.4. These demonstrate the ap-
plication of the incidence estimator to a simulated population with epidemiological
and demographic dynamics. This demonstrates reproducibility as well as bias intro-
duced by imperfect calibration.
In the conclusion, we note that the framework presented here is quite general and
is applicable to any TRI, as long as any non-zero probability of assay non-progression
can be calibrated, survival is the same for assay progressors and non-progressors,
and there is no regression below the recency threshold. It may be possible to modify
the analysis to relax these requirements.
2.2 Relating the Prevalence of ‘Recent Infection’ to
Incidence
We now outline a quite general approach to relating the key demographic, epidemi-
ological and biological processes which are relevant to the estimation of incidence
from cross-sectional surveys of the prevalence of ‘recent infection’. This refines the
na¨ıve intuition that a high prevalence of ‘recently infected’ individuals means a high
incidence.
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2.2.1 The Basic Model
A test for recent infection, such as the CDC STARHS algorithm (Serological Testing
Algorithm for Recent HIV Seroconversion [47]), is typically obtained through the
administration of two assays of different sensitivity. The more sensitive test distin-
guishes infected from healthy individuals and the less sensitive test, applied to the
infected individuals, distinguishes ‘recent’ from ‘long’ established infection.
Consider an assay which yields a quantitative result, the value of which typically
increases with time from infection. The BED assay is of this type, the quantitative
result being a normalized optical density (ODn), which is an increasing function
of the proportion of HIV-1 specific IgG. Such an assay becomes the less sensitive
component of a test for recent infection when we declare a threshold value and define
‘observed to be recently infected’ to be a test value under the threshold.
As there is inevitably inter-individual variation in the threshold crossing times,
the category ‘observed to be recently infected’ is not sharply defined by a time
boundary. We now adopt the more precise labels under threshold (U) and over
threshold (O). The variability of times spent in the under-threshold category, condi-
tional on being alive long enough to reach the threshold, is captured by a distribution
of waiting times fU|A.
It is now possible to construct the basic epidemiological model shown in Fig-
ure 2.1A. Since our analysis will focus on a variety of survival functions S(t), we
shall refer to the susceptible population as the healthy population H(t). Upon infec-
tion, individuals move from the healthy population to the under-threshold infected
population U(t). Those that live long enough reach the threshold after a waiting
time, distributed according to fU|A, and enter the over-threshold population O(t).
We denote by τU|A a waiting time generated by the density fU|A. The corresponding
cumulative probability function is given by
FU|A(t) =
∫ t
0
fU|A(s) ds, (2.1)
while the probability of ‘survival’ (persistence) in the population U, conditional on
being alive, is
SU|A(t) = P(τU|A > t) = 1− FU|A(t), (2.2)
and the mean waiting time is
E [τU|A] =
∫ ∞
0
τfU|A(τ) dτ =
∫ ∞
0
SU|A(t) dt. (2.3)
Analogously, we define fA, τA, FA, SA and E [τA] to describe how long individuals
remain alive after the moment of infection, and fU, τU, FU, SU and E [τU] to describe
how long individuals remain simultaneously alive and under the threshold on the
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Fig. 2.1:
A) The basic epidemiological/TRI progression model. Members of the
healthy population H are subject to a per unit time hazard (incidence) I
of infection. After infection, individuals enter the under-threshold popula-
tion U. Those that survive to progress into the over-threshold population
O do so after delays distributed according to fU|A.
B) The basic model modified to accommodate non-progressors on the
TRI. Now, upon infection, a proportion PNP of individuals remain under
the threshold of the TRI for the rest of their lives, i.e., they enter the
NP category. The remaining proportion, 1 − PNP, the progressors, enter
the progressing, under-threshold population PU. Those that survive long
enough enter the progressing, over-threshold population PO with waiting
times from fPU|A.
C) Modified model with separation of non-progressors into recent and
long infected categories. This model contains the same epidemiology and
biology as the model in B), with the introduction of a bookkeeping device
which facilitates the definition of a calibratable category of recently in-
fected individuals. The non-progressors are assigned waiting times drawn
from the distribution observed in the progressing population, and spend
this waiting time in the non-progressing recently infected (NPR) category,
before moving to the non-progressing long infected (NPL) category.
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assay. We assume that survival time and waiting time to threshold are independent
in this model. Hence, the probability, at a time delay ∆t after infection, of being
simultaneously alive and under the threshold on the assay is
P(τA > ∆t AND τU|A > ∆t) = SA(∆t)SU|A(∆t) = SU(∆t). (2.4)
Similarly, the probability of being simultaneously alive and over the threshold is
P(τA > ∆t AND τU|A ≤ ∆t) = SA(∆t)(1− SU|A(∆t)). (2.5)
Hence, the mean time spent in the category U, accounting for both assay progression
and mortality, is E [τU].
New infections are generated by a non-homogeneous Poisson process with an
intensity (probability per unit time of new arrivals) λ(t). Let the instantaneous
incidence be given by I(t). Then, in a period dt around time t, the expected number
of new cases dC is given by
dC = λ(t) dt = I(t)H(t) dt. (2.6)
We can now write down numerous expressions resulting from the model. For ex-
ample, the expected number of historically accumulated cases, at time t, is given
by
C(t) =
∫ t
−∞
λ(s) ds =
∫ t
−∞
I(s)H(s) ds. (2.7)
The expected populations of infected persons under and over the threshold at time
t are
U(t) =
∫ t
−∞
I(s)H(s)P(τA > t− s AND τU|A > t− s) ds
=
∫ t
−∞
I(s)H(s)SU(t− s) ds (2.8)
and
O(t) =
∫ t
−∞
I(s)H(s)P(τA > t− s AND τU|A ≤ t− s) ds
=
∫ t
−∞
I(s)H(s)SA(t− s)(1− SU|A(t− s)) ds. (2.9)
Our goal is to relate I for recent times to instantaneous values of H, U and O.
Note that there is fundamentally a loss of information when one tries to characterize
the history of a population based on observations made at a single time point. The
recent historical course of a population, and even instantaneous values of state vari-
ables which are rates, like incidence, are in general not inferable from counting data
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obtained in a single survey. This is due to the fact that instantaneous population
states are, unavoidably, convolutions of historical epidemiological variables, as in
(2.8) and (2.9) above. Any attempt to derive incidence estimates from the counting
of infections accumulated in the recent past faces this problem, and at best some
sort of weighted average of the recent values of incidence can be inferred without
additional assumptions.
In general, a well defined construction of an estimate for incidence, based on
data obtained in a survey conducted at time t, will be some sort of weighted average
of past values
IW(t) =
∫ t
−∞ I(s)W (s, t) ds∫ t
−∞W (s, t) ds
, (2.10)
where W (s, t) is a statistical weight arising from a convolution of population history
and biology. Since our goal is to estimate incidence from a count of recently infected
individuals, a natural weighting function is one that reflects the relative contributions
to this count made by infections from different times in the recent past. Hence, we
consider
W (s, t) = H(s)SU(t− s) (2.11)
since W (s, t) is proportional to the probability that individuals are
1. available for being infected at time s < t, and
2. still alive and classified as under the threshold at time t, if infected at time s.
Using (2.11) as the weighting function leads to an expression for the weighted inci-
dence given by
IW(t) =
∫ t
−∞ I(s)H(s)SU(t− s) ds∫ t
−∞H(s)SU(t− s) ds
=
U(t)∫ t
−∞H(s)SU(t− s) ds
. (2.12)
The numerator in this expression is an instantaneous state variable, while the de-
nominator in principle involves data from the entire history of the system as well as
full knowledge of the survival function SU.
A few remarks about the practical meaning of this weighted average are in order.
In the case of constant incidence, the weighted average is the instantaneous value.
In the case of a narrowly peaked distribution fU|A, a constant rate of change of I
and a constant healthy population, the weighted average is approximately equal to
the instantaneous incidence at a time E [τU] /2 prior to the cross-sectional survey.
If trends are fitted to the results of multiple cross-sectional surveys, this time lag
could be more systematically accounted for.
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2.2.2 A Simple Expression for Incidence
A simplified expression for weighted incidence in terms of sample and calibration
data is now derived. We express the healthy population using the expansion
H(t+ s) = H(t) +H1s+H2s
2 + . . . (2.13)
and use the identity ∫ 0
−∞
snSU(−s) ds = (−1)
n
n+1 E
[
τn+1U
]
, (2.14)
which follows directly from integration by parts. It then follows that the weighted
incidence (2.12) can be expressed as
IW(t) =
U(t)∫ t
−∞H(s)SU(t− s) ds
(2.15)
=
U(t)∫ 0
−∞H(t+ s)SU(−s) ds
=
U(t)
H(t)E [τU]− H12 E [τ2U] + . . .
.
If the healthy population is approximately constant for the times where the
weight W is non-vanishing, we obtain the simple relation
IW ≈ U(t)
H(t)E [τU]
, (2.16)
which gives a weighted recent incidence in terms of instantaneous state variables
(H and U) and the expected waiting time in the under-threshold category and is
formally equivalent to the well known steady state result (for example [17]).
Expectation values of the form E [τnU ] are not state variables and should in prin-
ciple be measured independently of a particular cross-sectional survey. Usually this
would be accomplished in a calibration cohort follow-up study. Thus, after calibrat-
ing some of these expectation values, we can deal with a truncated expansion for H
without further assumptions about the behavior of I.
It will be difficult to obtain accurate estimates of terms of higher order than
just E [τU] for any assay forming the basis for a TRI. Finding the non-leading terms
Hi (for i ≥ 1) in the expansion of H will also require considerable demographic
research. This means that one will most likely be constrained to use the simple
expression (2.16), even if the healthy population is not approximately constant over
the times where W is non-vanishing. The key question then is: how severe is the
bias introduced by using the simple formula under realistic non-constancy of the
healthy population?
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Consider a non-constant healthy population given by H(t) = H0e
αt. This has
a conveniently tunable degree of failure to conform with the constancy assumption
required for (2.16). When α = 0 we have a constant number of healthy individuals,
while a value of α = ln(x) means the population grows by a factor of x in one
year. We can provide a survival function SU(t) for time measured in years, roughly
inspired by the ODn progression on the BED assay, by specifying fU to be a Weibull
distribution with scale parameter l = 0.44 and shape parameter k = 7, corresponding
to a mean of 150 days and a standard deviation of 25 days. We now numerically
evaluate the denominator of (2.15) and compare it to the denominator of the simple
formula (2.16). Note that this bias calculation is independent of the actual time
dependence in I.
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Fig. 2.2: Fractional error in the simple incidence relation (2.16) versus the full
relation (2.15), as a function of growth rate of the healthy population,
quoted as a percentage annual growth. The scenario is defined by: H(t) =
H(0)eαt and fU is a Weibull distribution with scale parameter l = 0.44 and
shape parameter k = 7. The parameter α is varied to produce deviation
from a constant healthy population (α = 0) in which limit equation (2.16)
is exact.
In Figure 2.2, the bias in the simple formula (reported as a fraction of the
unbiased value) is shown as a function of α, reported as the annual percentage
growth. Note that, under the distributional assumptions made above, the bias is
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about 2% for a population growing at an impressive rate of 10% per annum. As a rule
of thumb, for a distribution of times spent under threshold which is not too diffuse
around its mean, the bias, expressed as a percentage of the estimate, is approximately
the annual percentage growth in the susceptible population multiplied by half the
mean window period, measure in years. As we shall see later when analyzing a
slightly more complex model of a TRI, this is a very minor source of error compared
with the statistical error that arises as a result of using realistic sample sizes, not
to mention imperfect calibration. Thus, in this example, bias arising from the non-
constancy of the healthy population is not a key concern unless there is very dramatic
variation in H, such as in a population of refugees. This analysis should in principle
be carried out using the distributions applicable for any other assay intended for
use as a TRI. The bias calculation demonstrated here is also applicable to the more
complex model that now follows.
2.2.3 Modeling Assay Non-progressors
A known complicating factor for the BED assay (and likely also of any other TRI,
such as an antibody avidity test) is that a small number of individuals utterly fail to
progress beyond any practical threshold used to define recency. This is due to indi-
vidual variation in biochemical details such as immune response, for example. The
assay non-progression phenomenon leads to a long-term accumulation of apparently
recently infected individuals, as classified by the TRI. The analysis in the previous
section is perfectly valid even when assay non-progressors are present. However,
if some individuals leave U only through death, possibly after long waiting times,
then the calibration parameter E [τU] arises from a distribution with a long, difficult
to characterize, tail. Moreover, the evolving context of real populations (eg. roll
out of ART.) will presumably lead to these survival functions changing over time.
Also, when the weighting (2.11) of the incidence estimator has support over longer
periods, the estimator is less representative of recent incidence. We now extend the
previous analysis in order to provide a better estimate of incidence accounting for
the presence of assay non-progressors. Henceforth, we will use ‘progression’ to mean
assay progression, not disease progression.
Consider the model captured in Figure 2.1B. At the moment of infection, indi-
viduals transition from the healthy population to either a non-progressing popula-
tion (NP) or to a progressing under-threshold population (PU). The probability of
non-progression is PNP, and hence the probability of progression is 1 − PNP. Those
individuals in PU wait for a stochastic delay after which they move into the pro-
gressing over-threshold category PO or die. In the previous model, fU|A was the
distribution of waiting times governing the transition, but since the waiting times
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for non-progressing individuals are infinite, fU|A can now not be normalized. There-
fore, in order to specify the transition times from PU to PO in terms of a normalized
density, we introduce the density of waiting times in the state of being a progres-
sor and under the threshold, conditional on being a alive, denoted by fPU|A. Then
SU|A(t), SPU|A(t) and PNP are related by
SU|A(t) = (1− PNP)SPU|A(t) + PNP. (2.17)
The difficulty is that the TRI will classify as ‘recently infected’ all the individuals
in the NP and PU categories even though some potentially large number in NP are
long infected. This can systematically be addressed by the following two key steps.
Firstly, we assume that the same survival function SA is applicable to both
progressing and non-progressing individuals. This is true if the differences between
individuals which account for progression versus non-progression do not translate
into significant differences in post-infection survival. This assumption has also been
made, at least implicitly, in previous work on use of the BED assay for estimating
HIV incidence (for example, see [117, 67] for analysis of [63]). Its applicability should
in principle be tested for any assay used as a TRI.
Secondly, we introduce two artificial categories by separating the non-progressing
population into ‘recently infected’ (NPR) and ‘long infected’ (NPL) sub-populations.
Individuals entering the NPR sub-population are assigned a waiting time drawn
from fPU|A after which they transition to the NPL category. Note that this is a
book-keeping device used for convenience and, unlike the assumption about survival,
does not rely on any property of disease progression. It is now possible to provide
a sensible definition for the class of recently infected individuals (R) which has a
population given by
R(t) = PU(t) + NPR(t). (2.18)
Note that, since both PU and NPR now have the same exit waiting times, the distri-
bution of waiting times for R is given by fR|A = fPU|A, with corresponding survival
function SR|A.
These two steps lead to the model in Figure 2.1C. It is now possible to recycle our
preceding analysis and write down expected counts in these new classes. Survival
in the state of being simultaneously alive and recently infected, is given by SR(t) =
SA(t)SR|A(t), and hence for the progressing populations we obtain
PU(t) = (1− PNP)
∫ t
−∞
I(s)H(s)SR(t− s) ds (2.19)
and
PO(t) = (1− PNP)
∫ t
−∞
I(s)H(s)SA(t− s)(1− SR|A(t− s)) ds. (2.20)
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Note the similarity with expressions for U(t) and O(t) in the basic model. For the
non-progressing populations we obtain
NPR(t) = PNP
∫ t
−∞
I(s)H(s)SR(t− s) ds (2.21)
and
NPL(t) = PNP
∫ t
−∞
I(s)H(s)SA(t− s)(1− SR|A(t− s)) ds. (2.22)
For convenience we define
ϕ =
PNP
1− PNP , (2.23)
and note that
NPR(t) = ϕPU(t) (2.24)
and, more importantly,
NPL(t) = ϕPO(t). (2.25)
These equations express the symmetry between the progressing and non-progressing
sub-populations of Figure 2.1C. Substituting (2.19) and (2.21) into (2.18), we can
write
R(t) =
∫ t
−∞
I(s)H(s)SR(t− s) ds. (2.26)
It is appropriate to use a weighting scheme analogous to the one used in the basic
model
W (s, t) = H(s)SR(t− s), (2.27)
since W (s, t) is now proportional to the probability that individuals are alive and
classified as recently infected at time t if they become infected at time s, regardless
of whether they are progressors or non-progressors. Then the weighted incidence,
denoted IW, is given by
IW(t) =
∫ t
−∞ I(s)H(s)SR(t− s) ds∫ t
−∞H(s)SR(t− s) ds
=
R(t)∫ t
−∞H(s)SR(t− s) ds
. (2.28)
The populations of under-threshold and over-threshold individuals are related to the
populations defined in Figure 2.1C by
U(t) = PU(t) + NPR(t) + NPL(t) (2.29)
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and
O(t) = PO(t). (2.30)
Using the above two equations and (2.18) and (2.25), the population of recent in-
fections is related to the under-threshold and over-threshold populations by
R(t) = U(t)− ϕO(t). (2.31)
Performing the same expansion as before and assuming a slowly varying healthy
population gives
IW(t) ≈ U(t)− ϕO(t)
H(t)E [τR]
. (2.32)
This expresses the incidence in terms of the calibration parameters E [τR] and ϕ
(equivalently PNP), and the state variables H, U and O.
All that has changed, as a result of allowing non-progressors into the model, is
the shift in the numerator from U to R = U − ϕO. The same bias calculations as
before apply immediately, but there is an increase in statistical sensitivity.
2.3 Statistics and Calibration
The population models of the preceding section are expected to be in ever closer
correspondence to a real population as the population size increases. To model the
sampling process of a cross-sectional survey with a sample size N , we rescale the sub-
populations of the continuous time model, at any time t, by the total population
size T = H + U + O, to obtain the population proportions PH = H/T , PU =
U/T and PO = O/T . The result of a survey employing the TRI is the set of
three counts NH + NU + NO = N . We do not address the difficulties relating to
study design and selection bias which would need to be confronted in the field, but
proceed on the assumption that sampling is unbiased. For large populations, where
the assumption of sampling with replacement is benign, the counts are trinomially
distributed around their means. These observed counts turn equation (2.32) into an
estimator for the recently weighted incidence Iest given by
Iest =
1
E [τR]
NU − ϕNO
NH
. (2.33)
The quantities in this estimator can conveniently be regarded as being of two types:
1. population counts (NH, NU and NO) observed in a cross-sectional survey, and
2. calibration parameters (PNP and E [τR]) which are estimated from follow-up.
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In the simplest application, each of these five variables is estimated just once. A
delta method expansion (see, for example, Chapter 14 in [3]) leads to a coefficient
of variation (CV) denoted by cv:
c2v =
1
N
1
PO + PU
(
1
PH
+
POPU(1 + ϕ¯)2
(PU − ϕ¯PO)2
)
+
σ2ω
ω¯2
+
σ2PNPP
2
O
(1− P¯NP)4(PU − ϕ¯PO)2 . (2.34)
In the appendix we define the conventions which lead to this expression. We note
that the assumption of Gaussian uncertainty in the calibration parameters is a
heuristic at best.
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Fig. 2.3: Coefficient of variation (2.34) of the incidence estimator, under the as-
sumption of perfect calibration (i.e. σω = σPNP = 0). A sample size of
5000 is drawn from a steady state scenario implicit in choices for I and
PNP, given a mean post-infection survival of 8 years and a mean window
period of 150 days. The bold lines are contours of constant CV.
Assuming perfect calibration and a sample size of 5000 individuals, Figure 2.3
shows how the counting error component of the CV depends on incidence and the
fraction of assay-non-progressors for a steady state epidemic. The appendix outlines
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Fig. 2.4: Coefficient of variation (2.34) of the incidence estimator. A sample size
of 5000 is drawn from a steady state scenario implicit in choices for I
and PNP, given a mean post-infection survival of 8 years and a mean
window period of 150 days. The parameters PNP and ω are now assumed
to be generated from normal distributions around their true values, with
coefficients of variation of 15%. The bold lines are contours of constant
CV.
how the steady state proportions were derived. Figure 2.4 shows the total CV for
the same sample size when one assumes both calibration parameters are drawn from
a normal distribution with a CV of 15%2.
Although it is difficult to verify the accuracy of all terms in equation (2.34), it
is straightforward to verify that it handles counting error with high precision. For
a specific set of population proportions, a coefficient of variation can be computed
using an enumeration of all possible trinomially distributed counts (excluding those
2 A PNP estimate of 5% obtained by following 850 seroconvertors would have a CV of 15%. The
uncertainty associated with estimates of the mean window period depends in detail on methodolog-
ical choices and is consequently more complicated to characterize.
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that lead to an infinite estimate, i.e. when NH = 0). Comparing the coefficient of
variation using the trinomial counts with the counting error component of (2.34), a
maximum relative discrepancy of 0.01% was found for the range of values shown in
Figure 2.3.
Depending on the study design, and the availability of locally relevant calibration
data, various scenarios can be envisaged which involve more or less ability to reuse
calibration parameters between cross-sectional surveys. For example, if one wishes
merely to estimate trends in incidence, as opposed to absolute incidence values, then
it is not necessary to have an estimate for E [τR] at all, since it is just an overall factor.
However, surveys conducted at different times will not yield comparable values of
Iest ∝ (U − ϕO)/H unless ϕ (equivalently PNP) is known with some accuracy, since
it appears in one of two terms in the numerator. Consider two surveys which use
the same point estimate
ϕ = ϕ¯+ δϕ, (2.35)
where ϕ¯ is the real value and δϕ is the error due to methodological and statistical
factors. The first survey obtains counts N
(1)
H , N
(1)
U and N
(1)
O and the second obtains
counts N
(2)
H , N
(2)
U and N
(2)
O . This leads to an estimate of the difference between the
two incidences of
∆Iest(ϕ) = I
(1)
est (ϕ)− I(2)est (ϕ) = N
(1)
U − ϕN (1)O
N
(1)
H E [τR]
− N
(2)
U − ϕN (2)O
N
(2)
H E [τR]
. (2.36)
Knowledge of the exact value ϕ¯ leads to
∆Iest(ϕ¯) = I
(1)
est (ϕ¯)− I(2)est (ϕ¯) = N
(1)
U − ϕ¯N (1)O
N
(1)
H E [τR]
− N
(2)
U − ϕ¯N (2)O
N
(2)
H E [τR]
, (2.37)
from which we see that the error in ∆Iest, due to the error in ϕ, is
∆Iest(ϕ)−∆Iest(ϕ¯) = δϕE [τR]
(
N
(2)
O
N
(2)
H
− N
(1)
O
N
(1)
H
)
. (2.38)
The direction and magnitude of error depend in detail on many factors, such as
population renewal and long-term post-infection survival. While it is not possible
to summarize all the effects that may be produced by imperfect estimation of PNP,
in Section 2.4 we conduct a number of numerical simulations which demonstrate the
kind of bias that may arise.
2.4 Numerical Simulations
In this section we present results of numerical simulations that demonstrate the use of
the simple expression (2.33) for incidence estimation in a non-steady state epidemic.
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Arrival times of new infections were generated according to a non-homogeneous
Poisson process with intensity given by λ(t) = H(t)I(t). Uniform random numbers
(ri) between 0 and 1 were generated, and new infection arrival times ti computed
as solutions of
exp
(
−
∫ ti
ti−1
λ(t) dt
)
= ri. (2.39)
Newly infected individuals were initially classified as under the recency threshold of
a TRI and assigned survival times generated by fA. A fraction 1−PNP progressed to
the over-threshold category according to waiting times generated by fR|A. Weibull
distributions were used for fR|A and fA, i.e. post-infection waiting times ∆t solve
exp
(
−
(
∆t
l
)k)
= r, (2.40)
where k and l are the relevant shape and scale parameters and r is a uniformly
distributed random number between 0 and 1. Unique individuals were drawn from
the population at intervals, to produce counts NH, NU and NO, and hence estimates
for incidence.
To demonstrate the incidence estimation process, a 50 year population scenario
was produced. The Weibull shape and scale parameters for fA and fR|A were chosen
to give approximately realistic values for the mean and standard deviations for the
window period and infected life expectancy, as detailed in Table 2.1. The healthy
population was set to H(t) = 100, 000 + 5, 000t, with t measured in years. The
incidence was set at 0.01 (hazard per person per year) for the first ten years, climbing
linearly to 0.1 over the next ten years, then remaining at this high level for a further
ten years, followed by ten years of linear decline to 0.03 and maintained at this level
for the last ten years of the simulation.
Shape (k) Scale (l) Mean Standard Dev.
Life expectancy (fA) 4.5 8.83 8 years 2 years
Window period (fR|A) 7 0.44 150 days 25 days
Tab. 2.1: Weibull parameters for the Monte Carlo simulation (survival time mea-
sured in years).
Figure 2.5 shows output from this simulation. The input incidence parameter
is indicated as the dotted instantaneous incidence curve. A sample of 5, 000 indi-
viduals was surveyed every year, and an incidence estimate was produced using the
simple estimator (2.33) with exact values of E [τR] and PNP, i.e., assuming perfect
calibration. These point estimates are indicated as estimated incidence values, us-
ing ‘+’ symbols. The combined effects of the previously noted time convolution in
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Fig. 2.5: Full stochastic simulation of population with epidemic, individual survival
times, and annual sampling of 5, 000 individuals. The healthy population
was set to H(t) = 100, 000 + 5, 000t with time measured in years. The
instantaneous incidence parameter is the dotted curve. The target of
the estimates is the weighted incidence (solid line), which was calculated
explicitly as per (2.28) from all the known inputs. This is flanked by a
two standard deviation counting error envelope (dashed lines). Simulated
estimated incidence (+ symbols) were obtained by using sample counts
in the simple estimator (2.33). The calibration parameters E [τR] and PNP
were assumed to be known exactly.
IW, as well as stochastic departure from means in the simulated population, make
the input incidence parameter an unrealistic target for simulated incidence measure-
ments. Thus, the solid weighted incidence line has been displayed, which uses full
knowledge of all population members’ classification into H, U or O, inserted into
(2.28) with full knowledge of the denominator, (both the non-constant H(t) and the
exact SR). This is essentially all that the incidence estimation algorithm can be
asked to reproduce. A two standard deviation counting error envelope around the
weighted incidence line, calculated using the first term of (2.34) and knowledge of
the full population state and calibration parameters, is shown as two dashed lines.
In Section 2.3 it was shown that incidence trends can be extracted without
E [τR] calibration, while an estimate for PNP is vital. We now explore the extent to
which the accuracy of the estimate of PNP affects the ability to determine a trend in
incidence. Population fractions for H, U and O were extracted at six times from the
population simulation described above and are shown in Table 2.2. Four instances
of incidence trend estimation were simulated by selecting the time intervals (15, 20),
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(20, 30), (30, 35) and (40, 50). We considered the trends that would be observed if
incidence were measured at the beginning and end of each of these intervals. In
order to focus on the bias introduced by imperfect estimation of PNP, rather than
sample size effects, we assumed perfect knowledge of PH, PU and PO. For each of
these intervals, we calculated an incidence estimate at the beginning and end, as a
function of the estimated value of PNP (the true value being 0.05), assuming E [τR]
is known exactly. We also calculated the estimated fractional change in incidence,
which does not depend on E [τR]. The results are shown in Figure 2.6, where the
four intervals are referred to as scenarios A, B, C and D, respectively.
In each case, the effect of the error in the estimation of PNP is quite different, as
can be understood by considering how (2.38) is impacted by the system history. Note
that case B and case D both simulate intervals over which incidence is approximately
constant, but the impact (on the estimated incidence change) of incorrect estimation
of PNP does not even agree in sign. Negative incidence estimates are obtained in
panels C and D above critical overestimates of PNP. In panel D this breakdown of
the model results in the divergence of the fractional change in estimated incidence.
In short, incorrect estimates of PNP can lead to the fundamental breakdown of the
inference scheme. This makes sense, as PNP impacts the long-term accumulation of
individuals in the PO category.
Time (years)
15 20 30 35 40 50
PH 0.850 0.688 0.576 0.602 0.694 0.814
PU 0.024 0.041 0.044 0.036 0.024 0.019
PO 0.126 0.271 0.380 0.362 0.282 0.167
Tab. 2.2: Population fractions in H, U and O within a 50 year epidemic scenario.
2.5 Discussion and Conclusion
We have presented a detailed analysis of relations between recent incidence in a pop-
ulation and counts of ‘recently infected’ individuals. These are in principle complex
convolutions involving the epidemiological history as well as all information about
the distribution of waiting times in the recently infected category. When the healthy
population undergoes realistically modest variation on the time scale of the defini-
tion of recency implied by the TRI, we obtain simplified forms which incur very
little bias. The simplified relations yield estimators which are shown to have con-
siderably more variance than bias under realistic demographic and epidemiological
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Fig. 2.6: Absolute incidence estimates and estimated fractional incidence changes
for four pairs of successive times with population proportions from Ta-
ble 2.2.
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assumptions.
A key observation is that, for the purposes of estimating incidence from a TRI,
there is no fundamental obstacle posed by having a known fraction of individuals fail
to progress over the recency threshold. An accurate estimate of the non-progressing
fraction alone, is sufficient (and necessary) to infer trends in incidence from cross-
sectional surveys. However, as demonstrated in the calculations of Section 2.4, a
suitably large error in the estimate of PNP can render TRI based incidence estimates
meaningless. This fraction could possibly be estimated for the BED assay from
historical records, since there are many viable samples in storage with supporting
clinical information indicating long-infected status. A calibration of the mean finite
waiting time is required in order to estimate absolute values of incidence. Prospective
follow-up is probably the only practical way to estimate this parameter.
In contrast to our model, which has only two calibration parameters, the well
known model of McDougal et al. [63] appears to have four (window period, sensi-
tivity, short-term specificity and long-term specificity). Hargrove et al. [40] have
previously proposed a heuristic simplification of the McDougal approach, and we
have recently shown that a rigorous simplification is possible under the original as-
sumptions [117]. This allows a reduction of the parameters in the McDougal model
to the ones that naturally occur in our approach. This has two advantages—our
parameters are easier to calibrate, and assuming independence of correlated param-
eters leads to incorrect estimates of calibration error.
Noting that the assumptions of our model are the least restrictive of any TRI
based incidence estimation method of which we are aware, we now consider its
limitations. We have only modeled one direction of progression of individuals from
an experimentally defined state of ‘recent’ infection to ‘non-recent’ infection. The
reverse apparently occurs for BED optical density in some terminal stage AIDS
patients and patients on ART. This process constitutes a substantial complication,
and further work is required to investigate how it may be incorporated into an
analytical model of the kind developed here. It may be worth exploring previous
suggestions [63] to use additional information, from questionnaires or other assays,
to remove end-stage/ART patients from the observed recent count. In accounting for
assay non-progression we have assumed that the same post-infection survival applies
to assay progressors and assay non-progressors. Data on the similarity or difference
in mortality is preliminary at best, but we are aware of unpublished claims that the
HIV long-term non-progressors are somewhat over represented in the population
of BED assay non-progressors. We have also not considered the possibility that
calibration parameters vary regionally, for example as a result of environmental
impacts on immunity, or that they are functions of time, for example as a result
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of substantial vaccine uptake in a population. All these complications are under
investigation as part of ongoing work.
Besides the explicit assumptions noted, the analysis presented here is quite gen-
eral. Tests for recent infection continue to be of interest, and new assays are likely
to be developed both for HIV infection and other important diseases. In summary,
we have presented a simple incidence estimator, which can inform design of appro-
priate calibration studies and cross-sectional incidence estimation surveys, and can
also form the basis of systematic inference algorithms for processing the data ob-
tained from such surveys. Our analysis provides a broad framework for a consistent
approach to the estimation of non-constant hazard from instantaneous population
counts, including explicit attention to the limits of validity and/or utility of such
estimates in light of knowledge of the relevant survival functions.
2.6 Appendix
Given a sample of N subjects tested using the TRI, we use the delta method to
derive a systematic error estimate for the estimator
Iest =
NU − PNP1−PNPNO
ωNH
, (2.41)
where ω = E [τR]. The counts NX fluctuate trinomially around their means N¯X =
PXN . We assume the counts are sufficiently large so that binomial distributions
can be approximated by normal distributions—which will be the case if the survey
is to have any reasonable accuracy. In order to account for correlation, we express
the three counts as the result of two independent random draws. We also assume
that ω and PNP fluctuate normally with standard deviations σω and σPNP . The error
estimate is derived using the delta method as follows:
• Let ~α = [α1, α2, α3, α4] be draws from a standard normal distribution.
• Set
NH = N¯H + σHα1, (2.42)
where
σH =
√
NPH(1− PH). (2.43)
• Set
NU = PUN − σUα1 + σUO(α1)α2 (2.44)
and
NO = PON − σOα1 − σUO(α1)α2 (2.45)
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where
σU =
PU
PO + PU
σH, σO =
PO
PO + PU
σH (2.46)
and
σUO(α1) =
√
(N − PHN − σHα1)POPU
PO + PU
. (2.47)
• Set
ω = ω¯ + σωα3. (2.48)
• Set
PNP = P¯NP + σPNPα4. (2.49)
Substituting these expressions into the incidence estimator (2.41) and taking partial
derivatives with respect to each αi, we get
∂Iest
∂α1
∣∣∣∣
~α=0
= − I¯est√
N(PO + PU)PH
(2.50)
∂Iest
∂α2
∣∣∣∣
~α=0
=
√
PUPO
N(PO + PU)
(1 + ϕ¯)I¯est
PU − ϕ¯PO (2.51)
∂Iest
∂α3
∣∣∣∣
~α=0
= −σω I¯est
ω¯
(2.52)
∂Iest
∂α4
∣∣∣∣
~α=0
= − σPNPPOI¯est
(1− P¯NP)2(PU − ϕ¯PO) , (2.53)
where
I¯est =
PU − ϕ¯PO
ω¯PH
and ϕ¯ =
P¯NP
1− P¯NP . (2.54)
The coefficient of variation (cv = σ(Iest)/I¯est) is thus given by
c2v =
1
N
1
PO + PU
(
1
PH
+
POPU(1 + ϕ¯)2
(PU − ϕ¯PO)2
)
+
σ2ω
ω¯2
+
σ2PNPP
2
O
(1− P¯NP)4(PU − ϕ¯PO)2 . (2.55)
To evaluate this formula for a suitable range of inputs, we construct a family of
steady state epidemics, tunable by varying I and PNP for fixed values of ω and the
mean post-infection survival time Ω. At equilibrium, the ratio of recent infections
to long infections is given by the ratio of times spent in these categories. Under the
assumption that there is no mortality in the recent category, this can be written as
PU − ϕPO
PO + ϕPO
=
ω
Ω− ω . (2.56)
The equilibrium total prevalence is given by the product of the recruitment rate and
mean post-infection survival:
PO + PU = IPHΩ. (2.57)
The two equations above, together with PH + PU + PO = 1, uniquely define the
equilibrium proportions.
Chapter 3
A Comparison of Biomarker Based Incidence
Estimators
∗ This chapter was coauthored with A. Welte [69].
Abstract
Background: Cross-sectional surveys utilizing biomarkers that test for recent
infection provide a convenient and cost effective way to estimate HIV incidence.
In particular, the BED assay has been developed for this purpose. Controversy
surrounding the way in which false-positive results from the biomarker should be
handled has lead to a number of different estimators that account for imperfect
specificity. We compare the estimators proposed by McDougal et al., Hargrove
et al. and McWalter & Welte.
Methodology/Principal Findings: The three estimators are analyzed and
compared. An identity showing a relationship between the calibration param-
eters in the McDougal methodology is shown. When the three estimators are
tested under a steady state epidemic, which includes individuals who fail to
progress on the biomarker, only the McWalter/Welte method recovers an unbi-
ased result.
Conclusions/Significance: Our analysis shows that the McDougal estimator
can be reduced to a formula that only requires calibration of a mean window
period and a long-term specificity. This allows simpler calibration techniques
to be used and shows that all three estimators can be expressed using the same
set of parameters. The McWalter/Welte method is applicable under the least
restrictive assumptions and is the least prone to bias of the methods reviewed.
3.1 Introduction
Although prospective follow-up of an initially HIV-negative cohort is widely regarded
as the “gold-standard” for estimating incidence, the idea of utilizing a biomarker
to define a suitable class of “recently infected” individuals, and then to use the
prevalence of this class as the basis for estimating HIV incidence, is attractive for a
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number of reasons. Since this can be implemented using a cross-sectional survey, it is
logistically simpler, cheaper and less prone to the biases that result from intervention
and loss to follow-up.
The BED capture enzyme immunoassay (BED assay) has been developed for this
purpose [79, 28] and widely used [8]. It measures the proportion of IgG that is HIV-
1 specific as a normalized optical density (ODn). Since this proportion increases
over time after the infection event, specifying an ODn threshold allows seropositive
individuals to be classified as recently infected, if they are below threshold, and as
non-recently infected, if they are above threshold. Initially, an incidence formula
was proposed [79] that did not explicitly account for the possibility of assay non-
progressors (i.e. individuals who never develop enough of an immunological response
to cross the threshold). This method was similar to the earlier approaches of Brook-
meyer and Quinn [17]], and Janssen et al. [47]. Later, the methodology proposed by
McDougal et al. [63] was the first to deal with assay non-progressors. They derived
an incidence formula which can be expressed in terms of the prevalence of below-
threshold seropositive, above-threshold seropositive and seronegative individuals,
and four assay calibration parameters, being the mean window period (ω), sensitiv-
ity (σ), short-term specificity (ρ1) and long-term specificity (ρ2). Introducing the
long-term specificity parameter provided a way to quantify assay non-progression.
Two other incidence paradigms that explicitly account for assay non-progressors
have since been formulated. Hargrove et al. [40] proposed a simpler incidence estima-
tor which is equivalent to the McDougal estimator when one sets σ = ρ1 . Recently,
we have also proposed a formally rigorous incidence paradigm [8], which accounts for
assay non-progression using fewer assumptions than are made by McDougal et al.
The parameters that emerge naturally in our estimator are a mean window period
and a probability of not progressing on the assay (which can also be expressed as a
long-term specificity).
A large portion of this paper is dedicated to an analysis of the assay parameters
of the McDougal methodology, showing how they are related. By using a survival
analysis formulation of the problem, we are able to write down precise expressions
for the parameters. This allows us to derive a relationship between three of the
parameters, which simplifies the McDougal estimator by showing that only ω and
ρ2, which are considerably easier to calibrate than σ and ρ1, are required in the final
formula. The reduction of the McDougal approach is important in that it shows that
all three incidence estimators are, in effect, based on the same underlying parameters
characterising the performance of the assay, and are therefore amenable to direct
comparison.
We then compare the performance of the three incidence estimators by substi-
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tuting analytic expressions for population counts, derived from a model steady state
epidemic, into the various formulae. This analysis shows that only our formula [71]
produces a bias-free result. Although the biases are typically small, we demonstrate,
using numerical examples, that there are regimes where bias may be significant.
The paper is structured as follows: We start by describing the McDougal method-
ology and, in doing so, write down mathematical expressions for the assay calibration
parameters. In the next section we restate the assumptions made by McDougal et
al. in a mathematically precise manner. This allows us to derive the identity that
shows the relationship between the parameters. We then present the three incidence
formulae and compare them by inserting the population counts from a model steady
state epidemic. We conclude the paper with a discussion of the implications of the
identity and the steady state analysis.
3.2 The McDougal Methodology
Denote the number of individuals in a cross-sectional sample who are respectively
under-threshold, over-threshold and healthy (susceptible) by NU, NO and NH. Then
the McDougal estimator [63] can be written as
I¯ =
fNU
fNU + ωNH
, (3.1)
where ω is specified in years and the “correction factor”,
f :=
Pt
Po
=
Po + ρ2 − 1
Po(σ − ρ1 + 2ρ2 − 1) , (3.2)
is the ratio of the “true” proportion Pt of recent infections and the proportion
Po = NU/(NU + NO) of the HIV positive individuals that are under the threshold.
This correction factor, which depends on subtle definitions for the sensitivity and
specificity parameters, explicitly accounts for the fact that the BED assay imper-
fectly classifies individuals as “recently infected”.
McDougal et al. calibrate these parameters using seroconversion panels which
show BED optical density as a function of time since infection (some of these are
published [79, 28]). The calibration occurs in two stages. A window period is
estimated, and then estimates of the sensitivity, short-term specificity and long-
term specificity are determined with respect to the window period.
The window period is estimated as “the mean period of time from initial sero-
conversion to reaching an ODn of 0.8” [63]. Although it is not explicitly stated, we
presume that those individuals that never reach the threshold, either because they
do not progress above the threshold or because they die before reaching the thresh-
old, are not included in the calculation of the mean. More specifically this implies
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that the window period is the mean observable threshold crossing time, conditional
on assay progression (i.e. actually reaching the threshold).
In order to calibrate the sensitivity, short-term specificity and long-term speci-
ficity, “a plot of the proportion of specimens positive in the assay versus time since
seroconversion” is generated (also later referred to as “the curve”). This is the sam-
pled survival function (essentially a Kaplan-Meier curve) in the state of being under
the threshold, conditional on being alive, which we denote SU|A(t).
The sensitivity of the test is estimated for an interval corresponding to the win-
dow period by “integrating the curve within the window”. Short-term specificity is
calculated for “the interval immediately after, and equal in duration to, the win-
dow period”. Long-term specificity is for “the period thereafter (where the curve is
flat)”. McDougal et al. explicitly make the following assumptions, with the justifi-
cation that they “are reasonable as very little attrition (from death) during the first
two time intervals after infection would be expected”:
1. “Recent infections are randomly distributed within the first window period”.
2. “The number of persons in the interval of equal duration immediately after
the mean window period equals the number in the first window period”.
3. “The remainder of the population is more than two window periods since
seroconversion”.
While it may be true in the situation being explored here, we note that it is not
a priori obvious that the choice of equal window periods ensures that SU|A(t) is flat
after twice the window period. With this in mind, we propose a generalization in
which there are two window periods with arbitrary values ω1 and ω2, chosen so that
all individuals that progress do so in a time less than ω1 + ω2 after seroconversion
(i.e. SU|A(t) is flat for t > ω1 + ω2, see the bottom graph of Figure 3.1). It should
be noted that this is a special survival curve in that it never reaches a zero value,
capturing the fact that a certain proportion of individuals will never progress above
the threshold. This is what differentiates this approach from other approaches that
do not account for assay non-progression (Such as Brookmeyer and Quinn [17],
Janssen et al. [47], and Parekh et al. [79]).
For analytical convenience, we introduce SPU|A(t), the survival of assay progres-
sors in the state of being under-threshold. We also introduce PNP, the probability of
individuals not progressing on the assay. Then SU|A(t), SPU|A(t) and PNP are related
by
SU|A(t) = (1− PNP)SPU|A(t) + PNP.
The introduction of SPU|A(t) allows us to provide a precise definition of the
window period used by McDougal et al. It is the mean time between seroconversion
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Fig. 3.1: The six sector model of McDougal et al. The top graph shows counts ni
and the bottom graph shows the survival functions SU|A(t) versus time
since infection.
and reaching threshold, for individuals who progress:
ω =
∫ ∞
0
SPU|A(t) dt. (3.3)
Assumption 1 above can only mean that infection times in the first window
period are uniformly distributed. Although Assumption 2 merely states that the
number of infections in the second window period is equal to the number in the
first, we shall see later that for ρ1 to be a property of the assay, independent of the
epidemic state, we require the stronger assumption that the infection events in the
second window period are also uniformly distributed with the same intensity as in
the first window period. We see below that this assumption is implicit in the work
of McDougal et al. To make this more explicit, we define f(t) to be the density of
times since infection realized in the sample. The number of seropositive individuals
is then given by
Nsp =
6∑
i=1
ni =
∫ ∞
0
f(t) dt,
where ni are the counts of individuals in the various categories depicted in the top
graph in Figure 3.1.
Setting f(t) = f0 over the first two window periods means that the ratio of the
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number of infected individuals in the second window period to those in the first
period is ω2/ω1. Assumption 2 is recovered when the length of the window periods
is equal. It should be noted that depends on incidence, susceptible population and
life expectancies over the history of the epidemic. With reference to Figure 3.1, we
are now in a position to write expressions for the number of seropositive individuals
in each sector:
n1 =
∫ ω1
0
f(t)(1− SU|A(t)) dt = f0(1− PNP)
∫ ω1
0
(1− SPU|A(t)) dt
n2 =
∫ ω1
0
f(t)SU|A(t) dt = f0ω1PNP + f0(1− PNP)
∫ ω1
0
SPU|A(t) dt
n3 =
∫ ω1+ω2
ω1
f(t)(1− SU|A(t)) dt = f0(1− PNP)
∫ ω1+ω2
ω1
(1− SPU|A(t)) dt
n4 =
∫ ω1+ω2
ω1
f(t)SU|A(t) dt = f0ω2PNP + f0(1− PNP)
∫ ω1+ω2
ω1
SPU|A(t) dt
n5 =
∫ ∞
ω1+ω2
f(t)(1− SU|A(t)) dt = (1− PNP)
∫ ∞
ω1+ω2
f(t) dt
n6 =
∫ ∞
ω1+ω2
f(t)SU|A(t) dt = PNP
∫ ∞
ω1+ω2
f(t) dt.
Using the above expressions, the sensitivity, the short-term specificity and the long-
term specificity are given by
σ =
n2
n1 + n2
=
(1− PNP)
∫ ω1
0 SPU|A(t) dt+ ω1PNP
ω1
ρ1 =
n3
n3 + n4
=
(1− PNP)
∫ ω1+ω2
ω1
(1− SPU|A(t)) dt
ω2
ρ2 =
n5
n5 + n6
= 1− PNP.
We can now see why the assumption of uniformly distributed infection events for
the first and second window periods is required—it is the only way in which a
cancelation of f(t) in the expressions for σ and ρ1 is possible. Note that under
bias-free recruitment into a survey, at time t = 0, we have
f(t) =
Nsp
Tsp
I(−t)H(−t)SA(t), (3.4)
where I(t) is the instantaneous incidence,H(t) is the number of healthy (susceptible)
individuals, SA(t)is the life-expectancy survival function measured from the time
since infection and
Tsp =
∫ ∞
0
I(−t)H(−t)SA(t) dt
is the total number of seropositive individuals alive in the population at the time of
the survey. The ratio Nsp/Tsp is just the fraction of the total population that has
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been recruited. Thus, the only sensible way to ensure that f(t) = f0, for t < ω1+ω2,
is to assume that the incidence and the susceptible population are constant, and the
survival function SA(t) = SA(0) = 1.
We also see why SU|A(t) must be flat after both window periods—this ensures
that SU|A(t) is constant and can be pulled out of the integrals in the expressions for
n5 and n6 as the factor PNP. This is necessary for ρ2 to be independent of f(t).
Furthermore, in order to specify ρ2 so that it is independent of the state of the
epidemic, an implicit assumption is being made that survival is the same for assay
progressors and assay non-progressors. Note that f(t) appears in the expressions for
both n5 and n6. If different life expectancies were used in these formulae, reflecting
a difference in survival for assay progressors and assay non-progressors, the f ’s in
these formulae would need to be different, and would not cancel in the expression
for ρ2. This assumption is not explicitly stated by McDougal et al. but is implicit
in their assumption that ρ2 is independent of epidemic state.
With the calibration parameters specified in the more general setting of unequal
window periods ω1 and ω2, we now generalize the expression for the correction factor
f =
Pt
Po
,
where Pt = (n1 +n2)/Nsp is the proportion of seropositive individuals who are truly
infected at a time less than ω1. Recalling that Po = (n2 + n4 + n6)/Nsp and using
the definitions of the parameters, it is easy to verify that
Po = Ptσ + Pt
ω2
ω1
(1− ρ1) +
(
1− Pt − Ptω2
ω1
)
(1− ρ2).
This means that the correction factor can be expressed as
f =
Po + ρ1 − 1
Po
[
σ − ω2ω1 ρ1 +
(
1 + ω2ω1
)
ρ2 − 1
] . (3.5)
Note that this equation simplifies to the previous expression (3.2) when one sets
ω1 = ω2.
3.3 Elimination of Parameters
For completeness, we now provide a precise specification of the assumptions that
are required in order to facilitate the analysis in the rest of this paper. We note
that with the exception of arbitrary sized window periods, these assumptions are
equivalent to the assumptions—either explicit or implicit—that are being made by
McDougal et al. [63].
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Model Assumptions. Specify window periods ω1 and ω2. We assume that:
1. The window periods are chosen so that the survival function SU|A(t) is flat
(and equal to PNP) for t > ω1 +ω2. This means that SPU|A(t) only has support
on the time interval t ∈ [0, ω1 + ω2].
2. Arrival times of infection events are uniformly distributed on the interval
[0, ω1 + ω2]. An equivalent way of stating this assumption is that over the
interval t ∈ [0, ω1 + ω2], H(t) and I(t) are constant and SA(t) = 1.
3. Survival is the same for assay progressors and assay non-progressors.
We are now able to provide the identity relating the parameters in the McDougal
approach.
Proposition 3.1. Under the model assumptions stated above, the following identity
holds:
σ − ω2
ω1
ρ1 +
(
1 +
ω2
ω1
− ω
ω1
)
ρ2 = 1. (3.6)
Proof. Since we assume that SPU|A(t) only has support on t ∈ [0, ω1 + ω2], we have∫ ω1+ω2
0
SPU|A(t) dt =
∫ ∞
0
SPU|A(t) dt = ω.
Then, simply evaluating
σ − ω2
ω1
ρ1 =
(1− PNP)
∫ ω1
0 SPU|A(t) dt+ ω1PNP
ω1
− ω2
ω1
(1− PNP)
∫ ω1+ω2
ω1
(1− SPU|A(t)) dt
ω2
=
(1− PNP)
∫ ω1+ω2
0 SPU|A(t) dt−
∫ ω1+ω2
ω1
(1− PNP) dt+ ω1PNP
ω1
=
(1− PNP)(ω − ω2 − ω1) + ω1
ω1
= 1−
(
1 +
ω2
ω1
− ω
ω1
)
ρ2,
yields the result directly. 
Using the proposition, the correction factor (3.5) simplifies to
f =
ω1
ω
Po + ρ2 − 1
Poρ2
.
This expression no longer relies on estimates for σ and ρ1. It is also interesting
to note that it does not depend explicitly on ω2. Calibrating ρ2, however, requires
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identifying individuals who have been infected for at least ω1 + ω2. Thus, ω2 need
not be precisely known, but a safe upper bound for ω1 + ω2 is required.
Furthermore, if we set ω1 = ω as in McDougal et al. then we recover
f =
Po + ρ2 − 1
Poρ2
. (3.7)
Note that (3.2) as stated in McDougal et al. contains three calibration parameters
(σ, ρ1 and ρ2), while (3.7) contains only one calibration parameter (ρ2). Incidence
estimates using (3.1) and (3.7), however, still require the estimation of ω. The
method of McDougal et al. can in principle be applied to an arbitrarily declared (as
opposed to measured) window period, as long as σ, ρ1 and ρ2 are calibrated for that
value. We have therefore reduced the number of calibration parameters by one.
Estimation of extra parameters may unnecessarily dilute the statistical power
of the calibration data at hand. Moreover, estimates of the uncertainty due to
calibration, based on the assumption of the independence of σ, ρ1 and ρ2, will be
incorrect. Note that when one sets ω1 = ω2 = ω, the identity is reduced to
σ − ρ1 + ρ2 = 1.
Substituting the estimates of the parameters found by McDougal et al., namely
σ = 0.768, ρ1 = 0.723 and ρ2 = 0.944, into this equation gives a value of 0.989 ≈ 1
for the left hand side. The slight discrepancy is a manifestation of the combined
fluctuations in the estimates of σ, ρ1, ρ2 and ω. Although ω is superficially absent
in the identity, it enters as the period over which the other parameters are defined.
When one assumes that ρ2 = 1 (corresponding to the situation where there are
no assay non-progressors) and ω1 = ω, the identity reduces to
ω(1− σ) = ω2(1− ρ1). (3.8)
and the ratio of counts over this period is given by
n1 + n2
n3 + n4
=
ω
ω2
.
Using this ratio and substituting the definitions for σ and ρ1 into (3.8), yields
n1 = n4. Therefore, for tests with perfect long-term specificity, the observed count
of individuals who are under-threshold is an unbiased estimate of the number of
infections in the last period ω. This was noted in a less general analysis of Brook-
meyer [15] where assay non-progressors were a priori excluded.
It should be noted that there is a subtlety in the definition of the window period
that emerges in the above analysis. If, instead of (3.3), the window period is defined
by
ω :=
∫ ∞
0
SPU|A(t)SA(t) dt. (3.9)
3.4 Comparison of Estimators Under Steady State Conditions 41
then the two definitions are equivalent under the model assumptions leading to
the proposition. This follows from the fact that SPU|A(t) only has support on
t ∈ [0, ω1 +ω2] and that SA(t) = 1 over that interval. We have suggested an alterna-
tive incidence estimation paradigm [71] which requires fewer assumptions than the
method of McDougal et al. In this approach PNP and ω, as defined in (3.9), emerge
as the natural calibration parameters.
3.4 Comparison of Estimators Under Steady State
Conditions
We now provide a simplified form for the McDougal incidence estimator based on
the proposition. Substituting the new correction factor (3.7) into their estimator
(3.1) and expressing the result in terms NU, NO and NH gives
I¯a =
NU − PNP(NU +NO)
NU − PNP(NU +NO) + ω(1− PNP)NH . (3.10)
where ω is specified in years. Here the subscript a indicates that the estimator is
quoted as an “annualized incidence”. Note that in writing down this expression,
we have chosen to use PNP rather than the long-term specificity as this is a biologi-
cally more intuitive parameter. In addition, the other two estimators to which this
estimator will be compared were originally specified in terms of PNP.
In a previous attempt to simplify the McDougal formula, Hargrove et al. [40]
proposed the following incidence formula
I˜a =
NU − PNP(NU +NO)
NU − PNP(NU +NO +NH) + ωNH . (3.11)
where ω is specified in years. Note that they use the symbol ε where we use PNP.
We have recently rigorously derived a weighted incidence estimator under less
restrictive assumptions than those that are required for the McDougal or Hargrove
approach [71]. Unlike the other two estimators, our estimator is expressed as a rate
(indicated by a subscript r) and is given by
Iˆr =
NU − PNP1−PNPNO
ωNH
=
NU − PNP(NU +NO)
ω(1− PNP)NH . (3.12)
To convert between an annualized incidence and an incidence expressed as a rate,
one can use the standard conversion formula
Ia = 1− e−IrT ⇔ Ir = − ln(1− Ia)
T
,
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where T = 1 year.
In Appendix 3.6 we show that, under steady state conditions, NU and NO are
specified in terms of NH and an incidence rate I as
NO = INH(1− PNP)(α− ω) (3.13)
(3.14)
and
NU = INH(1− PNP)ω + INHPNPα (3.15)
where α is the post-infection life expectancy. Using these population counts, it is
now possible to compare the performance of the incidence estimators. Substituting
(3.14) and (3.15) into the McDougal formula (3.10) yields
I¯a =
I
I + 1
.
Converting this to a rate, we have
I¯r = ln(I + 1) = I +O(I
2),
where the last step results from a Taylor series expansion. Thus the estimator is
accurate for small values of I , but yields a discrepancy at O(I2). The reason
for this discrepancy is subtle. In deriving the correction factor, McDougal et al.
assume uniform infection events over the window periods. We have shown that
this is consistent with assuming that the incidence and susceptible population are
constant. In using this factor to estimate an incidence with (3.1) they have, however,
inconsistently assumed that these infection events are generated in a susceptible
population which is being depleted by the infection events over a period of a year.
This is implied by their choice of denominator in that formula, which adds back
an annualized number of recent infections into the susceptible population. This
is at odds with the assumption of a constant susceptible population, and leads to
dimensionally inconsistent incidence estimators, (3.1) and (3.10).
To illustrate the magnitude of the bias, Figure 3.2 shows the difference between
the McDougal incidence estimate and the equilibrium incidence, expressed as a per-
centage. Note that the range of incidence values used is large (up to 50% per annum).
Although incidence for HIV is not likely to be larger than about 15% in the highest
risk groups (e.g. injection drug users [44]), if this methodology were used to monitor
other rapidly spreading epidemics, where incidence is large when stated in units of
years, it would certainly produce unacceptable bias.
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Fig. 3.2: Bias in the McDougal estimator. Relative difference between the Mc-
Dougal estimate and the equilibrium incidence plotted as a function of
equilibrium incidence.
Substituting the counts into the Hargrove formula (3.11) yields
I˜a =
I
I + ω−PNP(1−PNP)ω
,
which, when converted to a rate, gives
I˜r = ln
(
I(1− PNP)ω
ω − PNP + 1
)
= I +
PNP(1− ω)
ω − PNP I +O(I
2).
The Hargrove estimator incorporates the same form of denominator which leads
to the second order discrepancy and dimensional inconsistency in the McDougal
formula, and, in addition, it includes a linear bias term. Figure 3.3 demonstrates
the bias introduced as a function of ω and PNP for an equilibrium incidence of 5%
per annum. Although the bias is worst in the regimes where all the estimators have
little statistical power and are unlikely to be used, there are nevertheless intermediate
regimes where the bias is significant. Note that the estimator produces the same
result (and bias) as the McDougal estimator when PNP or ω = 1.
Finally, substituting the counts into our formula (3.12), which is already specified
as a rate, yields
Iˆr = I.
3.4 Comparison of Estimators Under Steady State Conditions 44
0
1
2
3
4
5
6
7
8
9
10 0.3
0.4
0.5
0.6
0.7
0.8
0.9
1
−5
0
5
10
15
20
25
30
35
 ← Zero Bias
 ← 5% Bias
Mean Window
Period (years)
 ← 10% Bias
 ← 20% Bias
Bias in Hargrove Estimator
(Equilibrium incidence=5% per annum)
Probability of not
progressing (%)
Bi
as
 (%
)
Fig. 3.3: Bias in the Hargrove estimator. Relative difference between the Hargrove
estimate and the equilibrium incidence plotted as a function of ω and
PNP for an equilibrium incidence of 5% per annum. Black lines indicate
contours of equal bias.
Thus, under the assumption of a steady state epidemic, our weighted incidence
estimator recovers the steady state incidence exactly. It is also the maximum likeli-
hood estimator. This can be seen by writing the estimator in terms of the population
proportions
Iˆr =
PU − PNP1−PNPPO
ωPH
, where PX =
NX
Nsp
,
and noting that, since the counts are trinomially distributed, the sample propor-
tions are the maximum likelihood estimates of the population proportions. We have
already seen that the estimator solves for the equilibrium incidence. Thus, by the
invariance property of maximum likelihood estimators (see e.g. p. 105 of van den
Bos [106]), it is the maximum likelihood estimator for the incidence. This has also
recently been demonstrated by Wang and Lagakos [112] by explicit maximization of
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the log likelihood function.
A weighted incidence will in general not be equal to the instantaneous incidence
under non-steady state conditions. We should, however, demand that any incidence
formula exactly recover the incidence under this rather idealized situation.
3.5 Discussion
We have shown that under a precise restatement of the McDougal et al. assumptions,
there exists a redundancy in the parameters they chose to characterise the assay.
This allows the elimination of σ and ρ1 from their estimator, with the important
advantage that the remaining parameters are easier to calibrate. The calibration
of σ and ρ1 requires obtaining specimens from individuals with confidence about
their time since infection (i.e. using frequent follow-up). On the other hand both ω
and PNP (or equivalently ρ2) can be estimated through long follow-up intervals. The
estimate for PNP is the proportion of under-threshold samples known to be obtained
more than ω1+ω2 post-infection. Given an estimate for PNP, an estimate of ω can be
obtained from data with follow-up intervals greater than ω1 +ω2 using an extended
version [54] of the Bayesian approach previously described by Welte [115].
We have also shown that under steady state conditions the only estimator that is
dimensionally consistent and produces an unbiased result is the one we have previ-
ously derived [71]. It is also the maximum likelihood estimator. The new approach
makes fewer assumptions than the other methods. In particular, it consistently ac-
counts for a dynamic epidemic by adopting a weighted definition of incidence. This
overcomes a drawback of the other two methods which assume epidemic equilibrium
for at least a period equal to the maximum progression time (ω1 + ω2). It should
be noted that this methodology is applicable to any biomarker, not only the BED
assay—all that is needed is a suitable calibration of the assay parameters. It also
follows that cross-sectional incidence estimates using this approach are applicable to
infections other than HIV, as long as suitably calibrated assays that test for recent
infection are available.
A shortcoming of all the methods explored here is that they make the assump-
tion, either implicitly or explicitly, that survival for assay non-progressors and assay
progressors is the same. As we have shown, relaxing this assumption means that
the long-term specificity becomes epidemic state dependent and hence is time de-
pendent. We are involved in ongoing work to address this issue.
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3.6 Appendix
We derive the population level counts associated with a steady state epidemic. As-
sume that the number of susceptible individuals and the incidence are constant, and
that the sample for our incidence calculation consists of the entire population. Let
the susceptible population be H(t) = NH and the incidence, expressed as a rate, be
I(t) = I. Since our sample is the whole population we have Nsp = Tsp. Then, from
(3.4) we obtain
f(t) = INHSA(t),
and the number of over-threshold and under-threshold individuals in the total pop-
ulation are given by
NO = n1 + n2 + n3
=
∫ ∞
0
f(t)(1− SU|A(t)) dt
= INH(1− PNP)
∫ ∞
0
SA(t)− SPU|A(t)SA(t) dt
= INH(1− PNP)(α− ω)
and
NU = n2 + n4 + n6
=
∫ ∞
0
f(t)SU|A(t) dt
= INH
∫ ∞
0
(1− PNP)SPU|A(t)SA(t) + PNPSA(t) dt
= INH(1− PNP)ω + INHPNPα,
where α is the post infection life expectancy. It must be stressed that the survival
functions SA(t) and SPU|A(t) are arbitrary. Thus, apart from assuming constant
incidence and susceptible population, this is a quite general model.
Chapter 4
A Simplified Formula for Inferring HIV
Incidence from Cross-Sectional Surveys Using
a Test for Recent Infection
∗ This chapter was coauthored with A. Welte and T. Ba¨rnighausen [117], and is
reproduced with permission from Mary Ann Liebert, Inc: Aids Research and Human
Retroviruses (2009) 25:125-6 DOI: 10.1089/aid.2008.0150.
4.1 Correspondence
The paper of McDougal et al. [63] is becoming a standard reference used for the
estimation of HIV incidence from applications of the BED IgG-Capture Enzyme
Immunoassay (BED assay) to cross-sectional blood samples [48, 86]. Their approach
provides an estimate for an annual risk of infection in a hypothetical cohort, using an
estimate for the true proportion, Pt, of ‘recent infections’ amongst HIV-seropositive
individuals. The estimate Pt is in turn derived from the proportion, Po, of seropos-
itive individuals in a survey who test below a threshold value for normalized BED
optical density (OD-n) [79]. The condition of being below the OD-n threshold is
declared to be an imperfect test for recent infection.
True ‘recent infection’ is defined as having been infected for less than a period
ω, where ω is the mean time individuals spend below the OD-n threshold. Since
it is well known that not all individuals progress to a given threshold, even after
arbitrarily long times, ω needs to be carefully defined as the mean threshold crossing
time amongst those who do progress. It is also known that during late stage illness,
or under the influence of antiretroviral therapy, individuals may regress to OD-n
values below the recency threshold. It is further plausible, and indeed appears to
be the case [10, 52], that the parameters characterising progression through the
BED-defined states of infection vary regionally. These complications have caused
doubt about the prospects for using the BED assay as a robustly characterisable
test for recent infection for the purposes of estimating HIV incidence, as reflected in
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a UNAIDS statement in 2006 [105] recommending it not be used for this purpose.
Hence, new assays, or combinations of assays (such as a BED and an antibody
avidity test) are being developed, to provide more robust tests for recent infection.
The fraction of individuals who progress atypically through an assay-defined class
of ‘recently infected’ may thus be reduced, but is unlikely to be zero. Therefore,
the methodology developed to deal with this problem for the BED assay appears,
at face value, to be immediately transferable, requiring only minor modification
(namely in the values of its parameters) to be applicable to other imperfect tests
for recent infection. We argue that several subtle points need to be addressed to
ensure that incidence inferences based on imperfect tests for recent infection are not
unnecessarily limited, or even in error, and we do this by a critique of the original
application.
The inter-individual variability of BED OD-n progression is captured in the
McDougal model by three parameters:
• The sensitivity (σ) of the BED assay as a test for the condition of being
‘recently infected’, as defined above.
• The short term specificity (ρ1) of the BED assay as a test for the condition
of being ‘recently infected’, when restricted to persons who have been infected
for a time between ω and 2ω.
• The long term specificity (ρ2) of the BED assay as a test for the condition of
being ‘recently infected’, when restricted to persons who have been infected
for a time longer than 2ω.
Using data from a major epidemiological and demographic surveillance study
in South Africa [99, 9], we and our collaborators are currently comparing various
approaches to HIV incidence estimation using the BED assay [10, 12]. Given the long
intervals between follow-up visits in this study (about a year), it was not possible
to calibrate the McDougal formula in its published form. Calibration of σ and ρ1
requires a follow-up interval of at most ω (which is of the order of half a year [63]).
While trying to address this issue, we discovered that a simplification of the
McDougal formula is possible. In their paper, the key result relating Pt to the
calibration parameters is given by
Pt =
Po + ρ2 − 1
σ − ρ1 + 2ρ2 − 1 . (4.1)
As is shown by McWalter and Welte in a separate short note [67], the above equation
can be simplified using the following identity:
σ − ρ1 + ρ2 = 1. (4.2)
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This identity is derived using no more assumptions than are used by McDougal
et al. to derive their formula—these assumptions are, however, stated with greater
precision in [67]. The idea that these parameters might be related was inspired by
the analysis of the incidence estimation problem undertaken in [68]. Inserting the
identity into (4.1) gives
Pt =
Po + ρ2 − 1
ρ2
. (4.3)
This means that, in order to estimate incidence, one needs only to calibrate the
long term specificity ρ2 (to estimate Pt) and the window period ω (to convert Pt
to an annual risk of infection). Unlike σ and ρ1, these can both be inferred from
infrequent follow-up. Incidentally, using the values of σ, ρ1, and ρ2 reported in [63],
we find that
σ − ρ1 + ρ2 = 0.989 ≈ 1, (4.4)
which manifests the combined fluctuations in the estimates of σ, ρ1, ρ2 and ω.
Although ω is superficially absent in the identity, it enters as the period over which
the other parameters are defined.
The appropriately simplified form (4.3) is amenable to calibration using data
obtained with long intervals of follow-up [12]. This seems to us to be an important
point, as many demographic and epidemiological surveillance studies we are aware of,
or expect to see implemented, are characterized by follow-up intervals of the order of
a year—almost ideal for calibrating the reduced formula, and clearly inadequate for
calibrating the previously published form. There is likely to be substantial data of
this sort available. On the other hand, the cost of obtaining short interval follow-up
data is high, and the opportunities for doing so are rare.
Note that even given an appropriate data set for estimating σ, ρ1, and ρ2, the
use of the naive formula, for the purpose of systematically quantifying uncertainty
due to imperfect calibration, would require additional specification of non-trivial
covariances implied by the identity (4.2).
The attraction of using a test for recent infection for HIV surveillance, pro-
gramme evaluation and policy making, lies in the fact that it allows HIV incidence
estimation from cross-sectional blood samples. Cross-sectional HIV status informa-
tion alone, however, does not allow estimation of the calibration parameters. These
must be estimated in separate studies, involving follow-up of an intensity compara-
ble to a prospective observation of incidence. Only once this has been done can the
more efficient cross sectional survey be employed on a suitably similar population.
The more robust and locally validated the calibration parameters are, the more
informative cross sectional surveys can be. Therefore it is important that the neces-
sary parameters be calibrated as widely and thoroughly as possible, using such data
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as is available. The parameters of the simplified formula are independent and can
be estimated from comparatively long interval follow-up data, while the parameters
used by McDougal et al. have non-trivial correlation and require short intervals of
follow-up.
Chapter 5
Using Tests for Recent Infection to Estimate
Incidence: Problems and Prospects for HIV
∗ This chapter was coauthored with A. Welte, O. Laeyendecker and T.B. Hallet [118].
Abstract
Tests for recent infection (TRIs), such as the BED assay, provide a convenient
way to estimate HIV incidence rates from cross-sectional survey data. Contro-
versy has arisen over how the imperfect performance of a TRI should be char-
acterised and taken into account. Recent theoretical work is providing a unified
framework within which to work with a variety of TRI- and epidemic-specific
assumptions in order to estimate incidence using imperfect TRIs, but suggests
that larger survey sample sizes will be required than previously thought. This
paper reviews the framework qualitatively and provides examples of estima-
tor performance, identifying the characteristics required by a TRI to estimate
incidence reliably that should guide the future development of TRIs.
5.1 Introduction
When monitoring HIV epidemics it is vital to estimate incidence in order to plan
and evaluate HIV programs [60]. Prospective cohort studies are the most direct way
to achieve this. They are, however, expensive, prone to recruitment and retention
bias, and potentially rendered unrepresentative by ethical obligations. The use of
prevalence data in conjunction with mathematical modelling is an alternative ap-
proach [38, 97], but is indirect and requires accurate knowledge of mortality and
migration. The disadvantages of these methods have focused attention on estimat-
ing incidence from cross-sectional surveys [17, 47, 80, 63, 40], with the result that
a number of assays and algorithms that test for recent infection have been devel-
oped [64, 74]. In the context of HIV, such an assay or algorithm has sometimes
been termed a STARHS (Serologic Testing Algorithm for Recent HIV Seroconver-
sion) [64, 74], but we prefer to use the generic term ‘test for recent infection’ (TRI),
because it does not specify a particular disease and method of testing. Recently,
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the World Health Organization (WHO) Technical Working Group on Statistical
Approaches for Development, Validation and Use of HIV Incidence Assays has pro-
posed using the term ‘recent infection testing algorithm’ (RITA). The term has not,
however, gained universal acceptance.
TRIs identify HIV-positive individuals who have been infected recently. By using
a TRI in a serosurvey, incidence (I) can be estimated by applying the epidemiological
relationship1:
I =
R
SD
,
whereR and S are the counts of ‘recently infected’ and ‘susceptible’ (HIV-uninfected)
individuals observed in the cross-sectional survey and D is the mean duration spent
in the ’recently infected’ state, often called the (mean) window period. This inci-
dence estimate is an average of the instantaneous incidence over a period of approx-
imately D prior to the survey. The problem of incidence estimation then reduces to
measuring the prevalence of ‘recent infection’, given knowledge of its duration.
TRIs usually discriminate recent from established infections by measuring spe-
cific aspects of the immune system which evolve during the course of initial infection.
For HIV, this is typically the antibody response, with the titre, proportion of HIV-
specific IgG, or antibody avidity (or a combination of these) providing quantitative
output [74]. Laboratory defined thresholds are chosen to convert these outputs into
categorical results. These results may be augmented with other clinical informa-
tion, such as CD4 lymphocyte counts and antiretroviral therapy (ART) status, to
classify individuals as either TRI-positive (P i.e. recent) or TRI-negative (N i.e.
non-recent). Positive and negative in this context should not be confused with
HIV-positive and HIV-negative.
The interaction between the virus and the immune system is complex, and indi-
viduals vary in their response to infection as assessed by a particular TRI. Modest
variation is not intrinsically problematic, but serious complications arise if, in some
individuals, the immune response is such that they remain indefinitely classified as
TRI-positive or if individuals revert back to a TRI-positive classification as a result
of advanced disease or in the presence of antiretroviral therapy. Unfortunately, both
these complications arise for TRIs currently in use. This not only limits the appli-
cability of the simple incidence estimator above, but also makes it difficult to define
and estimate the mean duration spent in the recently infected state (i.e. to evaluate
D). Methods for ‘adjusting’ estimates of incidence have been proposed [63, 40] and
adopted by the United States Centers for Disease Control and Prevention [24] but
are currently under debate [15, 39, 62, 116]. Recently, a formally rigorous framework
1 This follows directly from the classical “Prevalence = Incidence × Duration” relationship.
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has been developed [71, 69]. We provide a summary of the framework and explore
its implications for the analysis of surveys and development of new TRIs.
5.2 Theoretical Framework
We now briefly describe the theoretical framework and how it can be generalised.
The key results that emerge from the analysis are:
• A TRI is ideal if all individuals eventually progress permanently out of the
TRI-positive state before there is any disease-related mortality. In this case,
the TRI-positive category directly corresponds to a useful definition of ‘recently
infected’ [51, 71], which means that an estimate for the number of recent
infections is:
R = P.
• For a non-ideal TRI (i.e. when some individuals never progress out of the
TRI-positive state), it is in principle still possible to estimate the number of
individuals in a well-defined ‘recently infected’ state, even though this state
is not directly observable in all individuals. If PNP is the proportion of the
HIV-positive individuals who never progress on the TRI under consideration,
then an estimate for the number of recent infections is [71]:
R = P − PNP
1− PNPN. (5.1)
When the TRI is ideal, then PNP = 0, and this formula reduces to the previous
expression.
• For all applications (including determination of a trend without regard to the
absolute level of incidence), an estimate of PNP is required.
• To determine the absolute level of incidence, it is also necessary to estimate
the mean time spent TRI-positive in the subset of individuals who eventually
do progress to become TRI-negative. This quantity, which we denote by ω, is
analogous to the duration D in the simple estimator, but differs in the require-
ment that it should be estimated in the subset of individuals that progress on
the TRI.
• As PNP increases (i.e. a larger fraction of individuals fail to progress on the
TRI) and as ω decreases (i.e. individuals spend less time in the TRI-positive
state) statistical power is lost. This means that estimates of incidence will have
more uncertainty (i.e. wider confidence intervals), and it is less likely that a
true change in incidence will be detected.
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Previous work by McDougal and colleagues [63], used terminology usually em-
ployed to characterise the performance of diagnostic tests, such as sensitivity and
specificity, to characterise TRI performance. ‘Recent infection’ was defined as being
infected for less than a particular time (chosen to be the mean window period). A
sensitivity and two specificity parameters were introduced to characterise imperfect
classification. No procedure incorporating the effect of parameter uncertainty has
thus far been proposed to estimate statistical error or power for the McDougal ap-
proach. It has recently been shown that use of sensitivity and specificity parameters
is a redundant description of the TRI characteristics [69, 117]. In contrast, the new
framework defines the condition of being ‘recently infected’ directly in terms of the
TRI result. This approach is applicable under less restrictive assumptions, is less
prone to bias, and admits an equally informative description of TRI performance
using only ω and PNP [69].
In deriving the results outlined above, two assumptions were made. Firstly, it
was assumed that individuals who do not progress on the TRI have the same sur-
vival outcomes as TRI progressors. There is, however, evidence for some TRIs that
individuals that fail to progress on the test have a survival advantage2. Secondly, it
was assumed that TRI progressors never regress back to the TRI-positive state, but
there are indications that this is not true for some TRIs3. When these assumptions
are true, PNP is always equal to the proportion of non-recently infected individuals
who are classified TRI-positive. When the assumptions are violated, this propor-
tion, or false-recent rate, denoted by ε, varies according to the historic trajectory
of the epidemic4 [69, 36]. It is, however, still possible to estimate the number of
recent infections by replacing PNP, in the expression (5.1) above, with an estimate
of ε applicable to the time and place of an incidence survey [10] (See Appendix 5.6
for justification). The incidence estimator can then be written as:
I =
P − ε1−εN
ωS
. (5.2)
The inputs to this estimator are of two types: survey counts (P , N and S), which
need to be estimated in every incidence survey, and parameters that describe the
characteristics of the TRI (ω and ), which ideally are estimated in a smaller number
of parameter estimation studies.
2 For example, in Baltimore, USA, 60% of elite suppressors (individuals with naturally suppressed
virus below 50 copies per ml) failed to progress on the BED assay [57], and elite suppressors have
been observed to survive for longer than others [45].
3 For example, the rate of misclassification by the BED assay is observed to be higher in individ-
uals with advanced infection [61] and individuals on ART [61, 41, 43].
4 This would be consistent with the apparently higher BED assay false recent rate in Uganda [52]
(an older, declining epidemic) than in South Africa [10] (a younger, growing epidemic) [36].
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When ε and ω are known with sufficient accuracy, there are no theoretical rea-
sons why an imperfect TRI should not allow the accurate estimation of incidence.
However, two distinct types of practical problems arise—counting error and TRI
parameter error. An important component of recent developments is the first con-
sistent analysis of incidence uncertainty accounting for both counting and parameter
error (see Appendix 5.6 for a description of the uncertainty expression). We now
illustrate this uncertainty with a somewhat idealised model of the BED assay, which
has received much attention and application [8].
5.3 Counting Error
Even in the largest HIV epidemics, infection events are relatively rare (about 2% of
the population per year) and ’recent’ infections (infections in the last 155 days or so,
for the BED assay [63, 20]) are even less common (about 0.85% in a cross-section
of the population). Thus, estimates of incidence are associated with substantial
uncertainty since there are few recent infections to be counted. Figure 5.1 shows
the coefficient of variation (CV)5 for the estimator (5.2) calculated under various
survey sample sizes and steady-state HIV incidence rates (See Appendix 5.6 for a
description of the uncertainty and steady-state calculations). The TRI parameters
(ω and ε) are assumed to be known with absolute certainty. Low values of CV
are desirable and indicate that estimates of incidence have small confidence bounds,
while high values indicate that incidence estimates will be less certain. For example,
in a cross-sectional survey of 5000 individuals from a population with a steady-state
incidence of 2.0 per 100 person years at risk (pyar) the CV is 25.8%, i.e. the 95%
likelihood interval for an incidence estimate is 1.0–3.0 per 100 pyar.
To explore the ability to detect a change in incidence, a substantial reduction
(halving) in incidence is simulated (initially in a steady-state epidemic, with preva-
lence remaining constant between the two surveys), and a two-tailed test of the null
hypothesis that incidence is the same in the two surveys is performed. The possible
outcomes are: sustaining the null hypothesis, or concluding that incidence has ei-
ther increased or decreased. Figure 5.2 shows the probability of correctly inferring
a reduction in incidence, when testing the null hypothesis at a significance level of
α = 5%. A probability close to 100% indicates that reductions in incidence will
be reliably detected, with a probability of less than 90% indicating that results will
be unreliable. The South African National Strategic plan for HIV AIDS [95] has
ambitiously set a target of halving incidence between 2007 and 2012. Our calcula-
tions suggest that the sample size of each of two surveys (in 2007 and 2012) required
5 A coefficient of variation is the ratio of the standard deviation to the estimate.
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Fig. 5.1: The coefficient of variation of estimates of incidence using a TRI depends
on the sample size of the survey and the true incidence rate. Note that
a sample size of 10,000 approximates to the typical size of household-
based surveys in sub-Saharan Africa, and that incidence in South Africa
(where there is one of the largest epidemics) is estimated to be about 2
per 100 pyar. (Assumptions: ω = 155 days; ε = 0.05; no TRI parameter
uncertainty; steady-state epidemic conditions; mean survival with HIV:
11 years [31, 100].)
to reliably conclude that incidence has decreased, at the 5% significance level, is
approximately 25,000.
5.4 TRI Parameter Error
In the previous section, it was assumed that the correct TRI parameters were known
with certainty. The incidence estimates are very sensitive to changes in the values of
ω and ε, however, and small differences between the values used in the calculation
and the true values can lead to large errors. These parameters have to be estimated
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Fig. 5.2: The probability of detecting a reduction in incidence between two sur-
veys, when incidence has actually been reduced by half, as a function of
the sample size of the surveys (both assumed to be the same) and the
baseline incidence rate. (Assumptions: ω = 155 days; ε = 0.05;=0.05; no
TRI parameter uncertainty; significance α = 5%; steady-state epidemic
conditions at first survey, with equal prevalence at second survey; mean
survival with HIV: 11 years [31, 100].)
in separate studies, usually using cohorts of individuals whose infection time is known
approximately. Such cohorts are rare, however, and the numbers of individuals in
them are typically small, resulting in substantial uncertainty for the values of ω and
ε. In Figure 5.3 we explore the uncertainty of the estimator (expressed as a CV)6,
as a function of the uncertainty in the TRI parameters. For example, when the
BED-like parameters are known with a CV of 15.0%, at a sample size of 5000 and a
steady-state incidence of 2.0 per 100 pyar the CV, as a result of both counting error
6 Reference to a CV for ω relates to the uncertainty of the estimate of ω, not the variation
associated with progression times.
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and parameter uncertainty, is 35.7%, i.e. the 95% likelihood interval for an incidence
estimate is 0.6–3.4 per 100 pyar.
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Fig. 5.3: Coefficient of variation of incidence estimator, using a BED-like assay on
a sample size of 5,000, in a population exposed to an incidence of 2 per 100
pyar, as a function of the uncertainty in the TRI parameters, assumed to
be normally distributed. (Assumptions: ω = 155 days; ε = 0.05; steady-
state epidemic conditions; mean survival with HIV: 11 years [31, 100].)
Since the TRI parameter estimation study may be conducted in a separate pop-
ulation, it is possible to introduce systematic bias if the true values of the TRI
parameters vary between populations or over time. The few estimates of ε that
have been published vary widely7 presumably due to population differences in the
historic courses of the epidemics, viral subtypes, host immune-profiles, and uptake
of antiretroviral therapy. This undermines confidence in the ability to use an es-
timate for ε obtained in a different population to the one in which incidence is to
7 For example, the false recent rate is estimated at 1.7% in a South African survey [10] and 26.7%
in Rwanda and Zambia [52].
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be estimated, and could contribute to the apparently inflated estimates of incidence
reported recently [73, 75]. There is also currently no general theoretically unbiased
procedure for estimating ε—work on this problem is in progress [65]. In Figure 5.4
we explore the systematic error in the incidence estimate, expressed as a percent-
age of the correct value, introduced by systematic errors in the TRI parameters,
also expressed as percentages. There is a region in which bias may be small due to
cancellation of systematic errors(see the zero error contour).
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Fig. 5.4: Systematic error expressed as a percentage of the correct estimate, exclud-
ing counting error, observed in the incidence estimator, using a BED-like
assay, as a function of a precisely known systematic error in the TRI pa-
rameters. (Assumptions: ω = 155 days; ε = 0.05; steady-state epidemic
conditions; mean survival with HIV: 11 years [31, 100].)
5.5 Conclusion
In the short-term, reports from early studies using BED should be interpreted with
caution [8], given the substantial uncertainties identified above. Analysis of TRI data
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should be performed within a more general theoretical framework [71, 69], rather
than earlier methods. Most importantly, incidence surveillance should not currently
rely on any single methodology, but make use of multiple methods for estimating
incidence [30], such as interpretation of prevalence trends and epidemiological and
demographic modelling [97, 37].
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Fig. 5.5: Coefficient of variation of incidence estimator, on a sample size of 5,000, in
a population exposed to an incidence of 2 per 100 pyar, as a function of the
TRI parameters. (Assumptions: no TRI parameter uncertainty; steady-
state epidemic conditions; mean survival with HIV: 11 years [31, 100].)
The search for robust means of estimating incidence from cross-sectional surveys
is at a crucial juncture. Although an imperfect TRI can be used to estimate HIV
incidence reliably, the reliance on having accurate and precise values of two key
aspects of TRI performance (ω and ε) can undermine the use of this technology.
The effect of ω and ε on statistical power is shown in Figure 5.5. While larger val-
ues of ω provide sufficient numbers of TRI-positive individuals to ensure statistical
power, ω should not be so large that the estimated incidence is not representative
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of the recent past. On this basis, a value of approximately six months to a year
is desirable. It is also essential that ε be small8. Ideally, to ensure that the frac-
tion of misclassifications is independent of time and epidemic state, inter-individual
variability in TRI progression should be unrelated to survival outcomes, and there
should be no regression to the TRI-positive state. These form the core requirements
for the development of new TRI assays and algorithms used to estimate incidence.
In the next phase of TRI development, it will be essential to be guided by these
insights into the key determinants of test performance, and to focus on characterising
the performance of the test within a systematic framework.
5.6 Appendix
5.6.1 Justification for Replacing PNP with ε
Denote the number of non-recently infected individuals that are incorrectly classified
TRI-positive by F . The false recent rate ε is defined to be the fraction of all
non-recently infected individuals that are classified as TRI-positive, which may be
expressed in terms of F and the number of TRI-negative individuals, N , as:
ε =
F
N + F
.
This may be rearranged to provide an expression for the number of false recent
results:
F =
ε
1− εN.
An estimate of the number of individuals that are truly recent, R, is the difference
between the number of individuals that are TRI-positive, P , and the number of false
recent results, i.e.
R = P − ε
1− εN.
This is the same expression as before (5.1) with PNP replaced by ε.
5.6.2 Uncertainty Expression
An expression for the uncertainty of the incidence estimator (5.2) may be derived
using the Delta method [71]. Given the three survey counts (P , N and S), which
are trinomially distributed, and the TRI parameters (ω and ε), which are assumed
to be normally distributed (with coefficients of variation Cω and Cε), the expression
for the coefficient of variation (CV) of the incidence estimator (CI) is given by:
CI =
√
1
N + P
(
N + P + S
S
+
NP [1 + ε/(1− ε)]2
[P −Nε/(1− ε)]2
)
+ C2ω +
C2ε ε
2N2
(1− ε)4[P −Nε/(1− ε)]2 .
8 Progress in this regard is being made, for instance using TRIs consisting of an assay in combi-
nation with clinical information [56].
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This expression is used to compute 95% confidence intervals (I±1.96×CII) and
to generate the plots for Figures 5.1, 5.3 and 5.5 under the applicable assumptions.
When no TRI parameter uncertainty is assumed (Figures 5.1 and 5.5) then Cω and
Cε are set to zero. The hypothesis test simulation of Figure 5.2 consists of the
following steps:
• The counts from two surveys are pooled to generate an estimate for the inci-
dence implicit in the Null hypothesis;
• The above expression for CI is used to generate a CV for the observed difference
in the disaggregated incidence point estimates from the two surveys;
• The p value for the observed difference is computed and the Null hypothesis
sustained/rejected according to a chosen level of significance.
The plot shows the probability of obtaining incidence differences consistent with
inferring a reduction in incidence.
5.6.3 Steady-state Incidence
At equilibrium, the ratio of recent infections to non-recent infections is equal to the
ratio of mean times spent in these categories. Under the assumption that there is
no mortality in the recent category, this can be written as:
P −Nε/(1− ε)
N +Nε/(1− ε) =
ω
Ω− ω ,
where ω is the mean post-infection survival time [71].
The equilibrium prevalence is given by the product of the recruitment rate and
the mean post-infection survival:
N + P = ISΩ.
The above two equations together with the fact that the sum of P , N and S is equal
to the total number of individuals recruited in the cross-section survey uniquely
define the equilibrium counts.
Chapter 6
HIV Incidence in Rural South Africa:
Comparison of Estimates from Longitudinal
Surveillance and Cross-sectional cBED Assay
Testing
∗ This chapter was coauthored with T. Ba¨rnighausen, C. Wallrauch, A. Welte,
N. Mbizana, J. Viljoen, N. Graham, F. Tanser, A. Puren and M.-L. Newell [10].
Abstract
Background: The BED IgG-Capture Enzyme Immunoassay (cBED assay),
a test of recent HIV infection, has been used to estimate HIV incidence in
cross-sectional HIV surveys. However, there has been concern that the assay
overestimates HIV incidence to an unknown extent because it falsely classifies
some individuals with non-recent HIV infections as recently infected. We used
data from a longitudinal HIV surveillance in rural South Africa to measure
the fraction of people with non-recent HIV infection who are falsely classified
as recently HIV-infected by the cBED assay (the long-term false-positive ratio
(FPR)) and compared cBED assay-based HIV incidence estimates to longitu-
dinally measured HIV incidence.
Methodology/Principal Findings: We measured the long-term FPR in in-
dividuals with two positive HIV tests (in the HIV surveillance, 2003–2006) more
than 306 days apart (sample size n = 1, 065). We implemented four different
formulae to calculate HIV incidence using cBED assay testing (n = 11, 755)
and obtained confidence intervals (CIs) by directly calculating the central 95th
percentile of incidence values. We observed 4,869 individuals over 7,685 person-
years for longitudinal HIV incidence estimation. The long-term FPR was 0.0169
(95% CI 0.0100–0.0266). Using this FPR, the cross-sectional cBED-based HIV
incidence estimates (per 100 people per year) varied between 3.03 (95% CI 2.44–
3.63) and 3.19 (95% CI 2.57–3.82), depending on the incidence formula. Using
a long-term FPR of 0.0560 based on previous studies, HIV incidence estimates
varied between 0.65 (95% CI 0.00–1.32) and 0.71 (95% CI 0.00–1.43). The lon-
gitudinally measured HIV incidence was 3.09 per 100 people per year (95% CI
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2.69–3.52), after adjustment to the sex-age distribution of the sample used in
cBED assay-based estimation.
Conclusions/Significance: In a rural community in South Africa with high
HIV prevalence, the long-term FPR of the cBED assay is substantially lower
than previous estimates. The cBED assay performs well in HIV incidence esti-
mation if the locally measured long-term FPR is used, but significantly under-
estimates incidence when a FPR estimate based on previous studies in other
settings is used.
6.1 Introduction
To understand the dynamics of the HIV epidemic and to target and evaluate inter-
ventions to prevent HIV infection, estimates of HIV incidence at the population level
are of prime importance. HIV incidence estimates can be obtained through repeated
HIV testing of individuals in longitudinal surveillances. Such surveillances, however,
are difficult to establish and expensive to maintain. Longitudinal data on HIV sta-
tus are thus rarely available [64]. Alternatively, HIV incidence can be estimated
from changes in HIV prevalence over time. The validity of these estimates, however,
depends on assumptions about survival time distributions among HIV-positive and
-negative individuals, which are commonly quite uncertain [33, 120]. Finally, HIV
incidence can be measured in a single cross-sectional survey using laboratory tests
which distinguish recent from non-recent HIV infections, reducing the need for both
longitudinal and repeated cross-sectional measurement in order to estimate HIV
incidence [64].
In recent years, a number of large-scale cross-sectional HIV serosurveys have been
conducted. For instance, between 2001 and 2008, 20 demographic health surveys
(DHS) in developing countries have included nationally representative HIV serosur-
veys [27]. A valid and affordable laboratory procedure to distinguish between recent
and non-recent infections would allow estimation of HIV incidence in these cross-
sectional surveys. One serological method to differentiate recent from non-recent
HIV infections uses the BED IgG-Capture Enzyme Immunoassay (cBED assay),
which measures the proportion of HIV-1-specific IgG out of total IgG. This propor-
tion should increase with time after HIV seroconversion [79]. Seropositive individuals
who test below a certain threshold of this proportion (the BED threshold) are clas-
sified as recently infected, while those testing above the BED threshold are classified
as non-recently infected [79]. The time period following seroconversion after which
infections are no longer considered to be recent (the so-called window period of the
cBED assay) is usually estimated at approximately half a year [79, 63, 40].
The cBED assay has been used to estimate HIV incidence in many countries,
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including in Ethiopia [121], Rwanda [52], South Africa [86, 92], Uganda [73], Zam-
bia [52], Zimbabwe [40], China [48, 58], and the United States [78, 35]. However,
there has been concern that the cBED assay-based methods overestimate HIV in-
cidence to an unknown extent because some non-recent infections are classified as
recent [105]. In some individuals (so-called non-progressors) the proportion of HIV-
1-specific IgG never rises above the recency threshold, and in other individuals (so-
called regressors) who have been HIV-infected for a long time, the proportion may
fall below the threshold after having previously progressed above it. Regression to
levels below threshold can occur for a number of biological reasons that decrease
HIV-1-specific IgG relative to total IgG, including viral suppression and immune
reconstitution on antiretroviral treatment (ART), concurrent infections, and late-
stage HIV disease [105]. It is in principle possible to account for non-recently
HIV infected individuals who are misclassified as recently infected, but the HIV
incidence estimates will depend on the estimate of a long-term false-positive ratio
(FPR) [63, 40, 71]. All current methods for this correction effectively assume that
by some finite time after HIV infection (the maximum BED progression time) all
individuals, with the exception of non-progressors, will have progressed to the BED
threshold [71]. From previous empirical observations, it is known that the maxi-
mum BED progression time is of the order of one year [63, 40]. Thus, the fraction
of all people who have been HIV-infected at least as long as the maximum BED
progression time who are below the BED threshold is the long-term FPR.
We use data from a large population-based longitudinal HIV surveillance to
measure the long-term FPR in a rural African community with high HIV preva-
lence [119] and HIV incidence [9], and then compare HIV incidence estimates based
on the cBED assay to estimates based on longitudinal HIV surveillance.
6.2 Methods
6.2.1 Setting
We used dried blood spot (DBS) specimens which were collected in the longitudinal
population-based HIV surveillance conducted by the Africa Centre for Health and
Population Studies (Africa Centre), University of KwaZulu-Natal [2]. The HIV
surveillance area is located near the market town of Mtubatuba in the Umkhanya-
kude district of KwaZulu-Natal. The area is 438 square kilometers in size; it has
a population of approximately 85,000 almost exclusively Zulu-speaking people who
are members of about 11,000 households [99]. In 2004, the overall HIV prevalence
among residents in the surveillance area was 27% in women (15 to 49 years of age)
and 14% in men (15 to 54 years of age) [119]. The surveillance methods have
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been described elsewhere [9, 7]. Ethics permission for the HIV surveillance at the
Africa Centre was obtained from the Research Ethics Committee at the College
of Health Sciences, University of KwaZulu-Natal. All participants in the study
provided written informed consent for the analysis of their samples.
6.2.2 Samples
All women aged 15–49 years and all men aged 15–54 years who were resident in the
surveillance area at the time of visit of an HIV surveillance fieldworker were eligible
for HIV testing. Different samples were used for the different analyses conducted
for this article. The samples for estimation of the long-term FPR consisted of cBED
assay results for blood specimens contributed by individuals who tested HIV posi-
tive in the surveillance in the time period from June 2003 through June 2006. In
order to be included in the sample, the specimens had to meet the following criteria.
First, they were follow-up specimens from individuals who had previously tested
HIV-positive in the surveillance. Second, the time period between the first posi-
tive HIV test and the follow-up specimen exceeded the maximum BED progression
time. Third, the specimen was the earliest follow-up specimen that met the second
criterion. Our count of long-term false-positive individuals included all individu-
als who were classified as recently HIV-infected and had been infected for longer
than the maximum BED progression time, i.e. it included both non-progressors and
regressors.
For the further cBED assay analyses we used a maximum BED progression time
of 306 days (sample size n = 1, 065) as baseline assumption. In order to assess
the sensitivity of the long-term FPR to the assumed maximum BED progression
time, we varied progression time length from 250 to 400 days in daily intervals.
Table 6.1 shows sample size and the number of individuals who were falsely identified
as recently HIV-infected for the BED progression times when the long-term FPR
reaches its maximum and minimum and for all progression times in ten-day intervals
from 250 to 400 days.
For the HIV incidence estimation based on longitudinal HIV status information,
we included all individuals who tested at least twice for HIV in the period from June
2003 through June 2006 and whose first HIV test in this period was negative (4,869
individuals observed over 7,685 person-years). As in previous studies of HIV inci-
dence based on data from longitudinal HIV surveillances [90, 32, 50, 22, 77], for the
purpose of estimating exposure time, we used the mid-date between the last available
negative HIV test and the first available positive HIV test as an estimate of the date
of seroconversion. In addition, in order to test the robustness of the longitudinally
measured HIV incidence estimates to changes in the assumption about serocon-
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version dates, we re-estimated HIV incidence using the most extreme assumptions
about the seroconversion date that are possible given the interval-censored informa-
tion on seroconversion dates. At the one extreme, we assumed that all individuals
in the longitudinal sample who seroconverted did so on the day immediately after
the day of their last HIV-negative test. At the other extreme, we assumed that
all individuals who seroconverted did so on the day of their first HIV-positive test.
Under changes in the assumption of date of seroconversion, these two extremes yield
maximum and minimum estimates of longitudinally measured incidence.
For the cross-sectional cBED-based HIV incidence estimation, we used the first
available HIV test for all individuals tested in the time period January 2005 through
June 2006 (n = 11, 755), i.e. the period in which all second HIV tests of the people
included in the longitudinal HIV incidence analysis took place. Thus, all 4,869
individuals in the longitudinal sample are also included in the sample for the cBED
assay-based analysis.
6.2.3 Laboratory procedures
HIV status was determined by antibody testing with a broad-based HIV-1/HIV-2
enzyme-linked immunosorbent assay (ELISA; Vironostika, Organon Teknika, Boxtel,
the Netherlands) followed by a confirmatory ELISA (GAC-ELISA; Abbott, Abbott
Park, Illinois, USA) [7]. If HIV-positive status was confirmed, we used another
spot from the same filter paper as used for the initial test in order to conduct
the cBED assay (cEIA; CalypteH HIV-1 BED Incidence EIA, Calypte Biomedical
Corporation, Maryland, USA). HIV-specific IgG were detected by the BED-biotin
peptide, followed by a colour reaction with streptavidin-peroxidase. The optical
density values were normalized in every run using a calibrator (normalized OD
(ODn)=mean specimen OD/mean calibrator OD). Specimens with ODn less than
or equal to 1.2 during an initial cBED screening test were confirmed by further
cBED testing of the sample in triplicate. We took the median value of the three
confirmatory test results as the final ODn value. As specified by the manufacturer,
an HIV-1-positive specimen for which the cBED assay gave a final ODn of less than
or equal to 0.8 was considered to be a specimen of recent HIV-1 infection. Otherwise,
the specimen was classified as a non-recent infection [79].
6.2.4 Statistical analysis
Different formulae that use information obtained from the cBED assay have been
proposed to estimate HIV incidence from cross-sectional surveys. These formulae
provide incidence estimates expressed either as a rate, Iˆr, (expressed, for instance, in
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Maximum BED Sample size No. of false- Long-term
progression time positive results FPR (ε2)
(days) (individuals) (individuals) Mean 95% CI
250 1100 18 0.0164 0.0097–0.0257
260 1094 18 0.0165 0.0098–0.0259
270 1090 18 0.0165 0.0098–0.0260
280 1083 18 0.0166 0.0099–0.0261
290 1081 18 0.0167 0.0099–0.0262
300 1070 18 0.0168 0.0100–0.0265
306 1065 18 0.0169 0.0100–0.0266
310 1056 18 0.0170 0.0101–0.0268
320 1043 18 0.0173 0.0103–0.0271
330 1035 18 0.0174 0.0103–0.0273
340 1017 18 0.0177 0.0105–0.0278
350 991 17 0.0172 0.0100–0.0273
360 936 17 0.0182 0.0106–0.0289
370 818 14 0.0171 0.0094–0.0285
374 789 14 0.0177 0.0097–0.0296
380 773 14 0.0181 0.0099–0.0302
390 755 14 0.0185 0.0102–0.0309
400 737 14 0.0190 0.0104–0.0317
Tab. 6.1: Long-term FPR. (FPR = false-positive ratio, CI = confidence interval.
Row in bold font shows FPR at twice the window period of 153, 180, and
187 days, respectively.)
number of new HIV infections per 100 person-years) [71] or as the probability that in
a given year a person will acquire HIV, i.e. an incidence proportion, Iˆp, (expressed,
for instance, in number of new HIV infections per 100 people per year) [63, 40].
Some of us have previously derived a formula from first principles to estimate HIV
incidence based on the cBED assay [71], and have commented on the assumptions
made in different formulae [69, 117]. Here, we implemented four different formulae
found in the literature. The formula for HIV incidence derived by McDougal and
colleagues (McDougal formula) [63] is
Iˆp =
fR
fR+ ωN
,
where R is the number of people who were classified as recently HIV-infected by
the cBED assay and N is the number of individuals who tested HIV-negative. The
mean window period of the cBED assay, ω, is the mean period of time from initial
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seroconversion to reaching an ODn of 0.800 expressed in years in people who progress
above the BED threshold [63]. The adjustment factor
f = [(R/P )ε2]/[(R/P )(σ + ε1 − 2ε2)]
takes into account that the cBED assay does not have perfect specificity or sensi-
tivity, P is the total number of people who tested HIV-positive, σ is the sensitivity
of the cBED assay, ε1 is the short-term FPR (i.e. over the period [ω, 2ω]), and ε2 is
the long-term FPR (i.e. over all times > 2ω). Note that the short- and long-term
specificities, ρ1 and ρ2, are related to the FPRs by ρ1 = 1 − ε1 and ρ2 = 1 − ε2,
respectively. The formula of Hargrove and colleagues (Hargrove formula) [40] is
Iˆp =
R− ε2P
R+ ωN − ε2(P +N) ,
while the formula derived by McWalter and Welte (McWalter/Welte formula) [71]
is
Iˆr =
R−
(
ε2
1−ε2
)
(P −R)
ωN
.
In addition, we implemented a simplified version of the McDougal formula. The
adjustment factor used in the formula can be simplified to
f = [(R/P )ε2]/[(R/P )(1− ε2)]
using the identity
σ + ε1 − ε2 = 1
which requires no more assumptions than are used by McDougal and colleagues [69,
117].
Note that in order to implement any of the above four formulae, estimates of
the long-term FPR ε2 and the window period ω are required. For our baseline
estimation, we use an ω of 153 days, i.e. the window period that is recommended by
the manufacturer of the commercially available cBED assay. Most previous studies
reporting HIV incidence based on the cBED assay have used window periods between
150 and 160 days [63, 52, 73, 48, 58, 78, 35, 18, 34, 44, 59, 87]. A few studies have
used a window period of 180 days [121, 86, 92], and a recent study from Zimbabwe
calibrated a window period of 187 days in postpartum mothers enrolled in a Vitamin-
A intervention trial [40]. In order to test whether our results are robust to changes
in the window period estimate, we repeated our analyses with window periods of
180 and 187 days. The Hargrove and McDougal formulae require that the maximum
BED progression time is twice the window period. The estimate of the long-term
FPR thus depends on the choice of the window period (see Table 6.1).
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Note also that the Hargrove, McWalter/Welte and simplified McDougal formulae
do not require estimates of σ and ε1, which—unlike ε2—cannot be calibrated from
longitudinal data if the intervals between the last negative and the first positive
HIV test in seroconverters are of the order of one year [117]. The mean period of
follow-up among seroconverters in our study was 1.4 years; we thus used estimates of
σ (0.7680) and ε1 (0.2770) from another study in order to implement the McDougal
formula [63] (compare also [86]).
The McWalter/Welte formula expresses HIV incidence as a rate, i.e. as the num-
ber of HIV seroconversions per person-time at risk, while all other formulae express
HIV incidence as an incidence proportion, i.e. the number of HIV seroconversions
within a specified time period divided by the size of the population initially at risk.
In order to directly compare all HIV incidence estimates in our study, we expressed
the estimates based on the McWalter/Welte formula and the longitudinally measured
HIV incidence both as rates (per 100 person-years) and as incidence proportions (per
100 people per year). We translated the rate estimates into proportions, assuming
that the incidence rate, Iˆr, is constant over time T , by using the relationship
Iˆp = 1− exp(−IˆrT ).
The authors of the four different formulae do not use equivalent methods for
the calculation of confidence intervals (CIs). Thus, uncertainty analysis on the inci-
dence estimates was performed as follows. Any observed proportion of HIV-negative,
cBED-recent and cBED-non-recent individuals is an unbiased estimate of the un-
derlying population proportions. Given an observed occurrence of the population
proportions and the sample size, all attainable draws of the three counts can be
enumerated and assigned their respective trinomial probability. Hence an exact cu-
mulative probability distribution of attainable values of the incidence estimator can
be computed. For each incidence estimate, we quote the estimator evaluated at
the observed counts (the maximum likelihood estimate) and a confidence interval
expressed as the central 95th percentile.
To control for differences in the sex-age composition between the sample used in
the longitudinal HIV incidence estimation and the sample used in the cBED assay-
based estimation, we weighted the sex- and five-year age group-specific longitudinal
mean incidence rates by the proportions of individuals in each of the sex-age groups
in the sample used for the cBED assay-based estimation
Iˆrs =
∑
i
wsiIˆri,
where Iˆrs is the sex-age adjusted mean incidence rate, wsi are the proportions of
individuals in each sex-age group in the cBED assay sample, and Iˆri are the sex-age
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specific mean incidence rates. We estimated the variance of Iˆrs, var(Iˆrs), as
var(Iˆrs) =
∑
i
w2si
Iˆ2ri
Cˆi
assuming that the number of HIV incident cases, Cˆi, is Poisson distributed [29].
We calculated the 95% confidence limits for Iˆrs using the method based on gamma
distributions described in Anderson and Rosenberg [4].
6.3 Results
Long-term FPR Counting the number of DBS specimens classified as recently HIV-
infected by the cBED assay in the sample of all individuals who had a previous
positive HIV test more than 306 days before the date of the cBED assay-tested
specimen, we obtained a long-term FPR of 0.0169 (95% CI 0.0100–0.0266). When
we varied the length of the maximum BED progression time from 250 to 400 days
(in daily intervals), we found that the estimate of the long-term FPR did not change
significantly over the time interval, with minimum and maximum long-term FPRs
of 0.0164 (95% CI 0.0097–0.0257) and 0.0190 (95% CI 0.0104–0.0317), respectively
(Table 6.1).
6.3.1 Incidence comparison
Of the 4,869 individuals included in the sample for longitudinal HIV incidence mea-
surement, 224 people seroconverted in 7,685 person-years. Assuming that serocon-
version occurred at the mid-date between the last available negative HIV test and
the first available positive HIV test, longitudinally measured crude HIV incidence
was 2.87 per 100 people per year (95% CI 2.53–3.27) (Table 6.2). Longitudinally
measured HIV incidence increased to 3.09 per 100 people per year (95% CI 2.69–
3.52), when we adjusted it to the age-sex distribution of the sample for the cBED
assay-based incidence estimate.
Of the 11,755 individuals included in the sample for the cBED assay-based HIV
incidence measurement, 9,236 tested HIV-negative and 2,519 HIV-positive. Of the
individuals who tested HIV-positive, 165 were classified in cBED assay testing as
recently HIV-infected and the remainder as non-recently infected. For given ε2
and ω, the four different formulae to calculate HIV incidence from cBED assay
measurement produced very similar results. Using the baseline estimate for ω of
153 days and the locally measured ε2 of 0.0169, HIV incidence point estimates (per
100 people per year) varied between 3.03 (95% CI 2.44–3.63; McDougal formula)
and 3.19 (95% CI 2.57–3.82; Hargrove formula) (Table 6.2). The cBED assay-based
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HIV incidence estimates were thus very similar in magnitude and did not differ
significantly from the estimates based on longitudinal measurement (crude and sex-
age adjusted) (Table 6.2). Furthermore, when we implemented the cBED assay
formulae using the lower bound or upper bound of the 95% CI of the locally measured
long-term FPR (0.0100–0.0266), the cBED assay-based HIV incidence estimates
did not differ significantly from the estimates based on longitudinal measurement.
By contrast, when we implemented the cBED assay formulae using the externally
measured long-term FPR of 0.0560 [63], all four cBED assay-based HIV incidence
estimates were significantly lower than the longitudinal estimates (Table 6.2).
Our finding that the cBED assay-based HIV incidence estimate was not sig-
nificantly different from the longitudinal HIV incidence estimate did not change
when we applied the window periods of 180 and 187 days (and their corresponding
long-term FPRs of 0.0182 and 0.0177 (see Table 6.1)). Using the McWalter/Welte
formula, the cBED assay-based HIV incidence was estimated at 2.63 per 100 peo-
ple per year (95% CI 2.10–3.18) with a 180-day window period and at 2.56 per
100 people per year (95% CI 2.04–3.08) with a 187-day window period. Neither
of these estimates was significantly different from the longitudinally measured HIV
incidence estimates or from the cBED assay-based incidence estimates based on a
153-day window period (see Table 6.2).
As described above, we conducted sensitivity analysis of the longitudinally mea-
sured HIV incidence estimate by changing the assumption about seroconversion
dates. Assuming that all seroconverters became HIV-seropositive on the day follow-
ing the last negative HIV test, crude HIV incidence was estimated at 2.97 per 100
person-years (95% CI 2.61–3.39). Assuming, on the other hand, that all serocon-
verters became HIV-seropositive on the day of their first positive HIV test, crude
HIV incidence was estimated at 2.85 per 100 person-years (95% CI 2.51–3.25). The
longitudinal HIV incidence estimates were thus highly robust to changes in the ap-
proach to computing the seroconversion date. Even under the most extreme possible
assumptions, the mean HIV incidence changed by only 2% of the estimate based on
the mid-date assumption, as reported in Table 6.2.
When we stratified HIV incidence by sex and five-year age group (starting at
15 years of age), we found that none of the cBED assay-based sex and age-specific
estimates differed significantly from the corresponding longitudinally measured sex
and age-specific estimates. However, our samples in each of the sex-age groups were
too small to detect significant differences with reasonable confidence. The coefficients
of variation (CVs) of the sex-age specific cBED assay-based HIV incidence estimates
ranged from 18% to 203%; in 13 of the 15 sex-age groups the CVs were larger than
25%; in 10 sex-age groups the CVs were larger than 50%; and in 4 sex-age groups
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Estimation type Units HIV incidence
Mean 95% CI
Longitudinal measurement (7,685 person-years, 224 seroconversions)
Crude (per 100 person-years) 2.91 2.56–3.32
Sex-age adjusted (per 100 person-years) 3.14 2.73–3.58
Crude (per 100 people per year) 2.87 2.53–3.27
Sex-age adjusted (per 100 people per year) 3.09 2.69–3.52
cBED assay measurement (n = 11,755)
Mean of locally measured long-term FPR (ε2 = 0.0169)
McWalter/Welte (per 100 person-years) 3.22 2.57–3.87
McWalter/Welte (per 100 people per year) 3.17 2.54–3.80
McDougal (per 100 people per year) 3.03 2.44–3.63
Hargrove (per 100 people per year) 3.19 2.57–3.82
McDougal, simplified (per 100 people per year) 3.12 2.51–3.73
Lower bound of 95% CI of locally measured long-term FPR (ε2 = 0.0100)
McWalter/Welte (100 person-years) 3.65 3.00–4.32
McWalter/Welte (per 100 people per year) 3.58 2.95–4.22
McDougal (per 100 people per year) 3.40 2.82–4.00
Hargrove (per 100 people per year) 3.57 2.95–4.19
McDougal, simplified (per 100 people per year) 3.52 2.91–4.14
Upper bound of 95% CI of locally measured long-term FPR (ε2 = 0.0266)
McWalter/Welte (100 person-years) 2.60 1.96–3.27
McWalter/Welte (per 100 people per year) 2.57 1.94–3.22
McDougal (per 100 people per year) 2.49 1.89–3.11
Hargrove (per 100 people per year) 2.63 1.99–3.29
McDougal, simplified (per 100 people per year) 2.53 1.92–3.17
Externally measured long-term FPR (ε2 = 0.0560)
McWalter/Welte (100 person-years) 0.65 0.00–1.33
McWalter/Welte (per 100 people per year) 0.65 0.00–1.32
McDougal (per 100 people per year) 0.66 0.00–1.33
Hargrove (per 100 people per year) 0.71 0.00–1.43
McDougal, simplified (per 100 people per year) 0.65 0.00–1.32
Tab. 6.2: HIV incidence estimates. (CI = confidence interval, FPR = false-positive
ratio.)
they were larger than 100%.
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6.4 Discussion
In a rural community in South Africa, we found a long-term FPR of the cBED
assay of 0.0169. This value is substantially lower than the two previous estimates
of the ratio. The first estimate (0.0560) was based on analysis of specimens from
longer-term-infected individuals not known to have clinical AIDS, opportunistic in-
fections, or to be on treatment in the USA [63]. The article, in which this value
was published, provides neither the sample size for the measurement nor the con-
fidence limits around the estimate [63]. Thus we cannot test whether the estimate
is significantly different from the value that we measure in rural South Africa. The
second estimate (0.0520) was based on specimens from 2,749 postpartum mothers
enrolled in a Vitamin-A intervention trial in Zimbabwe [40]. This second estimate
was significantly higher than the value measured in our study (p < 0.0001).
Many previous studies have used the first estimate of the long-term FPR in their
estimations of HIV incidence based on cross-sectional cBED assay surveys (e.g. [52,
86, 73, 58]). In comparing cBED-based HIV incidence estimates to HIV incidence
measured longitudinally in the same population, we have demonstrated that, had
we used the long-term FPR of 0.0560, we would have significantly underestimated
HIV incidence in this community. By contrast, using the locally measured ratio of
0.0169, we estimated an HIV incidence that does not differ significantly from the
longitudinally measured incidence.
Our findings thus confirm the previous results by McDougal et al. [63] and Har-
grove et al. [40] that cBED assay-based HIV incidence estimates are not significantly
different from longitudinally measured HIV incidence, when a locally calibrated long-
term FPR ratio is used to adjust for the imperfect long-term specificity of the cBED
assay. At the same time, we have shown for the first time that the long-term FPR
differs significantly across settings. Hence, results from studies that use a long-term
FPR measured in another setting should be viewed with skepticism.
We further found that the different formulae to estimate HIV incidence based on
the cBED assay results, did not produce significantly different values even though
they differ in their underlying assumptions, suggesting that the choice of formula
may not be very important for most practical purposes. Finally, we showed that the
estimates of the long-term FPR based on data from a longitudinal HIV surveillance
are very robust to changes in the definition of long-term (i.e. the choice of the
maximum BED progression time).
Our longitudinal HIV incidence estimates in this article are slightly lower than
previously published estimates from the same community [9], because the current
study uses a sample that is different from the one used previously. In particular,
unlike in the previous study, we excluded from the sample people who were identified
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as members of a household in the study area, but who did not themselves live in the
area. We excluded this population group (which faces a significantly higher risk of
HIV acquisition than household members who live in the study area [7]), because
cross-sectional cBED assay surveys usually do not trace such nonresident household
members.
HIV incidence estimates by sex and age group are important for validating the
cBED assay method as an approach to measure HIV incidence [40], and are an
important disaggregation for health policy and planning, e.g. in order to inform the
targeting of HIV prevention interventions. Our current sample lacked the statistical
power to meaningfully stratify the HIV incidence estimates. As more data becomes
available from our site, we will in the future analyze HIV incidence across population
subgroups.
The promise of the cBED assay for HIV surveillance, program evaluation and
policy making, lies in the fact that it allows HIV incidence estimation from cross-
sectional samples. Cross-sectional HIV status information, however, does not permit
estimation of the long-term FPR, requiring researchers to obtain this parameter
independently. It is thus important that the parameters necessary for HIV incidence
estimation are calibrated using data from those settings where longitudinal follow-
up is available. A meta-analysis of the long-term FPR of the cBED assay may help
explain why the parameter estimates differ and allow the determination of valid
regional parameter estimates.
It may further be necessary to measure the long-term FPR repeatedly over time.
For instance, one of the reasons why people with non-recent HIV infections are
falsely classified as recently infected by the cBED assay is viral suppression due to
ART [25]. In October 2004, ART started to become available through the public
health services in the community in which this study took place. However, only a
very small number of patients received ART during the study period. By the end of
December 2005, i.e. half a year before the end of the study period, approximately
500 patients received ART through the public ART programme in the district in
which this study took place. Because the HIV surveillance covers less than half of
the district population, we estimate that in December 2005 less than 250 people
in the surveillance area were receiving ART out of a total resident population of
approximately 65,000 [42]. Future studies will need to investigate whether our locally
estimated cBED long-term FPR changes with increasing ART coverage.
An alternative to using the long-term FPR in order to adjust cBED assay-based
HIV incidence estimates for the presence of people who are falsely classified as
recently HIV-infected is to use additional information on time since seroconversion
to identify these individuals and correct the misclassification. Information on time
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since seroconversion, which can be obtained in cross-sectional surveys, could be
based on biological parameters that change with time since infection (such as CD4
count, total lymphocyte count, or viral load), clinical assessment (such as screening
for HIV-related diseases that indicate late-stage HIV disease [123]), and screening
for ART (through a question or laboratory test).
In conclusion, our study demonstrates that without a locally measured long-term
FPR HIV incidence estimates based on the cBED assay may be severely biased,
but that the cBED assay performs well in HIV incidence estimation, if a locally
appropriate long-term FPR is used.
Chapter 7
HIV Incidence Estimation Using the BED
Capture Enzyme Immunoassay: Systematic
Review and Sensitivity Analysis
∗ This chapter was coauthored with T. Ba¨rnighausen, Z. Rosner, M.-L. Newell and
A. Welte [8], and is reproduced with permission from Wolters Kluwer Health (Right-
slink licence no. 2597010845421): Epidemiology (2010) 21:685-97 DOI: 10.1097/
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Abstract
Background: HIV incidence estimates are essential for understanding the evo-
lution of the HIV epidemic and the impact of interventions. Tests for recent
HIV infection allow incidence estimation based on a single cross-sectional survey.
The BED IgG-Capture Enzyme Immunoassay (BED assay) is a commercially
available and widely used test for recent HIV infection.
Methods: In a systematic literature search for BED assay studies, we identified
1,181 unique studies, 1,138 of which were excluded based on titles or abstracts.
We conducted reviews of the 43 remaining publications and a further 23 studies
identified on conference web sites or by colleagues. Thirty-nine articles were
included in the final review. We investigated the sensitivity of incidence values
to various estimation methods and parameter choices.
Results: BED assay surveys have been conducted on five continents in general
populations and high-risk groups, using one or more of ten distinct incidence
formulae. Most studies used estimators that do not account for assay imper-
fection. Those studies that correct for assay imperfection commonly do not
use locally-valid assay parameters. Incidence estimates were very sensitive to
methodological and parameter choices. Most confidence intervals provided good
assessment of uncertainty due to counting error, but only a few incorporated
parameter uncertainty.
Conclusions: BED assay surveys can produce valid HIV incidence estimates,
but many studies have not sufficiently accounted for assay imperfection. Fu-
ture studies should (1) report all information necessary for incidence point and
7.1 Introduction 78
uncertainty estimation, (2) use an unbiased estimator with locally-valid assay
calibration parameters, and (3) compute confidence intervals that take into ac-
count parameter uncertainty.
7.1 Introduction
Estimates of HIV incidence—the rate of new infections in a population—are essen-
tial for monitoring the progress of HIV epidemics and for targeting and evaluating
interventions that prevent HIV acquisition and transmission. Incidence estimates
can be obtained through repeated testing of individuals in longitudinal surveillance.
Such surveillances are, however, difficult to establish and costly to maintain; they
may suffer from bias due to loss to follow-up [13] and they lack generalizability
because participant behavior may change following risk-reduction counselling. An
operationally-less-demanding approach to the estimation of incidence relies on tests
that distinguish recent from non-recent infection in cross-sectional data.
While several tests for recent HIV infection have been developed [81, 64, 74, 98,
6], the BED IgG-Capture Enzyme Immunoassay (BED assay) has been frequently
applied, especially in developing countries [92, 73, 48, 44]. From the time of the
development of the BED assay in 2002 [79], there has been debate over how to
correctly analyze the data generated by use of this assay. Recently, a number of
authors have examined biases in the application of the BED assay using population
models of HIV infection [15, 36, 116, 69]. Others have estimated the bias in large
population-based surveys [11, 10].
We undertook a systematic review of the literature to survey the current practice
in BED-assay application and to identify how the concerns regarding the accuracy
of the test are being addressed. We present an overview of the current literature and
collect information on methodological choices that are made in applying the assay.
We show how sensitive the BED assay-based incidence estimates are to changes in
methodology, including the incidence formula and calibration parameter values.
7.1.1 Basic Description of the BED Assay
The BED assay was developed by researchers at the US Centers for Disease Con-
trol and Prevention (CDC) for the purpose of identifying recently acquired HIV-1
infections regardless of viral subtype [79]. This was accomplished by producing a
class-specific IgG antibody capture enzyme immunoassay (EIA) based on a trimeric
branched peptide that includes gp41 immunodominant sequences from HIV-1 sub-
types B, E and D—hence the name. The BED assay reports the proportion of HIV-
1-specific immunoglobulin G (IgG) in total IgG as an optical density (OD) from
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spectrophotometer measurements. To minimize the variations that occur in differ-
ent runs, a normalized OD (OD-n) is determined using a calibrator specimen [79].
The proportion of HIV-1-specific IgG (and thus OD-n) increases with time after HIV
infection.
Two major health organizations, the CDC and the United Nations Program on
AIDS (UNAIDS), have issued statements regarding the use of the capture BED as-
say. While endorsing the assay for use in the US, the CDC recommendation [25]
lists several situations in which the assay can produce false-recent results (i.e. non-
recently infected individuals that are falsely classified as recently infected), including
advanced HIV disease, chronic co-infection, and antiretroviral therapy. The state-
ment concludes that “the BED HIV-1 Capture EIA was developed for and is solely
used in the US in the context of HIV surveillance” and that the assay “may be
less successful in a specimen-based system where [...] critical data cannot be as-
certained.” The most recent UNAIDS recommendation [105] concluded that “the
BED-assay captures not only recent infections, but also late stage HIV infection
(with or without antiretroviral therapy)” and that “[t]here is evidence that assay
characteristics vary by HIV-1 subtype”. UNAIDS thus called for “more research on
the validity of the BED assay for estimating incidence” [105]. Neither the CDC nor
UNAIDS have commented on the use of the assay since 2007.
7.1.2 Development of Incidence Estimators
To discriminate recent from non-recent infections, an OD-n threshold value (or cut-
off) is chosen below which a specimen is classified as recently infected-specimens
with an optical density above this value are classified non-recent. To estimate HIV
incidence it is necessary to determine the mean length of time individuals remain
classified as “recently infected” by the assay. This duration is usually called the
“mean window period”; we denote it by ω. Estimating ω requires a calibration co-
hort study with frequent follow-up of individuals whose date of infection is approxi-
mately known. Using the well-known relationship between prevalence, incidence and
duration, incidence is then estimated as the ratio of the sample count of recently
infected individuals to the product of the count of susceptible individuals and the
mean window period.
Following initial applications, it was discovered that the BED assay is an im-
perfect test, misclassifying some proportion of non-recently-infected individuals as
recent. Two strategies have been used to correct for this shortcoming. The first
corrects for assay imperfection on the level of the individual by using additional
information (e.g. antiretroviral therapy [ART] utilization, AIDS diagnosis and pre-
vious HIV testing) to either re-classify or exclude individuals who are classified as
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recent by the BED assay but are obviously non-recently infected (false-recent in-
dividuals). The second strategy corrects for assay imperfection at the population
level, using incidence estimators that account for imperfect specificity of the BED
assay.
A number of estimators have been proposed. In order to structure our review, we
categorize the estimators into three “generations” (Figure 7.1). First-generation ap-
proaches include all simple applications of the prevalence-incidence relationship de-
scribed above, making no attempt to account for false-recent individuals [79, 17, 47].
This approach results in overestimates of incidence if a substantial number of people
are incorrectly classified as recent. The second-generation approach was initiated
by McDougal and colleagues [63]. To account for BED assay imperfection, they
introduced three additional assay-calibration parameters, i.e. sensitivity (σ), short-
term specificity (ρ1) and long-term specificity (ρ2). The third-generation approach
builds on the second-generation approach by simplifying the expressions. Whereas
the second generation formulae depend on four parameters (ω, σ, ρ1 and ρ2), the
third-generation approaches require only the window period and a false-recent rate
(ε), which can be expressed in terms of the long-term specificity, ε = 1−ρ2. Alterna-
tive names for the false-recent rate include false-positive rate [63], and false-positive
ratio [10]. Note that while most authors refer to this parameter as a “rate”, it is
in fact the ratio of two counts (the number of persons with long-standing infec-
tion classified incorrectly as recent, and the total number of individuals with long-
standing infection). Hargrove et al. [40] provided a new estimator that is equivalent
to the McDougal estimator under the assumption that the sensitivity is equal to
the short-term specificity. Later, Welte et al. [117] showed a formal mathematical
relationship, different from Hargrove’s assumption, between sensitivity, short-term
specificity, and long-term specificity. This insight allows a consistent reduction of
the McDougal estimator, and highlights the fact that the calibration parameters of
the McDougal approach are not independent—ω and ε provide an equally-precise
characterization of the performance of the assay when compared with the four pa-
rameters of the McDougal estimator. This over-parameterization in the McDougal
approach may introduce unnecessary statistical uncertainty if the parameters are
estimated independently, and makes it difficult to characterize the uncertainty in
a consistent manner. McWalter and Welte [71] have derived a formally-consistent
incidence relation that depends on fewer assumptions than either the McDougal or
Hargrove approaches. More recently it has been shown that the approach of McWal-
ter and Welte, when compared with the other third-generation approaches, is the
only one that produces an unbiased estimate of incidence under the assumption of
a steady state epidemic [69].
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Fig. 7.1: Overview of approaches, required parameters and formulae used to esti-
mate HIV incidence from cross-sectional surveys using the BED assay.
7.2 Methods
7.2.1 Literature Search Strategy
We carried out a systematic literature search in the PubMed electronic database [85].
To identify articles, we combined search themes using the Boolean operators “and”
and “or”: HIV “and” (BED assay “or” recent infection). Wherever possible, we
drew search terms for each theme from the Medical Subject Headings (MeSH) [72],
the controlled vocabulary used for subject indexing in PubMed:
("HIV"[MeSH] OR "HIV-1"[MeSH] OR "HIV-2"[MeSH] OR
"HIV Seroprevalence"[MeSH] OR "HIV Seropositivity"[MeSH])
AND
("IgG capture"[All Fields] OR "BED"[All Fields] OR
"CEIA"[All Fields] OR "EIA"[All Fields] OR
"IgG immunoassay"[All Fields] OR "immunoglobulin G"[MeSH] OR
"recency"[All Fields] OR "recent infection"[All Fields] OR
"incidence"[MeSH]).
We used all MeSH terms in their “exploded” versions so that all narrower terms
categorized below each selected term in the vocabulary hierarchies were also included
in the searches. In addition, we searched for terms that did not exist in MeSH using
the “All Fields” category of the PubMed electronic database.
The development of the BED assay was first described by Parekh et al. [79] in a
publication dated March of 2002. To ensure that we included all articles describing
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studies using the assay, we searched for articles published on or after the 1st of March
2000, i.e. two years prior to the publication describing the development. Our search
period ended on the 4th of March 2009. In addition to PubMed, we searched the
websites of the Conference on Retroviruses and Opportunistic Infections (CROI)
(covering all CROI from January 1997 to March 2009) [1] and the International
AIDS Society (IAS) (covering all Conferences on HIV Pathogenesis and Treatment,
and all International AIDS Conferences (AIDS) from 2001 through 2008) [46] for
abstracts containing the terms “BED”, “cBED”, “CEIA”, “EIA”, “immunoglobulin
G”, “IgG immunoassay”, “recency” and “recent infection”. These terms were also
used to search the National Library of Medicine Gateway (NLM Gateway) [76],
which includes abstracts from twenty-nine HIV-related conferences [76]. We further
searched the reference lists of reviews, editorials, commentaries and all publications
included in the final review. Finally, we asked colleagues with a research interest
in HIV epidemiology or prevention to identify studies that report findings based on
BED assay surveys.
Our initial PubMed search identified a total of 1181 unique studies, 1138 of which
were excluded based on titles or abstracts. Studies were excluded at this stage if
they did not report HIV incidence estimates, reported only HIV incidence estimates
that were not based on BED assay surveys, or did not specify the populations in
which a BED assay-based HIV incidence estimates were obtained. Studies were
further excluded if they were not written in English, or were reviews, letters, edito-
rials or commentaries. We conducted full-text reviews of the forty-three remaining
publications and twenty-three studies identified in conference abstract databases, in
NLM Gateway, or by colleagues. The only reason for exclusion after full-text review
was that studies reported only HIV incidence estimates that were not based on BED
assay surveys. We did not identify any studies through screening of references that
were not also identified in one of the other searches. Four conference abstracts were
excluded because they reported data contained either in a full-text article or in an
abstract with a later publication date.
We identified thirty-nine studies for the final review—a summary is provided in
Figure 7.2.
7.2.2 Sensitivity Analysis
In order to explore the robustness of the incidence estimates to various method-
ological and parameter choices, we performed a number of sensitivity analyses. For
each of the full-text articles that reported the formula, parameter values and sur-
vey counts used in incidence estimation, we recomputed incidence. To explore the
sensitivity with respect to choices of methodology, we computed incidence using
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Fig. 7.2: Flow chart of search and selection criteria for studies included in the final
review.
all the different estimators found in the literature, in each of the three generations
mentioned above.
It has been noted that the incidence estimate is sensitive to the choice of cali-
bration parameters [10, 40]. In particular, a locally-valid estimate of the long-term
specificity is necessary because overestimates and underestimates of incidence can
occur when false-recent results are not appropriately accounted for. For this reason,
we explore the sensitivity of the incidence estimates to changes in both the window
period and the false-recent rate (alternatively, the long-term specificity).
When presenting incidence estimates, it is important that the variability of the
estimate be stated as a confidence interval (CI). We computed CIs under a variety
of assumptions in order to explore the effect of the parameter uncertainty, using a
closed-form expression for the coefficient of variation of the estimator derived with
the delta method [71], which assumed parameter error was distributed normally.
For the calibration-parameter and CI sensitivity analyses, we used the incidence
estimator of McWalter/Welte, because it is the least biased of the estimators [69]
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and is the only estimator with an expression for standard deviation that incorporates
the effect of parameter uncertainty [71].
7.3 Results
From each of the thirty-nine studies, we extracted information on study character-
istics and results, as displayed in Table 7.1 and Figure 7.3 and described below.
Additional survey data, only available for the full-text articles, is shown in Table 7.2
and described below.
(1), (35) – (39)
(32)
(1)
(3) – (7) 
(21), (31)
(24)
(27) – (30) (25) – (26)
(23) – (24)
(22)
(20)
(8) – (14)
(15) – (17)
(21) (18) – (19)
(2)
(33) – (34)
 
 
(1) United States, The Netherlands (MSM, high-risk women) 1998-1999; (2) Russia (IDU) NR; (3) China (IDU) 2000-2006; (4) China (IDU) 2002-2005; 
(5) China (MSM) 2005-2006; (6) China (CSW) NR; (7) China (CSW) NR; (8) Thailand (military) 1991; (9) Thailand (IDU) 1996; (10) Thailand (IDU) 1999-2000; 
(11) Thailand (ANC, CSW) 2004-2005; (12) Thailand (military) 2005-2006; (13) Thailand (GP) NR; (14) Thailand (military, IDU) NR;  
(15) Cambodia (CSW, ANC, police) 1999-2002; (16) Cambodia (GP) 2006; (17) Cambodia (fishermen) NR; (18) India (STD) 2002-2004; (19) India (IDU) NR; 
(20) Ethiopia (ANC) 1995-2003; (21) Ivory Coast, Kenya (ANC, GP) 1998-2004; (22) Uganda (GP) 2004-2005; (23) Rwanda (ANC) 1989-1993; 
(24) Rwanda, Zambia (discordant couples) 2004; (25) Zimbabwe (postpartum mothers) 1997-2000; (26) Zimbabwe (GP) NR; (27) South Africa (GP) 2003-2006; 
(28) South Africa (GP) 2005; (29) South Africa (GP) 2005; (30) South Africa (GP) 2006-2007; (31) Ivory Coast (blood donors) 1997-2003; 
(32) Dominican Republic (CSW) 2004-2005; (33) Brazil (GP) 2004-2005; (34) Brazil (MSM) 2004-2005; (35) United States (ANC) 1991-1998; 
(36) United States (MSM) 2000-2003; (37) United States (MSM, STD, non-IDU) 2002-2004; (38)  United States (STD) 2004-2005; (39) United States (GP) 2006. 
 
Key: MSM indicates men who have sex with men; IDU, intravenous drug users; NR, not reported; CSW, commercial sex workers; ANC, antenatal care clinic 
attendees; GP, general population; STD, sexually transmitted disease clinic attendees. 
Fig. 7.3: Map showing location, population and observation period of 39 studies.
Location, Population Setting, Study Type and Assay
Thirty-nine relevant studies were published between 2003 and 2009 (twenty full-text
articles and nineteen abstracts) (Figure 7.2 and Table 7.1). In these studies, the BED
assay was used to assess HIV incidence in regions throughout the world. Seventeen
studies used data from Asia [44, 88, 89, 96, 103, 111, 110, 113, 114, 124, 48, 82, 104,
58, 49, 5, 94], twelve from Africa [19, 40, 52, 73, 86, 87, 92, 93, 121, 10, 101, 55], six
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Tab. 7.1: Descriptive table.
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  Authors Window Year Effective Sensitivity Short-term Long-term HIV- HIV+ BED+ 
    period length window   specificity specificity# (N) (P) (R) 
  Bärnighausen et al. 153 365.00 0.4192 - - 0.9831 9236 2519 165 
  Buchacz et al. 155 365.25 0.4244 - - 1 268 187 11 
  Gupta et al. 153 365.25 0.4189 - - 1 463 16 2 
  Hall et al.† 156 365.00 0.4274 NR NR NR NR 6864 2133 
  Hargrove et al. 187 365.00 0.5123 - - 0.9480 9562 4495 517 
  Hu et al. 160 365.00 0.4384 - - 1 1375 594 113 
  Jiang et al. (City D All) 155 365.00 0.4247 - - 1 2811 433 25 
  Jiang et al. (City D IDU) 155 365.00 0.4247 - - 1 585 275 25 
  Karita et al. (Masaka) 153 365.00 0.4192 0.7680 0.7230 0.9440 1191.8‡ 151 39 
  Karita et al. (Kakira) 153 365.00 0.4192 0.7680 0.7230 0.9440 1752.6‡ 190 47 
  Li et al. (Data for 2005) 155 365.00 0.4247 0.7682 0.7231 0.9443 509 17 7 
  Li et al. (Data for 2006) 155 365.00 0.4247 0.7682 0.7231 0.9443 515 26 9 
  McDougal et al.† 153 365.00 0.4192 0.7680 0.7230 0.9440 NR NR NR 
  Mermin et al. 155 365.00 0.4247 0.7680 0.7230 0.9440 16331.5‡ 1023 172 
  Nesheim et al. 160 365.25 0.4381 - - 1 48018 554 50.2§ 
  Priddy et al. 153 365.00 0.4192 - - 1 2136 66 12 
  Rehle et al.† 180 365.00 0.4932 0.7682 0.7231 0.9443 NR NR NR 
  Sakarovitch et al.† 160 365.00 0.4384 0.8570 0.7710 NR NR NR NR 
  Saphonn et al.† 168 365.00 0.4603 - - 1 NR 3599 NR 
  Shisana et al.† 180 365.00 0.4932 - - 1 NR NR 181 
  Simbayi et al.† 180 365.00 0.4932 0.7682 0.7231 0.9443 NR NR NR 
  Wolday et al.† 180 365.00 0.4932 - - 1 6394 1350 NR 
  Xiao et al. (IDUs) 153 365.00 0.4192 - - 1 945 225 34 
  Xiao et al. (County B) 153 365.00 0.4192 - - 1 6482 825 116 
    
  Table does not include studies for which only abstracts were available because abstracts did not include the required information. 
    
  Key: NR indicates not reported.
  †Insufficient data to recompute incidence.   
  ‡Adjustment for HIV+ individuals with missing BED samples. 
  §Non-standard adjustment for HIV+ individuals with missing BED samples. 
  # Long-term specificity = 1 − false recent rate. A specificity of 1 indicates use of a first-generation approach (i.e. a false-recent rate of 0). 
 
Tab. 7.2: Calibration information and sample counts.
from North America [35, 78, 84, 63, 18, 102], two from South America [107, 108], and
two from Europe [63, 109]. One study used data from more than one geographical
region [63]. Eleven studies were conducted in the general population [89, 5, 73, 86, 92,
93, 10, 101, 55, 35, 108] seven in intravenous drug users [44, 96, 113, 114, 124, 48, 109],
six in antenatal care (ANC) attendees [88, 82, 19, 121, 55, 78] five in commercial sex
workers (CSW) or female sex workers [88, 111, 110, 82, 34], five in men who have
sex with men (MSM) [58, 84, 63, 102, 107], three in the military [114, 49, 94], three
in sexually transmitted disease (STD) clinic attendees [103, 84, 18], and one each in
post-partum mothers [40], non-intravenous drug users [84], discordant couples [52],
blood donors [87], fishermen [104], and police [88]. Six studies used data from two or
more different populations [88, 114, 82, 55, 84, 63]; they are included in the counts
of each population above. The countries in which the reviewed studies took place
and the populations in which the BED assay surveys were conducted are shown in
Figure 7.3. The number of published studies using the BED assay to estimate HIV
incidence increased from one in 2003, to three in 2004, four in 2005, six in 2006, and
fourteen in 2007, but decreased slightly to eleven in 2008 (Table 7.1).
The BED assay was applied to samples collected as part of case-reporting surveil-
lance [35] (i.e. passive surveillance through which all individuals who are diagnosed
as HIV-infected in voluntary counseling and testing centers are reported to a central
organization, such as the US CDC), longitudinal population-based surveillance [10]
(i.e. active surveillance in which eligible individuals contribute blood samples for an
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HIV test repeatedly over time), sentinel surveillance [88, 48, 82, 121, 55], (i.e. active
surveillance that collects blood samples for HIV tests from all individuals belong-
ing to a certain population group, e.g. individuals attending one of a selected set
of antenatal care clinics), clinical cohort studies [114, 94, 19, 40, 86, 63, 109, 34],
preparatory studies for clinical trials [44, 113, 52], cross-sectional HIV surveys [111,
73, 86, 92, 93, 101], and stand-alone HIV incidence studies [89, 96, 103, 111, 124,
104, 58, 49, 5, 78, 84, 18, 102, 107, 108].
Total sample sizes in the reviewed studies ranged from 400 to 87,178 across the
33 studies that reported the sample size (Table 7.1). Nineteen studies reported us-
ing the commercially available BED immunoassay produced by Calypte Biomedical
Corporation [21], while the rest did not report the manufacturer of the assay used.
Incidence Estimation Approach
Fourteen studies [44, 88, 113, 114, 124, 48, 87, 92, 121, 78, 84, 18, 109, 34] used
only a first-generation approach, eight [103, 58, 73, 86, 93, 101, 63, 102] used only a
second-generation approach; one [10] used second- and third-generation approaches;
and two [40, 52] used formulae from all three generations. Fourteen studies [89, 96,
103, 111, 110, 82, 49, 5, 94, 19, 55, 35, 107, 108] did not report the formula used to
estimate HIV incidence.
Three studies collected additional clinical information on study participants but
did not consider using it to exclude or reclassify individuals [124, 52, 34]. Three
other studies indicated that their samples were unlikely to include individuals who
could be falsely classified as recently infected. McDougal et al. [63] used “specimens
largely derived from early infection,” which were known not to include individuals
with AIDS symptoms or on ART treatment. Ba¨rnighausen et al. [10] and Mermin
et al. [73] did not apply inclusion criteria, but indicated that ART roll-out was not
widespread at the time of the study.
Four studies used additional clinical information to reclassify or exclude individ-
uals from the sample for BED assay testing. Three studies used a previous positive
HIV test [35, 84, 18], two studies used ART status [35, 18], and two studies used
AIDS diagnosis [48, 35]. Buchacz et al. [18] excluded individuals from their sample
who were both classified as recent by the BED assay and identified as having long-
standing infection by additional information. Priddy et al. [84] and Jiang et al. [48]
excluded all individuals identified as having long-standing infection by additional
information, independent of BED assay test results. Hall et al. [35] did not exclude
any individuals from the sample but classified all individuals as non-recent who were
identified as having long-standing infection, independent of their BED assay test re-
sults. Li et al. [58] collected information on ART and AIDS diagnosis, but found
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that none of their study participants needed to be excluded or reclassified on the
basis of this information. None of the other studies reported using extra clinical
information for reclassification or exclusion from the sample for BED testing.
In addition to the two strategies described above to correct for BED assay imper-
fection, a few studies adjusted for selective HIV study participation. An important
example is the study of Hall et al. [35] which used a method developed by Karon
et al. [53] to estimate the annual number of recently infected individuals in the
US based on the number of recently infected cases detected by the national case-
reporting surveillance. This estimate was calculated by dividing the number of cases
detected in the surveillance by an estimate of the probability of detection. We have
not reviewed the remainder of these methods in detail because they are specific in
their application to certain study designs rather than to the BED assay.
Finally, two approaches were used to deal with HIV-positive individuals that had
missing information on recent infection (e.g. as a result of insufficient sample to allow
BED assay testing after an initial HIV test). The first approach [18, 34] excludes
these individuals from the incidence estimation sample. The second approach [52, 73,
78] assumes that the proportion of recent infections in these individuals is the same
as the proportion in HIV-infected individuals with known recent infection status,
and adjusts the incidence estimate accordingly.
Optical Density Cut-off and Calibration Parameters
Twenty-three of the thirty-nine studies reported optical density cut-offs, with seven-
teen using a value of 0.8 [111, 48, 58, 49, 5, 94, 40, 52, 73, 92, 10, 101, 35, 84, 63, 18, 34]
and six using a value of 1.0 [44, 88, 113, 104, 87, 78]. One study used a value of 0.75
in addition to a value of 1.0 [104].
Window periods used in the calculation of incidence varied from 153 to 187 days.
Of the nineteen conference abstracts, eleven [89, 96, 103, 110, 82, 104, 55, 102, 107,
108, 109] did not report the window period used, while four reported using a value
of 153 days [114, 49, 5, 94], two reported 155 days [111, 101] and two reported 180
days [113, 19]. The window periods reported in the full papers are presented in
Table 7.2. To compute annual incidence, unit consistency demands that a window
period specified in days must be converted to units of years before being used in the
calculation of incidence. In Table 7.2 we also report the length of year factor (365 or
365.25) used in each study and the corresponding effective window period specified
in units of years.
In addition to the window period, studies using a second-generation formula
required estimates of sensitivity, short-term specificity and long-term specificity,
while studies using third-generation formulae only required estimates of the false-
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recent rate. With the exception of one study [10] that used a locally-valid long-term
specificity, all the studies that used a second-generation formula used the sensitivity,
short-term specificity and long-term specificity as reported by McDougal et al. [63].
Some studies did, however, use varying degrees of precision for these parameters as
reported in Table 7.2. All three studies using third-generation approaches estimated
a false-recent rate for the local setting where the BED assay was applied [40, 52, 10],
although one of them (Karita et al. [52]) did not use this estimate when calculating
incidence.
Confidence Interval Calculation
With the exception of Wasinrapee et al. [114] who computed CIs using a normal ap-
proximation based only on the number of BED recent classifications (hereafter BED
recent counts), none of the conference abstracts indicated how CIs were calculated.
Two of the full-text articles [58, 92] did not report how CIs were calculated, while
eight [48, 52, 73, 87, 121, 84, 63, 18] used a normal approximation based only on the
number of BED recent counts, one [124] used a log transform of a normal approxi-
mation based only on BED recent counts, two [86, 93] used a normal approximation
based on the BED recent and HIV-negative counts, one [78] used a modified Wald
method, two [40, 35] used a delta method, and one [10] used a full trinomial distri-
bution to approximate CIs. In all of these studies only uncertainty resulting from
counting error was taken into account, while the remaining three papers [44, 88, 34]
additionally accounted for the uncertainty associated with the window period by
using a Bonferroni procedure that combined the window period CI with the CI
for the counting error that was calculated using a Poisson distribution [47]. None
of the studies using second- or third-generation approaches attempted to account
for uncertainty stemming from error in the estimation of sensitivity and specificity
parameters.
7.3.1 Incidence Formulae
We identified ten incidence formulae and classified them into three generations (Ta-
ble 7.3), as described above (Figure 7.1). There were four first-generation formulae,
two second-generation formulae and four third-generation formulae. The differences
among the first-generation formulae stem from the different heuristics used to esti-
mate the at-risk population, resulting in different denominators. The denominators
of the two second-generation formulae differ for similar reasons. The reasons for
differences in the third-generation formulae have been systematically explored else-
where [69].
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First-Generation Formulae
I =
R
Nω +R
(1)
I =
R
Nω +R/2
(2)
I =
R
(N +R)ω
(3)
I =
R
(N +R/2)ω
(4)
N is the number of HIV negative individuals,
P is the number of HIV positive individuals, and
R is the number of assay recent individuals.
Second-Generation Formulae
I =
fR
Nω + fR
McDougal et al. [63] (5)
I =
fR
Nω + fR/2
CDC [23] (6)
where
f =
R/P + ρ2 − 1
(σ − ρ1 + 2ρ2 − 1) .
Third-Generation Formulae
I =
R− εP
R− εP + (1− ε)Nω Welte et al. [117] (7)
I =
R− εP
R− ε(N + P ) +Nω Hargrove et al. [40] (8)
I =
R− εP
R/2− ε(N + P/2) +Nω CDC [23] (9)
Ir =
R− εP
(1− ε)Nω McWalter/Welte [71] (10)
where ε = 1− ρ2. To convert form a rate (Ir) to an annual risk of infection (I) use
I = 1− e−Ir .
Tab. 7.3: Formulae.
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7.3.2 Sensitivity Analysis: Recalculation of Incidence Values
For all the full-text articles that unambiguously reported the information required,
we recalculated HIV incidence to examine the impact of methodological choices. Ta-
ble 7.4 shows the incidence estimates as computed by all formulae listed in Table 7.3.
With the exception of a single entry, which may differ as a result of a rounding error,
we were able to recover all the estimates reported in the original papers.
Where the original paper used only a first-generation approach, we evaluated
second-generation formulae using the parameters of McDougal et al. [63] (σ = 0.723,
ρ1 = 0.768, ρ2 = 0.944), and third-generation formulae using ε = 1 − ρ2 = 0.056.
Note that for studies using a window period other than 153 days, the use of these
parameter values is inconsistent, because they were calibrated under the assumption
of a 153-day window period.
Considerable variability in incidence estimates occurs due to the choice of estima-
tor (Table 7.4). As expected, first-generation approaches produced larger incidence
estimates when compared with second- and third-generation approaches. If the
studies that used either a second- or third-generation approach had instead used
a first-generation approach, their incidence estimates would have increased by be-
tween 9% (Li et al. [58], data for the year 2005) and 70% (Hargrove et al. [40]). Had
the studies that used a first-generation approach used a second- or third-generation
approach (with calibration parameters of McDougal et al. [63]), their incidence esti-
mates would have decreased by between 27% (Priddy et al. [84]) and 97% (Jiang et
al. [48], data for “City D All”). It is important to note that the calibration param-
eters used for determining these decreases are unlikely to be valid for the particular
setting of each study; thus, the estimated decreases do not necessarily represent the
true relative overestimation of HIV incidence. They do, however, emphasize the
importance of estimator and parameter choices.
7.3.3 Sensitivity Analysis: Calibration Parameters
In order to explore the sensitivity of the incidence estimates to changes in the cali-
bration parameters, we applied the McWalter/Welte estimator to the sample counts
reported by full-text articles, using a range of false-recent rates and window periods.
Across all studies, we determined the maximum and minimum parameter values
used. To compute a conservative range of values for the sensitivity analyses, we
added a margin of half the difference between maximum and minimum value to the
maximum value (for both false recent rate and window period) and subtracted the
same margin from the lowest value (only in the case of the window period, because
a false-recent rate cannot be negative and the lowest observed value was zero). The
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resulting ranges were 0% to 8.4% for the false-recent rate and 136 to 204 days for
the window period.
Figure 7.4 demonstrates the impact on incidence estimates of changing the false-
recent rate. The figure shows the expected inverse relationship between incidence
and false-recent rate. It also shows that the rate of change of incidence as a function
of false-recent rate varies from survey to survey. This finding can be explained
by the fact that the various populations surveyed have a ratio of recent infections
to long-term infections that is relatively larger or smaller, suggesting a stage of
epidemic that is more or less mature. For some cases, when the false-recent rate is
too large, negative incidence values occur. This is due to the fact that the number
of false-recent results is overestimated, with the consequence that the numerator in
the estimator (Formula (10)) becomes negative.
Figure 7.5 demonstrates the impact on incidence estimates of changing the win-
dow period. Again, in all cases, incidence declines with increasing value of window
period, but because the window period appears in the denominator, the declines are
not linear. For the ranges of parameter values displayed, the declines are generally
smaller than those that occur due to changes in the false-recent rate.
7.3.4 Recalculation of Confidence Intervals
In Table 7.5 we compute 95% CIs for the reproduced incidence estimates under
several scenarios. To incorporate the effect of parameter uncertainty, we used a
closed-form expression for the coefficient of variation of the estimator derived using
a delta-method approximation [71]. Where a first-generation approach was used in
the original study, we compute the annual risk of infection and uncertainty assuming
that the false-recent rate is set to zero. In the column labeled “Counting error
only”, we report the CIs that result from counting uncertainty, excluding parameter
uncertainty. In subsequent columns, we report CIs taking into account several values
of the coefficient of variation for both the window period and the false-recent rate
(where it is not zero).
7.4 Discussion
We have identified thirty-nine English-language articles published between 2003 and
2009 that used BED assay surveys to estimate HIV incidence. The use of the assay
has generally increased since 2003 (the slight observed decline in the number of
studies from fourteen in 2007 to eleven in 2008 may be due to delayed entry of
studies into the PubMed database). Despite the increase in the use of the assay, the
methods of its application have not converged to one approach.
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Fig. 7.4: Sensitivity of incidence estimates to changes in the false-recent rate
(FRR). Filled circles and error bars show originally published estimates,
solid lines show annual risk of infection as computed using Formula (10)
and dashed lines show 95% confidence intervals due to counting error as
determined using a delta method approximation [71] (excluding parame-
ter uncertainty).
7.4.1 Estimator Choices
With three exceptions [10, 40, 52], all the studies reviewed used either a first-
generation estimator (which assumes that the BED assay has a false-recent rate
of zero, or a second-generation estimator (which adjusts for the fact that the BED
assay is an imperfect test using three additional calibration parameters). The choice
of method can produce very different incidence values. In particular, use of a second-
or third-generation approach, with applicable calibration parameters, leads to sub-
stantially lower incidence estimates than those calculated using a first-generation
approach.
All three studies [10, 40, 52] that used third-generation estimators implemented
the approach of Hargrove et al. [40] and only one study implemented the estimator
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Fig. 7.5: Sensitivity of incidence estimates to changes in the window period. Filled
circles and error bars show originally published estimates, solid lines show
annual risk of infection and dashed lines show 95% confidence intervals
(excluding parameter uncertainty).
 
  
Authors Reported incidence ARI Counting error CoV 5% CoV 10% CoV 15% CoV 20% 
  % (95% CI) %  95% CI 95% CI 95% CI 95% CI 95% CI 
Bärnighausen et al. 3.17 (2.54-3.80) 3.17 2.53-3.80 2.45-3.87 2.26-4.06 2.00-4.31 1.72-4.59 
Buchacz et al. 9.5 (3.9-15.1) 9.22 3.77-14.36 3.69-14.43 3.48-14.62 3.13-14.92 2.68-15.32 
Gupta et al. 1.0 (0.1-4.4) 1.03 0.00-2.43 0.00-2.44 0.00-2.45 0.00-2.46 0.00-2.49 
Hargrove et al. 6.0 (5.2-6.9) 5.92 5.04-6.79 4.78-7.04 4.24-7.57 3.59-8.19 2.90-8.84 
Hu et al. 17.3 (12.8-24.2) 17.10 14.06-20.02 13.68-20.38 12.72-21.25 11.46-22.38 10.03-23.61 
Jiang et al. (City D All) 2.07 (1.26-2.89) 2.07 1.26-2.88 1.24-2.90 1.17-2.97 1.06-3.08 0.93-3.21 
Jiang et al. (City D IDU) 9.58 (5.83-13.34) 9.57 5.86-13.14 5.74-13.25 5.43-13.54 4.94-13.98 4.33-14.53 
Karita et al. (Masaka) 7.5 (5.2-9.9) 7.51 5.18-9.78 5.07-9.89 4.77-10.17 4.32-10.59 3.79-11.09 
Karita et al. (Kakira) 6.2 (4.4-8.0) 6.20 4.44-7.92 4.34-8.01 4.07-8.27 3.69-8.64 3.23-9.08 
Li et al. (Data for 2005) 2.9 (0.8-5.0) 2.92 0.55-5.24 0.53-5.26 0.48-5.31 0.39-5.39 0.28-5.49 
Li et al. (Data for 2006) 3.6 (1.3-5.9) 3.59 0.94-6.17 0.91-6.20 0.84-6.26 0.73-6.37 0.58-6.51 
Mermin et al. 1.8 (1.5-2.1) 1.74 1.37-2.10 1.32-2.15 1.21-2.26 1.07-2.40 0.91-2.56 
Nesheim et al. 0.24 (0.20-0.29) 0.24 0.17-0.30 0.17-0.31 0.16-0.32 0.14-0.33 0.12-0.35 
Priddy et al. 1.3 (0.6-2.1) 1.33 0.58-2.08 0.57-2.09 0.53-2.12 0.48-2.17 0.42-2.24 
Xiao et al. (IDUs) 8.2 (5.9-11.5) 8.23 5.49-10.88 5.38-10.99 5.07-11.28 4.60-11.71 4.03-12.23 
Xiao et al. (County B) 4.2 (3.5-5.0) 4.18 3.43-4.93 3.32-5.03 3.07-5.27 2.75-5.59 2.39-5.93 
  
The significant digits in the reported incidence column are the same as reported in each of the studies. 
The table includes only studies which provide sufficient information for independent confidence interval estimation. 
  
Key:  ARI indicates annual risk of infection (using Formula 10 and conversion formula, see Table 3); CoV, coefficient of variation for parameters. 
 
Tab. 7.5: Confidence intervals.
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proposed by McWalter and Welte [71]. It is perhaps not surprising that third-
generation estimators had more limited application because these estimators have
only been recently published [40, 117, 71].
7.4.2 Calibration
It is incontrovertible that the BED assay produces a certain proportion of false-
recent results. All studies that have estimated a false-recent rate for the BED
assay have reported non-zero values [10, 63, 40, 52]. Three studies using a first-
generation approach reported incidence estimates based on the BED assay that were
substantially higher than incidence estimates using other techniques [44, 109, 113].
These results are consistent with the fact that failure to account for false-recent
samples produces estimates that are too high. Two further studies reported that
the BED assay overestimated incidence, but did not report the approach used to
calculate incidence [19, 55]. Since first-generation approaches do not account for
false-recent results, incidence estimates using these approaches should be considered
invalid unless further justification for using a false-recent rate of zero can be provided.
None of the studies reviewed provided such justification.
Second- or third-generation approaches provide more accurate incidence esti-
mates if the correct calibration parameters are used. However, calibration param-
eters differ by setting, as illustrated by four of the studies reviewed. The original
estimates for sensitivity and specificity were provided by McDougal et al. [63], who
verified that a second-generation incidence estimate was consistent with an incidence
estimate obtained in a longitudinal cohort study. Hargrove et al. [40] found that
the false-recent rate for postpartum women in Zimbabwe is similar to that found by
McDougal et al. [63], but that the mean window period was larger. Ba¨rnighausen
et al. [10] found that the false-recent rate for a population in rural KwaZulu Natal,
South Africa, was lower than the value reported by Hargrove et al. and McDougal
et al. All three of these studies found that BED assay-based incidence estimates,
computed using local parameters, were similar to incidence estimates based on longi-
tudinal data from the same population. Karita et al. [52] showed that the BED assay
in Uganda using second- and third-generation approaches (with the parameters of
McDougal et al. [63]) overestimates incidence values. They also reported prospec-
tive data that indicated a false-recent rate of 27% (8 of 30 individuals with follow-up
data past one year) with a 95% CI of 12-46%, which is higher than the false-recent
rate of 5.6% used in their incidence calculations. The binomial CI was not reported
in the original paper; it was computed using the exact method. Unfortunately, this
very uncertain point estimate for the false-recent rate leads to negative incidence
estimates. If, however, a false-recent rate of 22% had been used, the BED-based
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incidence estimates would have been similar to the values obtained by longitudinal
surveillance (e.g. applying Formula (10) to their survey counts for Masaka gives an
incidence of 1.5%, which is similar to the longitudinal incidence estimates of 1.7%
and 1.3%).
With one exception, all studies that used the second generation approach did so
in conjunction with the parameter values reported by McDougal et al. [63]. None
of these studies independently calibrated sensitivity and specificity, or justified on
other grounds why these values were likely to be correct for the particular study
setting. This potentially undermines their validity. It is perhaps not surprising
that researchers using second-generation approaches did so with parameter values
from another setting, because studies to calibrate these parameters require frequent
follow-up of large cohorts for periods of a year or longer, making calibration logisti-
cally complex and expensive to conduct [63].
It is important to emphasize that the use of exclusion or reclassification cri-
teria should be applied consistently in the calibration-parameter-estimation and
incidence-estimation surveys. Even if the value of a calibration parameter is lo-
cally estimated, it may not be appropriate for incidence estimation if the estimation
sample differs systematically from the calibration sample. For example, McDougal
et al. estimated long-term specificity using “specimens from longer-term-infected
individuals not known to have clinical AIDS, opportunistic infections, or to be on
treatment” [63]. The same exclusion criteria should thus be applied to samples in
studies using the McDougal parameter values in incidence estimation. However,
only one of the studies that used the McDougal parameter values collected informa-
tion on AIDS diagnosis and antiretroviral treatment with the intention to exclude
individuals from the sample for incidence calculation [58]. This issue of systematic
differences between calibration and incidence samples is especially important if the
differences relate to variables associated with the probability of false-recent BED
assay diagnosis.
7.4.3 Confidence-interval Calculation
Comparing the CIs reported in the literature with those we computed under the
assumption of no parameter uncertainty shows that the reported CIs were reasonable
and in some cases overestimated uncertainty [44, 34]. Only three studies computed
CIs that took into account the uncertainty of the calibration parameters [44, 34, 88].
When we included calibration uncertainty, the CIs of many incidence point estimates
were substantially widened. We used somewhat artificial values for the coefficient
of variation for the parameters—obviously, in real-life applications, the uncertainty
due to error in the measurement of parameters will be a function of the statistical
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power of the particular calibration study.
As shown by our CI calculations, surveys with fewer than several thousand indi-
viduals produce results with large uncertainty. Findings of studies with such small
sample sizes should be interpreted with caution. We do not discuss the issue of sam-
ple size calculations further, but refer the reader to ongoing work on characterizing
the necessary sample sizes to ensure reasonable precision [118].
7.5 Conclusion
Valid tests for recent HIV infection hold great promise for HIV research in that
they allow the estimation of incidence using cross-sectional surveys. Such tests
could thus substantially increase the capacity to monitor and understand the de-
velopment of the epidemic and the impact of interventions at the population level.
In the past five years, the BED assay has found worldwide application as a test
for recent infection. However, as this review and sensitivity analysis demonstrate,
many of the BED-derived HIV incidence estimates may not be valid. In particular,
incidence estimates derived using first-generation approaches should be considered
invalid, because they assume a false-recent rate equal to zero. Incidence estimates
derived using second and third-generation approaches may be valid, but only if the
calibration parameters are locally appropriate. Confidence intervals in general un-
derestimated the associated incidence uncertainty because they did not account for
parameter uncertainty.
It is possible to produce accurate incidence estimates if false-recent results are
correctly accounted for and if studies recruit a sufficiently large number of partici-
pants. Based on these findings, we make recommendations for the future use of the
BED assay. These recommendations are applicable not only to the BED assay, but
also more broadly to other tests for recent HIV infection (including algorithms [56]
with multiple tests and clinical information).
• Studies should report all information necessary for readers to independently
determine incidence point and uncertainty estimates. In particular, studies
should report (1) sufficient data to permit reconstruction of the population
counts of HIV-negative, HIV-positive and recently-infected individuals; (2) the
approach, formulae and parameter values used in incidence point estimation;
and (3) the method used to estimate CIs.
• The estimation of incidence should be based on methods that account for
false-recent results. In particular, the third-generation approach of McWalter
and Welte [71] should be used because it is both parsimonious (as opposed to
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second-generation estimators that are over-parameterized) and the least biased
of the estimators reviewed [69].
• Locally-valid estimates of the calibration parameters should be used for com-
puting incidence. If locally-valid estimates are not available, sensitivity of
incidence to changes in these parameter values should be explored. It is par-
ticularly important to use an accurate estimate for the false-recent rate.
• As far as possible, further clinical or biomarker information should be used
to reduce the false-recent rate. Furthermore, any additional information used
to exclude or reclassify individuals should be applied consistently in both the
study estimating the false-recent rate and the subsequent incidence estimation
study. (For example, it would be incorrect to calculate incidence in a sam-
ple that includes individuals on ART using a false-recent rate estimated in a
sample that excluded individuals on ART).
• CIs for incidence estimates should be computed using approaches that take
into account parameter uncertainty.
Debate on the most appropriate approach for dealing with false-recent results
continues [15, 116, 14, 39, 62]. The above recommendations reflect our judgments on
best current practice as identified through a systematic review of published studies
and theoretical considerations.
Chapter 8
Reply to ‘Should biomarker estimates of HIV
incidence be adjusted?’
∗ This chapter was coauthored with A. Welte and T. Ba¨rnighausen [116], and is
reproduced with permission from Wolters Kluwer Health (Rightslink licence no.
2601230822792): AIDS (2009) 23:2062-3 DOI: 10.1097/QAD.0b013e32832eff59.
8.1 Correspondence
Brookmeyer [15] is right to attempt the important task of reviewing and contrasting
different approaches to biomarker-based HIV incidence estimates. The two ‘results’
highlighted in his abstract are as follows:
1. “The McDougal adjustment has no net effect on the estimate of HIV incidence
because false positives exactly counterbalance false negatives”.
2. “The Hargrove adjustment has a mathematical error that can cause significant
underestimation of HIV incidence rates”.
These findings appear to undermine the progress made in explaining why ear-
lier BED assay-based methods have tended to overestimate incidence. However,
both of Brookmeyer’s results are incorrect. Given the evidence for subpopulations
who fail to progress out of the biomarker-defined ‘recent’ category (so-called assay
nonprogressors), ‘adjustment’ is indeed necessary.
Brookmeyer outlines a conception of incidence estimation requiring demographic
and epidemic equilibrium conditions over the past M years, in which M is the
maximum time an individual remains classified ‘recent’ by the biomarker. He then
claims that M is 3 years for the BED assay, thus excluding the possibility of assay
nonprogressors. This seems hard to sustain in light of various data of which we
are aware [63, 40, 10]. Hargrove et al. [40] provide data on postpartum mothers
indicating that 5.2% of those surveyed remain persistently classified as ‘recent’ by
the BED assay. McDougal et al. [63] infer from their data that an individual has
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a 5.6% probability (reported as a long-term specificity ρ2 = 0.994) of testing below
BED threshold, if infected longer than twice the mean window period of the assay.
Under the assumption of no assay nonprogressors, Brookmeyer presents an argument
to demonstrate that no ‘adjustment’ is required. His first result (point one above)
is therefore inappropriate, as it depends on an assumption that is inconsistent with
the data-driven findings in the publications he critiques.
Brookmeyer reports a numerical simulation in which the Hargrove estimator (us-
ing ε = 0.052 = 1− ρ2) apparently produces egregious underestimates of incidence,
possibly even negative values. The cause of the underestimate is inconsistent calibra-
tion. The simulated epidemic has no assay nonprogressors, but he uses Hargrove’s
‘adjusted’ estimator that assumes them to be 5.2% of the population. Although
it is not reported, a near identical underestimate arises with the McDougal for-
mula (when, equivalently, ρ2 = 0.948 is used). The bias merely reflects that the
incidence estimators are unavoidably very sensitive to the calibration of ρ2, a very
important and usually neglected point [10]. Conversely, if one samples or simulates
a population in which there is a subpopulation of assay nonprogressors, then ‘un-
adjusted’ estimators are well known to overestimate incidence because a dispropor-
tionate number of ‘false recent’ classifications accumulate in the population. In this
situation, the McDougal and Hargrove estimators, when appropriately calibrated,
yield results with modest bias, dominated by counting error for reasonable sample
sizes [40, 10]. We provide an analytical closed-form demonstration of inherent bias
in each of these methods [69]. Brookmeyer’s other result (point two above), thus
incorrectly attributes substantial bias exclusively to the Hargrove estimator when in
fact both the McDougal and Hargrove estimators exhibit similar bias, which results
from Brookmeyer’s inconsistent calibration of the estimator.
As we have shown elsewhere [69, 117], it is possible to simplify the McDougal
framework, under its own assumptions, but not as Hargrove or Brookmeyer sug-
gest. Detailed analysis reveals an identity relating the sensitivity and specificity
parameters, leading to a simpler estimator that is easier to calibrate. We have also
derived a formally rigorous framework for biomarker-based incidence estimation that
specifically accounts for assay nonprogressors [71], and can also account for assay
regressors under suitable calibration [10]. This approach requires fewer assumptions
and is less prone to bias than either the McDougal or Hargrove method.
Brookmeyer notes the unsatisfactory correspondence between published bio-
marker-based incidence estimates and estimates based on prospective follow-up. His
discussion of possible sources of error focuses on sampling bias and imperfect mean
window period estimation. Although these issues are important, he proposes no
way of dealing with assay nonprogressors. In his conclusion, Brookmeyer remarks
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that “if, however, a proportion of HIV-positive persons are identified who remain in
the window period indefinitely, then an adjustment would be necessary”. This does
little to soften his strong statements, which undermine prior work addressing the
issue of nonprogressors that has helped us move beyond the naive estimators.
Using data from cross-sectional surveys to estimate incidence will remain an
attractive approach, but it requires the use of a robust estimator for which the correct
applicable calibrations have been performed. In particular, accurate calibration
of long-term specificity is of vital importance to correctly account for biomarker
misclassification.
Chapter 9
Incidence from Cross-sectional Surveys:
Improved Characterization of Tests for Recent
Infection
∗ This chapter was coauthored with A. Welte and R. Kassanjee [65].
Abstract
Background: Since it is cheaper, quicker and easier than prospective follow-up,
incidence estimation from cross-sectional surveys has gained much attention.
The estimators used with this methodology require a characterization of the
Test for Recent Infection (TRI), which has variously been specified using a
combination of mean window periods, sensitivities, specificities and false-recent
rates. Recent research has highlighted problems with such characterizations
and raised debate about how best to specify TRI properties.
Methods: By introducing a predetermined cutoff time (τ), and making the as-
sumption of constant incidence for a period τ preceding the survey, we provide
a precise and parsimonious characterization of a TRI, and derive a new inci-
dence estimator. The estimator depends on three parameters; the probability
of remaining in the window period at a time τ after infection, the mean window
period for those who leave it before τ and the proportion of the subpopulation
infected for longer than τ that are (incorrectly) classified recent by the test.
The new estimator is contrasted with the previous estimators of McDougal et
al., Hargrove et al. and McWalter & Welte.
Results: Although the epidemiological assumptions required are more restric-
tive than those of the McWalter/Welte method, the characterization of the TRI
is more general, better defined and more amenable to estimation. The McDou-
gal and McWalter/Welte estimators are shown to be special cases of the new
estimator. The extent to which the previous estimators differ from the new esti-
mator is shown under various scenarios. The assumption of constant incidence
for a period τ before the survey is shown to be benign under realistic epidemic
scenarios.
Conclusion: With a precise formulation of the TRI parameters and the as-
9.1 Introduction 104
sociated incidence estimator, the issues that have caused debate in the area of
cross-sectional incidence estimation are clarified.
9.1 Introduction
It is of considerable epidemiological importance to develop methodologies for es-
timating disease incidence. For some time there has been substantial interest in
methods for estimating incidence from cross-sectional data [17, 47, 80, 63, 40, 71].
Prevalence, in general, is a reflection of historical incidence, convolved with the
susceptible population dynamics and survival after disease acquisition. This con-
volution renders disease prevalence an indirect and unresponsive proxy for recent
incidence, unless disease duration is very short. In the case of lifelong infections
such as HIV, a more direct view of recent incidence is required. Cross-sectional test-
ing for “recent infection” in principle provides a simple proxy for recent incidence,
but tests for “recent infection”, based on some combination of laboratory assays
and clinical information exhibit considerable inter-subject variability, including sub-
populations with anomalous responses, sometimes loosely referred to as false-recent
results. These lead to subtle complications in the interpretation of data and deriva-
tion of provably consistent estimators, which have raised some controversy in the
recent literature [15, 39, 62, 116, 14]. This article briefly reviews the topic and
presents new analysis which synthesizes the ideas currently in contention.
A generic framework for recent infection tests applied to HIV can be formulated
by considering an immune response which increases1 over time post infection. A
quantitative result (typically an optical density of some analyte) can be cast into
a categorical result by use of a classification threshold, below which the response
is regarded as indicative of “recent infection”. An application of a cross-sectional
survey classifies individuals of the sample population as healthy (susceptible) indi-
viduals, or infected individuals who are either under or over the specified threshold
on the immune system response. The counts in the survey, corresponding to these
categories, are denoted NH, NU and NO respectively.
Developers of recent infection tests face a fundamental trade-off between the need
for the duration of recent infection to be long enough, to ensure that the population
proportion of individuals classified as recent is sufficiently large to provide statistical
power in sample populations of attainable size, and not so long that the test is
unrepresentative of “recent infection”. For example, a duration of one month is too
short, while a duration of three years is too long.
All candidate biomarkers exhibit non-trivial inter-subject variability in response,
1 There is no loss of generality if the response decreases with time.
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which is a source of complication in the analysis. Of serious concern is the subpopu-
lation of individuals that exhibit anomalous responses on the assay. Two important
classes are the assay non-progressors, who never develop enough of a response to HIV
infection to cross the threshold, and the regressors, who initially cross the threshold
but then drop below it again (e.g. due to immune failure as a result of late-stage
disease progression, or due to treatment). When the classification threshold for a
biomarker is increased there is a corresponding increase in the duration of recent in-
fection. There is, however, also an increase in the proportion of anomalous results.
Thus, developers must also face another fundamental trade-off between length of
duration and the proportion of anomalous results.
We review a number of approaches that have been suggested to deal with these
anomalous cases and describe some of the shortcomings associated with each. Ini-
tially, we describe a simple estimator that does not directly account for anomalous
results. We then describe generalizations of this approach that have been suggested
in the literature.
All these methods require some investment in parameterizing the interaction of
the proposed test with the intended study population (i.e., estimator calibration).
There is currently no consensus on a unified framework within which to compare
these approaches or to address their limitations [15, 39, 62, 116, 14]. By providing
precise definitions for the parameters that characterize a test for recent infection,
we derive a new estimator which unifies the previous approaches.
9.2 Previous Estimators
A recent infection test in which all individuals progress to the recent/non-recent
infection threshold, and there is no significant reversion below it, leads to the simple
estimator
I =
NU
ωNH
, (9.1)
where ω is the duration of recency (also known as the mean window period). In
the limit of a slowly varying susceptible population, this provides an estimate of the
weighted incidence, with the natural weighting proportional to the availability for
being infected and remaining classified recent once infected [51, 71]. The incidence
weighting scheme is given explicitly by
IW =
∫ 0
−∞ I(t)H(t)SU(−t) dt∫ 0
−∞H(t)SU(−t) dt
,
where I(t) is instantaneous incidence, H(t) is the susceptible population and SU(t)
is survival in the state of being under-threshold on the assay (i.e., being classified
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as recent). Alternatively, the incidence estimated in this manner can be interpreted
as the “incidence in the recent past” [16].
This estimator may be used even when anomalous results are present—there
are, however, two undesirable consequences. Firstly, incidence will be weighted
over the time periods for which the anomalous results are present. When assay
non-progressors are present, this means that the estimated incidence is a weighted
average over the whole course of the epidemic. This effect has been demonstrated in
a recent paper by Brookmeyer [16], where he calculates a “shadow time” associated
with such weighted incidence estimates. These shadow times are unreasonably large
when even a small percentage of assay non-progressors are present in the population
of interest. Secondly, and perhaps more seriously, the calibration of ω becomes more
onerous. When a subpopulation of assay non-progessors is present, then estimation
of ω must take place over the full life-span of these individuals. Moreover, since
individuals in this subpopulation exit the “recently-infected” category as a result
of death or treatment, this means that ω is less a property of the assay and more
dependent on environmental factors that are likely to change with location and
time (e.g. access to primary health care, ART coverage, local mix of opportunistic
challenges and nutrition). For example, this implies that ω in North America would
be very different to ω in rural Africa. Since estimation of the mean window period is
difficult and expensive, requiring follow-up over the lifetime of the non-progressors,
this means that providing an accurate location- and time-specific estimate of ω
for use with estimator (9.1) will be difficult. In particular, it is hardly realistic to
expect that a calibration study be conducted over a period of 10 to 20 years, and that
analysis of cross-sectional data should wait for completion of such a study. Moreover,
since ω is time dependent, the result of such a calibration study may not be valid
for very long. This implies that, if even a very small proportion of individuals are
assay non-progressors, it will be impractical to calibrate this estimator.
As a result of these complications, a number of approaches have been proposed
to estimate, and account for, the effect of anomalous test results. The first approach
was proposed by McDougal and colleagues [63]. They impose hard time boundaries
to define up to three states of infection (recent, non-recent and long), which are
then conceived as imperfectly reflected in the test. An estimator making use of
three extra parameters (sensitivity, short-term specificity and long-term specificity)
is introduced.
Hargrove and colleagues [40], under the assumption that sensitivity is approxi-
mately equal to short-term specificity provide a reduced estimator that depends only
on a mean window period and a false-recent rate, being one minus the long-term
specificity in the McDougal approach. More recently, it has been shown that there is
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a consistent method for reducing the parameters in the McDougal approach [117, 69].
The biases inherent in the McDougal and Hargrove approaches have also been in-
vestigated [69].
The reduction of the McDougal estimator and bias comparisons for the McDougal
and Hargrove parameters were inspired and facilitated by the derivation of a new
estimator [71] that makes fewer assumptions than either of these two approaches.
In the next section we provide an intuitive derivation of this approach, but point
the reader to the original paper for the full survival analysis derivation.
For the remainder of the paper, we shall refer to the following simple incidence
estimator
I =
NTR
ωNH
, (9.2)
where NTR is the estimate of the number of individuals in the sample that are
“truly recent”. The subtlety will be in defining precisely what “recency” means,
and providing the procedures and parameters required to estimate NTR and ω. By
addressing these issues we aim to provide a new incidence estimator that accounts
for the sources of false-recent results and has clear guidelines on how it should be
calibrated.
9.3 Accounting for Assay Non-progressors
All previous attempts to derive incidence estimators, that account for false-recency,
have made the assumptions of no regression and equal survival for assay progressors
and assay non-progressors [69]. Under these assumptions, we have previously derived
an incidence estimator using survival analysis [71]. Briefly, “recent infection” and
the parameters that describe it are defined as follows:
• For individuals that progress on the assay, recency means testing below-thresh-
old.
• The duration of recency ωR is defined as the mean time spent under the thresh-
old, for those individuals that progress.
• False-recent results are produced by individuals that fail to progress on the
assay. The probability of not progressing is denoted by PNP.
The first point above means that recent infection is a characteristic of the test and
is not defined by a definite time boundary. If we now “assign” recency times for the
non-progressors from the same distribution applicable to assay progressors then we
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can define an explicit incidence weighting scheme as follows:
IW =
∫ 0
−∞ I(t)H(t)SR(−t) dt∫ 0
−∞H(t)SR(−t) dt
,
where, as before, I(t) is instantaneous incidence and H(t) is the susceptible popu-
lation. In contrast to the previous weighting scheme, SR(t) is now survival in the
state of being under-threshold on the assay conditional on progressing. In the limit
of a slowly varying susceptible population, the denominator may be written as ωRNH
(compare with (9.2)), and so it remains to find an estimate of the numerator
NTR =
∫ 0
−∞
I(t)H(t)SR(−t) dt.
The assumptions of no regression and equal survival mean that, at every stage
in the epidemic, the ratio of assay non-progressors to assay progressors is PNP to
1 − PNP. This is also the ratio of the number of false-recent results (denoted NFR)
to the number of individuals with a test result over-threshold:
NFR
NO
=
PNP
1− PNP .
The number of true-recent results is the number of individuals classified by the
biomarker as under the threshold minus the number of false-recent results:
NTR = NU −NFR = NU − PNP
1− PNPNO.
In conjunction with the expression for the denominator, this gives the estimator
I1 =
NU − PNP1−PNPNO
ωRNH
=
NU − PNP(NU +NO)
ωR(1− PNP)NH . (9.3)
The number of true-recent results in this estimator is the same as that which
arises in the estimator of McDougal et al. [63]. Their estimator does, however, use
a different denominator (See [69] for further details).
9.4 Relaxing Assumptions
By relaxing the assumptions of no regression and equal survival for assay progressors
and assay non-progressors, an incidence estimator, similar to the previous one, may
by obtained using a slightly different definition of the parameters that describe
recency:
• For individuals that progress on the assay, recency means testing below-thresh-
old.
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• The duration of recency ωR is defined as the mean time spent under the thresh-
old, for those individuals that progress.
• False-recent results are produced by individuals that fail to progress on the
assay and individuals that revert below the threshold as a result of immune
failure or treatment. A general false-recent rate (FRR)2, denoted by φ, is
defined as the proportion of non-recent infections that are incorrectly classified
as recent.
The first two points are the same as in the previous section, and, as a result, so is the
incidence weighting scheme. The FRR described in the third point is a nontrivial
function of the progression of the epidemic (including historical incidence and suscep-
tible population), the survival functions for assay progressors and non-progressors,
and the rate at which regression occurs.
To derive a new expression for NTR, we note that the definition of the FRR may
be written as
φ =
NFR
NO +NFR
,
which can be rearranged to provide an estimate of the number of false-recent results
NFR =
φ
1− φNO.
As before, the number of true-recent results is the difference between the number
of individuals that are under-threshold and the number of false-recent results, i.e.,
NTR = NU −NFR. Thus, the estimator can be written as
I2 =
NU − φ1−φNO
ωRNH
=
NU − φ(NU +NO)
ωR(1− φ)NH , (9.4)
which is the same as (9.3), except that PNP has been replaced by φ.
These definitions raise the question, “Is it possible to specify a precise and consis-
tent procedure to estimate the parameters (ωR and φ) required by this estimator?”
If one is sure that all individuals that will progress on the assay do so before a
known maximum progression time (T ), then there are at least two consistent meth-
ods to provide estimates for ωR. The first involves prospectively enrolling individuals
with an approximately known infection time into a follow-up study (with frequent
visits) for a period at least as long as the maximum progression time. An empirical
survival curve of being under the threshold, for individuals that progress, is then
2 Note that the FRR is in fact a false positive rate. We prefer to use the word ‘recent’ instead
of ‘positive’ to emphasize that it relates to the test for recency, and not to the test for disease
positivity.
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produced and integrated to obtain an estimate of the mean duration3. The sec-
ond method involves using a maximum likelihood approach on individuals that are
followed-up at intervals greater than the maximum progression time [115, 54].
Estimates of ωR will be biased if there are a significant number of late progressors,
i.e., individuals that progress at a time post-infection longer than the assumed cut-
off T . This raises the question, “How can one be confident that the value of T chosen
is at least as large as the maximum progression time?” This is an issue that has
been raised in the recent debate in the literature on biomarker based estimators [15,
39, 62, 116, 14].
The estimation of φ is perhaps more problematic. In a previous paper [10], a
cutoff time T equal to twice the mean window period was chosen, and the FRR was
estimated as the proportion of under-threshold individuals with a known infection
time greater than T . This makes the assumption that all such individuals are falsely
classified as recent, which may not be true if late progressors are present.
The FRR, as defined, is a product of the whole history of the epidemic. However,
the procedure outlined in the last paragraph produces an estimate for the FRR that
is only applicable to the subgroup of individuals with a time since infection greater
than T . If the proportion of false-recent results for the subgroup of individuals with
a time since infection less than T is different from this estimated FRR, then this
procedure provides a biased estimate of φ. An unbiased estimate of φ is a non-trivial
mixture of the FRR estimates applicable to both subgroups.
As noted previously, the change from using a probability of not progressing
to using a general false-recent rate has not fundamentally changed the incidence
weighting scheme described in the previous section. If the maximum progression
time T is known, however, then one may reduce the limits of integration and the
weighted incidence can be written as
IW =
∫ 0
−T I(t)H(t)SR(−t) dt∫ 0
−T H(t)SR(−t) dt
.
9.5 New Definitions for Parameters and a New
Estimator
The observation that knowledge of the maximum progression time changes the limits
of integration on the incidence weighting scheme suggests a new scheme in which
one specifies a cutoff time and explicitly writes the weighting scheme with the lower
3 This is similar to the procedure used by McDougal et al. [63], except that it is not clear from
their paper whether or not they removed the assay non-progressors when computing their curve.
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limit of integration specified by the cutoff time. New definitions for the parameters
that describe recency may then be proposed.
• For individuals that progress on the assay before a prespecified cutoff time τ ,
recency means testing below-threshold.
• The duration of recency ωτ is defined as the mean time spent under the thresh-
old, for those individuals that progress on the assay before τ .
• False-recent results are produced by the fraction of individuals that fail to
progress on the assay before τ . The probability of not progressing before τ is
denoted by Pτ .
• All individuals with an infection time longer than τ are by definition non-recent
infections. An FRR φτ is defined as the proportion of individuals infected for
longer than τ who are classified (falsely) as recent.
The first point means that recent infection is now a characteristic of the test and the
cutoff time, which is conveniently chosen (e.g. one year). The last point provides a
precise definition of an epidemic dependent FRR more amenable to estimation than
the FRR proposed in the previous section. Note that the three parameters ωτ , Pτ
and φτ have been written with the subscript τ to emphasize that they are functions
of the value chosen for τ . Of course, one would like τ to be chosen so that most
individuals who progress do so before that time. This ensures that the false-recent
rate, as defined, will not unduly depend on incidence in the recent past.
The incidence weighting scheme is then written as
IW =
∫ 0
−τ I(t)H(t)SR(−t) dt∫ 0
−τ H(t)SR(−t) dt
. (9.5)
As before, in the limit of a slowly varying susceptible population, the denominator
may be written as ωτNH, and so it remains to find an estimate of the numerator
NTR =
∫ 0
−τ
I(t)H(t)SR(−t) dt. (9.6)
Let the number of HIV seropositive individuals in the population be given by n
(i.e., n = NU +NO). The number of seropositive individuals can also be written as
n =
∫ 0
−∞
I(t)H(t)S(−t) dt,
which depends on the historical incidence, the number of susceptible individuals and
the post-infection survival of HIV infected individuals S(t). Denote the number of
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seroconverters with a time since infection less than or equal to τ by nt≤τ and those
with a time greater than τ by nt>τ . The number of individuals in the population
with a time since infection less than τ can be written as
nt≤τ =
∫ 0
−τ
I(t)H(t)S(−t) dt. (9.7)
We now make the following three observations:
• The total number of individuals in the population that are under-threshold
is equal to the number of individuals that are truly recent infections plus the
number of false-recent results.
• The number of individuals with an infection time less than τ that are truly non-
recent is nt≤τ−NTR. By definition, Pτ specifies the fraction of these individuals
that have failed to progress prior to τ , and, as a result, are incorrectly classified
as recent. Hence the number of false-recent results with an infection time less
than τ is Pτ (nt≤τ −NTR).
• The number of false-recent results with an infection time greater than τ is just
the FRR, φτ , multiplied by nt>τ = NU +NO − nt≤τ .
These observations lead to the expression
NU = NTR + Pτ (nt≤τ −NTR) + φτ (NU +NO − nt≤τ ). (9.8)
Now, in order to get an estimate for nt≤τ , make the assumption of uniform
infection events in the population over the last time period τ , i.e., I(t)H(t)S(−t) =
f0. This is the same assumption made by McDougal et al. [63, 69] and is equivalent
to the following assumptions:
• Incidence is constant over the last period τ ,
• Susceptible population is constant over the last period τ , and
• No death as a result of infection occurs in a period τ post-infection (i.e.,
S(t) = 1 for t ∈ [0, τ ]).
These assumptions, in conjunction with (9.7) and (9.6), mean that
nt≤τ = τf0 =
τ
ωτ
(ωτf0) =
τ
ωτ
NTR,
which, in conjunction with (9.8), yields an expression for NTR given by
NTR =
NU − φτ (NU +NO)
1− Pτ + τωτ (Pτ − φτ )
.
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Having computed an estimate for the numerator (compare with (9.2)) we obtain a
new estimator for incidence given by
I3 =
NU − φτ (NU +NO)
(ωτ (1− Pτ ) + τ(Pτ − φτ ))NH . (9.9)
Note that if Pτ = φτ = PNP we recover the previous estimator (9.3), and if Pτ =
φτ = φ we recover estimator (9.4).
As mentioned previously, the assumptions made in deriving this estimator are
the same assumptions made in the derivation (and reduction [69]) of the McDougal
estimator [63], with one important exception. McDougal et al. made the assumption
that the empirical survival curve, of individuals in the state of recency, used for
calibration was flat after τ = 2ω. This assumption has been relaxed by allowing Pτ
to be different from φτ .
9.6 Numerical Simulations
The assumption of constant incidence and susceptible population used in deriving
the new estimator is stringent, and it is necessary to understand the kinds of biases
that arise when realistic transient conditions occur. For this reason, we explore the
bias that may be expected under realistic violations of this assumption.
For demonstration purposes, suppose incidence and susceptible population vary
according to the exponential functions of time given by
I(t) = I0e
αt and H(t) = H0e
βt, (9.10)
where I0 and H0 are the instantaneous incidence and susceptible counts at the time
of the survey, and α and β are factors expressing the rate at which incidence and the
susceptible population are changing. We also assume that the survival function SR
is generated using a Weibull distribution with scale parameter l = 0.44 and shape
parameter k = 7, corresponding to a mean of 150 days and a standard deviation of
25 days. A cutoff time τ = 1 year is selected, which means that ωτ = 150 days, and
the probability of not progressing was set to Pτ = 2%.
Figure 9.1 shows the bias, being the relative difference between IW and I3, as
a function of the FRR φτ and the incidence growth rate (expressed as an annual
percentage, i.e., −50% means a halving of incidence in one year, while 100% means
a doubling). This plot was produced for the situation in which there is no growth
of the susceptible population. See the Appendix for a derivation of the expressions
used.
When the annual growth rate of the susceptible population is set to 10% the
plot produced is the same as that shown, except the surface is shifted upwards
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Fig. 9.1: Bias between IW and I3 expressed as a percentage.
by approximately 2%. Similarly, when the annual growth rate is set to -10% the
surface is shifted downward by about 2%. This is consistent with the bias findings
in McWalter & Welte [71].
This exercise shows that the bias introduced by making the assumption of con-
stant incidence and susceptible population over a time period τ prior to the survey
is benign—of the order of a few percent.
It is also interesting to explore the extent to which the estimator I2 is different
from I3. Using the parameter choices ωR = ωτ and φ = φτ for the estimator I2, the
Appendix derives an expression for the relative difference between the two estimators
as a function of δ, being the relative difference between Pτ and φ
δ =
Pτ − φ
φ
.
Figure 9.2 shows the relative difference between the estimators as a function of
φτ in the range 0 to 5% and the extent to which Pτ is different from φτ expressed
as a relative percentage difference (i.e., δ = −100% means Pτ = 0 and δ = 100%
means that Pτ = 2φτ ). The difference is also of the order of a few percent, but large
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enough to warrant further investigation.
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9.7 Appendix
9.7.1 Bias Computation
The expressions for I(t) and H(t) given by (9.10) mean that
IW =
I0
∫ 0
−τ e
(α+β)tSR(−t) dt∫ 0
−τ e
βtSR(−t) dt
.
In order to evaluate I3, recall that
NU = NTR + Pτ (nt≤τ −NTR) + φτ (NU +NO − nt≤τ ),
in which case the numerator of I3 can be written as
(1− Pτ )NTR + (Pτ − φτ )nt≤τ .
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We also have
NTR = H0I0
∫ 0
−τ
e(α+β)tSR(−t) dt
and
nt≤τ = H0I0
∫ 0
−τ
e(α+β)t dt.
Substituting these expressions into the estimator I3 and noting that NH = H0 yields
I3 = I0
(
(1− Pτ )
∫ 0
−τ e
(α+β)tSR(−t) dt+ (Pτ − φτ )
∫ 0
−τ e
(α+β)t dt
ωτ (1− Pτ ) + τ(Pτ − φτ )
)
.
The bias may now be computed using numerical integration on the expression
for the relative difference
r =
IW − I3
IW
.
Note that, when the relevant substitutions are performed, this expression is inde-
pendent of I0 and H0, which means that the bias is only dependent on the rates of
growth of the incidence and susceptible population, not the values at the time of
the survey.
9.7.2 Relative Difference Between I3 and I2
Here, we derive an expression for the relative difference (r) between estimator I3
and estimator I2
r =
I3 − I2
I3
,
assuming that φ = φτ is used as the FRR when computing I2. To simplify expres-
sions we use ω = ωR = ωτ and express Pτ = φ+δφ in terms of the relative difference
(δ) between Pτ and φτ . Then I3 may be expressed as
I3 =
NU − φ(NU +NO)
(ω(1− φ− δφ) + τδφ)NH ,
with
r = 1− NU − φ(NU +NO)
ω(1− φ)NH ×
(ω(1− φ− δφ) + τδφ)NH
NU − φ(NU +NO) =
(ω − τ)δφ
ω(1− φ) .
Remarkably, the final expression is independent of the sample counts. This also
means that the estimate I3 can be written as a constant factor multiplied by the
estimate I2
I3 = I2
(
ωR(1− φ)
ωτ (1− Pτ ) + τ(Pτ − φ)
)
,
which can be deduced by directly inspecting (9.4) and (9.9).
Appendix A
Selected MATLAB Code
A.1 Fig2-5.m
%
% Program to simulate a population and test incidence estimator on a
% number of cross-sectional samples. This simulation uses Weibull
% survival functions.
%
T=50; % Number of years
nsteps=50; % Number of time steps
H0=100000; % Initial number of susceptables
H1=H0/20; % Linear rate of change of susceptables
Pnp=0.05; % Probability of remaining in recently infected state
eps=Pnp/(1-Pnp);
lamle=8.83; % Scale parameter for life expectancy
kle=4.5; % Shape parameter for life expectancy
lamw=0.44; % Scale parameter for window period
kw=7; % Shape parameter for window period
ssize=5000; % Sample size
rand(’seed’,1);
itime=zeros(1,1500000);
ni=0;
t=0;
while t<T
ni=ni+1;
if t<10 % Set parameters for linear hazard rate based on current time
I1=0;
I0=0.01;
elseif t>=10 && t<20
I1=0.009;
I0=0.01-10*I1;
elseif t<30
I1=0;
I0=0.1;
elseif t<40
I1=-0.007;
I0=0.1-30*I1;
else
I1=0;
I0=0.03;
end
% Use cubic roots formula
z=cubic(I1*H1/3,(I0*H1+I1*H0)/2,I0*H0,log(rand)-I1*H1*t^3/3-(I0*H1+I1*H0)*t^2/2-I0*H0*t);
z=z(imag(z)==0);
t=min(z(z>t));
itime(ni)=t;
end
itime=itime(1:ni);
%%
falserecents=rand(1,ni)<Pnp; % Determine which individuals are false-recent
longtime=itime+lamw.*(-log(rand(1,ni))).^(1/kw); % Times are Weibull distributed
death=itime+lamle.*(-log(rand(1,ni))).^(1/kle);
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omega=lamw*gamma(1+1/kw); % Compute window period
omsqr=lamw^2*(gamma(1+2/kw)-gamma(1+1/kw)^2)+omega^2;
weightedinc=zeros(1,nsteps); sampleinc=zeros(1,nsteps); CoV=zeros(1,nsteps);
PH=zeros(1,nsteps); PU=zeros(1,nsteps); PO=zeros(1,nsteps);
for t=1:nsteps
ctime=t*T/nsteps;
Rt=sum(itime<ctime & longtime>ctime & death>ctime); % True recents
Rf=sum(longtime<ctime & death>ctime & falserecents); % False recents
L=sum(longtime<ctime & death>ctime & not(falserecents)); % Longs
S=H0+floor(H1*ctime); % Susceptables
totpop=S+Rt+Rf+L; % Total population
PH(t)=S/totpop; % Compute population proportions
PU(t)=(Rt+Rf)/totpop;
PO(t)=1-PH(t)-PU(t);
samp=[]; % Sample the population
while length(samp)<ssize
samp=[samp rand(1,ssize-length(samp))*totpop];
samp=unique(ceil(samp)); % Ensure sampling without replacement
end
NH=sum(samp<=(totpop-(Rt+Rf+L))); % Compute sample counts
NU=sum(samp<=(totpop-L))-NH;
NO=ssize-NH-NU;
weightedinc(t)=Rt/(S*omega-H1*omsqr/2); % Incidence using linear formula and true recents
sampleinc(t)=(NU-eps*NO)/(omega*NH); % Sample incidence (simple formula)
% Compute coefficent of variation
CoV(t)=sqrt((1/PH(t)+(PO(t)*PU(t)*(1+eps)^2)/(PU(t)-PO(t)*eps)^2)/(ssize*(PO(t)+PU(t))));
end
%%
fprintf(’Time %d PH %.5f PU %.5f PO %.5f\n’,15,PH(15),PU(15),PO(15));
fprintf(’Time %d PH %.5f PU %.5f PO %.5f\n’,20,PH(20),PU(20),PO(20));
fprintf(’Time %d PH %.5f PU %.5f PO %.5f\n’,30,PH(30),PU(30),PO(30));
fprintf(’Time %d PH %.5f PU %.5f PO %.5f\n’,35,PH(35),PU(35),PO(35));
fprintf(’Time %d PH %.5f PU %.5f PO %.5f\n’,40,PH(40),PU(40),PO(40));
fprintf(’Time %d PH %.5f PU %.5f PO %.5f\n’,50,PH(50),PU(50),PO(50));
t=(1:nsteps)/nsteps*T;
close all;
figure(’Position’,[1,1,1600,700]);
axes(’FontSize’,12);
I1=0;
I0=0.01;
plot(0:10,I0+(0:10).*I1,’:k’);
hold;
plot(t,weightedinc,’k’);
plot(t,sampleinc,’+k’);
plot(t,weightedinc+weightedinc.*2.*CoV,’-.k’);
I1=0.009;
I0=0.01-10*I1;
plot(10:20,I0+(10:20).*I1,’:k’);
I1=0;
I0=0.1;
plot(20:30,I0+(20:30).*I1,’:k’);
I1=-0.007;
I0=0.1-30*I1;
plot(30:40,I0+(30:40).*I1,’:k’);
I1=0;
I0=0.03;
plot(40:51,I0+(40:51).*I1,’:k’);
plot(t,weightedinc-weightedinc.*2.*CoV,’-.k’);
title(’Monte Carlo Experiment’,’fontsize’,14,’fontweight’,’b’);
xlabel(’Years’,’fontsize’,14);
ylabel(’Incidence’,’fontsize’,14);
axis([0 51 0 0.14]);
set(gcf,’color’,’none’);
legend(’Instantaneous incidence’,’Weighted incidence (total population)’,’Estimated incidence (sample)’, ...
’Two standard deviation envelope’,2);
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function z=cubic(a,b,c,d)
%
% Function to compute roots of a cubic equation. Used by Fig2-5.m
%
if a~=0
a1=b/a;
a2=c/a;
a3=d/a;
Q=(3*a2-a1^2)/9;
R=(9*a1*a2-27*a3-2*a1^3)/54;
D=Q^3+R^2;
Dsqrt=sqrt(D);
if D<0
S=(R+Dsqrt)^(1/3);
T=conj(S);
else
RpD=R+Dsqrt;
RmD=R-Dsqrt;
if RpD<0 S=-(-RpD)^(1/3); else S=RpD^(1/3); end % Make sure we get real cube roots!
if RmD<0 T=-(-RmD)^(1/3); else T=RmD^(1/3); end
end
sqrt3=sqrt(3);
z=[S+T -(S+T)/2+i*sqrt3*(S-T)/2 -(S+T)/2-i*sqrt3*(S-T)/2]-a1/3;
elseif b~=0
D=sqrt(c^2-4*b*d);
z=[(-c-D)/(2*b) (-c+D)/(2*b)];
else
z=-d/c;
end
return
A.3 Fig4-2.m
%
% Compute the probability of failing to detect an incidence reduction when
% in fact the incidence halves.
%
Pnp=0.05; % Probability of not progressing
eps=Pnp./(1-Pnp);
omega=0.425; % Window period
Inc=0.005:0.0025:0.05; % Incidence range
alpha=11; % Average survival time once infected
Ifactor=.5; % Factor indicating change in incidence
N1=5000:1250:25000; % Number of samples for survey 1
N2=N1; % Number of samples for survey 2
signif=0.05; % Alpha
% Functions for incidence estimator and CoV
Est=@(H,U,O,Pnp,omega) (U-O*Pnp/(1-Pnp))/(H*omega);
CoV=@(PH,PU,PO,N,Pnp) sqrt((1/PH+(PO*PU*(1+Pnp/(1-Pnp))^2)/(PU-PO*Pnp/(1-Pnp))^2)/(N*(PO+PU)));
% Functions to compute steady state proportions
k=@(eps,omega,alpha) eps+(1+eps)*omega/(alpha-omega);
PU=@(I,eps,omega,alpha) omega*I*k(eps,omega,alpha)/(k(eps,omega,alpha)-eps+omega*I*(1+k(eps,omega,alpha)));
PO=@(U,eps,omega,alpha) U/(eps+(1+eps)*omega/(alpha-omega));
Prob=zeros(length(N1),length(Inc));
for I=1:length(Inc)
for J=1:length(N1)
% Compute population proportions for two surveys
PU1=PU(Inc(I),eps,omega,alpha);
PO1=PO(PU1,eps,omega,alpha);
PH1=1-PU1-PO1;
Prev=PU1+PO1;
PU2=(Ifactor*Inc(I)*omega*(1-Prev)+eps*Prev)/(1+eps);
PO2=Prev-PU2;
PH2=1-PU2-PO2;
% Compute standard deviations
SDev1=CoV(PH1,PU1,PO1,N1(J),Pnp)*Est(PH1,PU1,PO1,Pnp,omega);
SDev2=CoV(PH2,PU2,PO2,N2(J),Pnp)*Est(PH2,PU2,PO2,Pnp,omega);
% Compute Null hypothesis population proportions
PHN=(N1(J)*PH1+N2(J)*PH2)/(N1(J)+N2(J));
PUN=(N1(J)*PU1+N2(J)*PU2)/(N1(J)+N2(J));
PON=(N1(J)*PO1+N2(J)*PO2)/(N1(J)+N2(J));
% Compute probability of failing to detect decrease
SDevN1=CoV(PHN,PUN,PON,N1(J),Pnp)*Est(PHN,PUN,PON,Pnp,omega);
SDevN2=CoV(PHN,PUN,PON,N2(J),Pnp)*Est(PHN,PUN,PON,Pnp,omega);
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SDevReal=sqrt(SDev1^2+SDev2^2);
SDevNull=sqrt(SDevN1^2+SDevN2^2);
Ilim=-sqrt(2)*erfcinv(2*(1-signif/2))*SDevNull;
meandiff=Est(PH1,PU1,PO1,Pnp,omega)-Est(PH2,PU2,PO2,Pnp,omega);
Prob(J,I)=1-0.5*(1+erf((Ilim-meandiff)/(SDevReal*sqrt(2))));
end
end
%%
% Graph probability
close all;
figure(’Position’,[1,1,1200,1000],’Colormap’,[(256:-1:0)’./512+0.4 (256:-1:0)’./512+0.4 (256:-1:0)’./512+0.4]);
axes(’FontSize’,12);
surf(Inc.*100,N1./1000,Prob*100);
xlabel(sprintf(’Initial incidence\n (per 100 pyar)’),’Fontsize’,14,’Position’,[-22.41 -109.488 286.624]);
ylabel(sprintf(’Sample size\n(thousands)’),’Fontsize’,14,’Position’,[-25.216 -97.015 286.624]);
zlabel(’Probability of detecting reduction (%)’,’Fontsize’,14);
axis([min(Inc)*100 max(Inc)*100 min(N1)/1000 max(N1)/1000 0 100]);
set(gca,’xtick’,.5:.5:5);
set(gca,’ytick’,5:2.5:25);
view([315 20]);
title(sprintf(’Probability of Detecting Reduction in Incidence\n
(Final incidence=half of initial incidence, \\omega=%.0f days, \\epsilon=%.0f%%, \\alpha=%.0f%%)’,
omega*365,Pnp*100,signif*100),’Fontsize’,14,’fontweight’,’b’);
% Compute and display contour
hold on;
set(gcf,’DefaultLineLineWidth’,2);
C=contour3(Inc.*100,N1./1000,Prob*100+0.1,[90+0.1 90+0.1],’-k’);
text(C(1,end),C(2,end),90+0.2,’ \leftarrow 90’,’HorizontalAlignment’,’left’,’fontsize’,10)
% Produce a 2D contour plot
figure(’Position’,[1,1,1200,1000]);
axes(’FontSize’,15);
[C,h]=contour(Inc.*100,N1./1000,Prob*100,[0.5 1 2.5 5 10 20 30 40 50 60 70 80 90 95 99],’k’,’ShowText’,’on’);
text_handle = clabel(C,h);
set(text_handle,’Fontsize’,14);
title(sprintf(’Probability of Detecting Incidence Reduction - Contours of Constant Probability (%%)\n
(Final incidence=half of initial incidence, \\omega=%.0f days, \\epsilon=%.0f%%, \\alpha=%.0f%%)’,
omega*365,Pnp*100,signif*100),’Fontsize’,20,’fontweight’,’b’);
xlabel(sprintf(’Initial incidence (per 100 pyar)’),’Fontsize’,18);
ylabel(sprintf(’Sample size (thousands)’),’Fontsize’,18);
set(gca,’xtick’,.5:.5:5);
set(gca,’ytick’,5:2.5:25);
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%
% Compute bias for new estimator using exponential incidence and
% susceptable population
%
lamw=0.44; % Scale parameter for window period
kw=7; % Shape parameter for window period
omega=lamw*gamma(1+1/kw);
inc=@(t,alpha) exp(log(1+alpha/100).*t); % Exponential incidence
sus=@(t,beta) exp(log(1+beta/100).*t); % Exponential susceptibles
Pnp=0.02; % Probability of not progressing
tau=1; % Cutoff time
Phirange=0:0.0025:0.05; % Range of FRRs
alpharange=-50:12.5:100; % Range of incidence growth rates
beta=0;
bias=zeros(length(Phirange),length(alpharange));
for i=1:length(alpharange)
% Compute integrals numerically
truedenom=quad(@(x)exp(-(x./lamw).^kw).*sus(-x,beta),0,tau);
Ntr=quad(@(x)exp(-(x./lamw).^kw).*inc(-x,alpharange(i)).*sus(-x,beta),0,tau);
HIVposletau=quad(@(x) inc(-x,alpharange(i)).*sus(-x,beta),0,tau);
weightedInc=Ntr/truedenom;
% Compute bais
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for j=1:length(Phirange)
Phi=Phirange(j);
estInc=((1-Pnp)*Ntr+(Pnp-Phi)*HIVposletau)/(omega*(1-Pnp)+tau*(Pnp-Phi));
bias(j,i)=(weightedInc-estInc)/weightedInc;
end
end
%%
% Graph computed bias
close all;
figure(’Position’,[1,1,1200,1000],’Colormap’,[(256:-1:0)’./512+0.4 (256:-1:0)’./512+0.4 (256:-1:0)’./512+0.4]);
axes(’FontSize’,12);
surf(alpharange,Phirange*100,bias*100);
view([45 50]);
axis([-50 100 0 5 -1.5 2]);
set(gca,’xtick’,-50:25:100);
set(gca,’ytick’,0:0.5:5);
title(’Bias in Estimator’,’fontsize’,14,’fontweight’,’b’);
xlabel(’Annual growth in incidence (%)’,’fontsize’,14,’Position’,[660.289 -20.241 21.578]);
ylabel(’False-recent rate (%)’,’fontsize’,14,’Position’,[711.902 -18.52 21.578]);
zlabel(’Bias (%)’,’fontsize’,14);
% Compute and display contours
hold on;
set(gcf,’DefaultLineLineWidth’,2);
el=0.01;
el2=0.05;
[alpha,Phi]=meshgrid(alpharange,Phirange);
C=contour3(alpharange,Phirange*100,alpha*100+el,[el el],’-k’);
text(C(1,2),C(2,2),0+el2,’ \leftarrow 0’,’HorizontalAlignment’,’left’,’fontsize’,10)
C=contour3(alpharange,Phirange*100,(Phi-Pnp)*100+el,[el el],’-k’);
text(C(1,end),C(2,end),0+el2,’ \leftarrow 0’,’HorizontalAlignment’,’left’,’fontsize’,10)
C=contour3(alpharange,Phirange*100,bias*100+el,[0.5+el 0.5+el],’-k’);
text(C(1,2),C(2,2),.5+el2,’ \leftarrow 0.5’,’HorizontalAlignment’,’left’,’fontsize’,10)
text(C(1,end),C(2,end),.5+el2,’ \leftarrow 0.5’,’HorizontalAlignment’,’left’,’fontsize’,10)
C=contour3(alpharange,Phirange*100,bias*100+el,[1+el 1+el],’-k’);
text(C(1,2),C(2,2),1+el2,’ \leftarrow 1’,’HorizontalAlignment’,’left’,’fontsize’,10)
C=contour3(alpharange,Phirange*100,bias*100+el,[1.5+el 1.5+el],’-k’);
text(C(1,2),C(2,2),1.5+el2,’ \leftarrow 1.5’,’HorizontalAlignment’,’left’,’fontsize’,10)
C=contour3(alpharange,Phirange*100,bias*100+el,[-0.5+el -0.5+el],’-k’);
text(C(1,C(2,1)+3),C(2,C(2,1)+3),-0.5+el2,’ \leftarrow -0.5’,’HorizontalAlignment’,’left’,’fontsize’,10)
text(C(1,C(2,1)+1),C(2,C(2,1)+1),-0.5+el2,’ \leftarrow -0.5’,’HorizontalAlignment’,’left’,’fontsize’,10)
C=contour3(alpharange,Phirange*100,bias*100+el,[-1+el -1+el],’-k’);
text(C(1,C(2,1)+3),C(2,C(2,1)+3),-1+el2,’ \leftarrow -1’,’HorizontalAlignment’,’left’,’fontsize’,10)
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A New Paradigm for Incidence
Estimation From Cross-sectional Data
Thomas A. McWalter and Alex Welte (University of the Witwatersrand, Johannesburg, and SACEMA)
Background
Incidence measurement using cross-sectional surveys is an attractive approach be-
cause it is cheaper, quicker, potentially less-biased and logistically simpler to imple-
ment than prospective follow-up. The basic approach is summarized as follows:
• Test the HIV status of a representative cohort. This yields two counts: N the
number of HIV negative and P the number HIV positive individuals.
• Among HIV positive individuals, find the number R of ‘recent infections’ as
classified by a biomarker.
• Under ideal circumstances, the survey counts can be used to compute inci-
dence using the estimator
I =
R
Nω
,
where the window period ω is the mean time individuals spend classified as
‘recent’ by the biomarker.
Unfortunately, biomarkers like the BED assay [6] are known to produce false posi-
tive results (i.e. non-recently infected individuals that are classified as recent). Con-
troversy has arisen over how to account for these false positive results.
Old Paradigm
Under the assumption of epidemic equilibrium, McDougal et al. [3] proposed an
approach to correct for false positive results which may be summarized as follows:
• Define ‘recent infection’ to mean an infection for a period shorter than ω.
• False positives are individuals that test recent but have been infected for
longer than the window period ω. False negatives are individuals that are
infected for shorter than ω but produce a non-recent biomarker result.
• Estimate the sensitivity σ, short-term specificity ρ1 (infected between ω and
2ω) and long-term specificity ρ2 (infected longer than 2ω) for the assay.
• Using survey counts, compute incidence using the estimator
I =
fR
Nω + fR
, where f =
R/P + ρ2 − 1
σ − ρ1 + 2ρ2 − 1 .
Calibration of this approach is complex, and since it is difficult to consistently incor-
porate calibration uncertainty into confidence intervals for incidence estimates this
has never been done.
New Paradigm
Without the need for epidemic equilibrium, we have derived a new incidence es-
timator using survival analysis [5]. Under the special case of equilibrium, the ap-
proach may be summarized as follows:
• Identify the proportion ε of individuals that will never be classified as non-
recent by the test — these are called assay non-progressors.
• For individuals that progress on the assay, define ‘recent infection’ to mean
classified as recent by the biomarker. Recent infection is now a characteristic
of the test, not a definite time boundary. The window period ω is now defined
as the mean time assay progressors spend classified as recent.
• False positives are assay non-progressors with a time since infection larger
than ω. There are no false-negatives under this definition.
• Using survey counts, compute incidence using the estimator
I =
R− εP
(1− ε)Nω .
The model can be generalized to the case where individuals regress, i.e. revert to
being classified as recently infected by the test as a result of end stage AIDS or use
of ARVs. In this case, the parameter ε is interpreted as a false positive rate and must
be appropriately calibrated for the setting in which the survey takes place.
Confidence Intervals
Confidence intervals for the estimator are derived using the delta method. They
include the error associated with calibration parameters, specified as normal distri-
butions with standard deviations σε and σω . The coefficient of variation of incidence
is:
Cv =
√
1
P
(
N + P
N
+
(P −R)R[1 + ε/(1− ε)]2
[R− ε/(1− ε)(P −R)]2
)
+
σ2ω
ω2
+
σ2ε(P −R)2
(1− ε)4[R− ε/(1− ε)(P −R)]2 ,
with 95% confidence intervals computed as I ± 1.96× CvI .
Estimator Validation
A model epidemic was simulated in which infection times were generated using
a non-homogeneous Poisson process, with individual recency times and lifetimes
generated using Weibull distributions. The susceptible population was linearly in-
creasing with S(t) = 100, 000+5, 000t (t in years). The red curve shown in the graph
below is the model instantaneous incidence parameter used. The target for the es-
timates was the realized weighted incidence (black line), which was calculated for
the complete population. This is flanked by a two standard deviation counting er-
ror envelope (blue lines). Simulated incidence estimates (+ symbols) were obtained
by drawing cross-sectional samples of 5,000 individuals from the simulated popula-
tion. Calibration parameters ω = 150 days and ε = 5% were assumed to be known
exactly.
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The above simulation shows that even under demographic and epidemic non-
equilibrium conditions the estimator performs well. Obviously, more precise
incidence estimates can be obtained with larger sample sizes.
We have also compared the performance of the estimator applied to field data with
an incidence estimate obtained from prospective follow-up [1], with favorable re-
sults. A key point arising from this validation exercise is that a locally applicable
calibration for the false positive rate ε must be used.
Parameter Reduction and Bias Comparison
Under the assumption of a steady state epidemic, we have shown [7] that there is
a relationship between the sensitivity and specificity parameters of the McDougal
approach:
σ − ρ1 + ρ2 = 1.
This allows the elimination of σ and ρ1 from their estimator. Since ρ2 = 1 − ε, it
also means that the parameters that remain are those required in the new paradigm.
Hargrove et al. [2] have proposed another estimator which results from a similar
reduction of the McDougal estimator under the assumption that σ = ρ1.
Comparing these two estimators with the new estimator, under a model steady state
epidemic, only the new estimator recovers an unbiased estimate of the incidence [4].
Results
The key findings of this work may be summarized as follows:
• The new estimator is applicable under more relaxed assumptions than any of
the previous estimators [5].
• Robust results are achieved when applied to a model epidemic which includes
significant transients.
• Confidence intervals are accurate under model epidemic conditions.
• When compared to the other estimators, the new estimator is least biased [4].
• When applied, under consistent calibration, to field data it performs well com-
pared to the incidence found by prospective follow-up [1].
• The calibration parameters ω and ε may vary with setting and care should be
taken to ensure that valid estimates for the particular setting are used [1].
Conclusion
This work explores some of the issues that have lead to the controversy surrounding
incidence measurement from cross-sectional surveys. In particular, it presents a
consistent estimator with accurate confidence bounds. It also highlights the crucial
role of using locally valid estimates for calibration parameters.
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